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ABSTRACT 
 
Aberrant activation of metabolic pathways has emerged as an hallmark of 
proliferating cancer cells and pharmaceutical approaches targeting cell 
metabolism hold great potential for cancer treatment. A critical factor in cellular 
metabolism is nicotinamide adenine dinucleotide (NAD+) and cancer cells highly 
rely on it to face increased metabolic demands and proliferation rates. 
Intracellular NAD+ is a key metabolite involved in several cellular processes, 
acting either as a coenzyme in redox reactions or as a substrate for NAD+-
degrading enzymes such as poly (ADP-ribose) polymerases (PARPs), CD38, 
and sirtuins, regulating processes that undergo fundamental changes during 
malignant transformation. Although NAD+ can be generated de novo from 
tryptophan precursor, the major route of biosynthesis is through a nicotinamide-
salvage process.  
Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme in 
NAD+ biosynthesis from nicotinamide in mammalian cells. A number of cancers 
present an increased expression of NAMPT, and high NAMPT levels have been 
shown to be essential to support cancer cell growth, survival and EMT transition 
and to correlate with adverse prognosis. 
NAMPT is therefore a key factor regulating tumor cell metabolism and is thus 
considered a promising anti-cancer target. FK866 is a specific NAMPT inhibitor 
that lowers NAD+ concentration in cancer cells, reducing the activity of NAD+-
dependent enzymes, impacting on ATP production and promoting cell death. 
NAMPT inhibition was proven to be highly effective in both lymphoid and 
myeloid-derived hematological malignancies in preclinical studies without 
affecting healthy cells, such as hematopoietic stem cells. FK866 has completed 
a phase I trial in oncology with advanced solid tumors. Thrombocytopenia was 
the dose-limiting toxicity, suggesting that this drug is a good candidate for 
clinical applications. 
We investigated the mechanism of action of FK866 in T-ALL derived cell lines 
as well as in primary leukemia cells. FK866-induced metabolic stress and 
NAMPT ablation elicited a strong arrest of protein synthesis as early cell 
response. FK866 induced activation of the AMP-activated protein kinase 
  
(AMPK), which subsequently drove the inhibition of the mTOR/4EBP1 signaling 
cascade and of the major initiation factor EIF2A, impairing protein synthesis. 
Furthermore, FK866-induced stress reduced the levels of the anti-apoptotic 
protein MCL1 and impacted on the endoplasmic reticulum homeostasis.  
In addition, we established and characterized an FK866-resistant model derived 
from the T-ALL cell line Jurkat. Target-specific acquired resistance has been 
described after several therapies and can be modeled in vitro by growing cells 
in presence of increasing concentrations of drug. In our resistant cells, FK866 
treatment only partially impacted on NAD+ content, whereas ATP levels were 
recovered and protein translation was resumed. Notably, during in vitro 
acquisition of drug resistance, mutations in the NAMPT gene have not 
occurred. Finally, FK866-resistant cells developed cross-resistance to the 
glucocorticoid dexamethasone. 
In the last years, many NAMPT inhibitors have been synthesized and 
characterized. The obtained results provide new insight into the role of the 
NAMPT-mediated NAD+ salvage pathway in cancer cell metabolism and the 
molecular mechanisms of FK866, which will be useful to formulate specific and 
effective combinatorial drug therapies. 
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ABBREVIATIONS and ACRONYMS 
Δψm Mitochondrial transmembrane potential 
4EBP1 Eukaryotic translation initiation factor 4E-Binding Protein 1 
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MTOR Mammalian Target of Rapamycin  
mTORC1 mTOR complex 1 
mTORC2 mTOR complex 2 
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NAM Nicotinamide 
  
NAMPT Nicotinamide PhosphoribosylTransferase 
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RT-PCR Reverse Transcription Polymerase Chain Reaction 
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T-ALL T-cell Acute Lymphoblastic Leukemia  
TCA TriCarboxylic Acid  
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INTRODUCTION 
 
1. Metabolism and cancer  
 
1.1 The hallmarks of cancer: reprogramming energy metabolism 
 
In 2000, Robert Weinberg and Douglas Hanahan published in Cell a very 
renowned article titled "The Hallmarks of Cancer", which comprised the 
description of six biological capabilities acquired during the multistep 
development of human tumors. In 2011, they updated their list by proposing 
four new hallmarks. Among these, the first was the capability of major 
reprogramming of cellular energy metabolism in order to support continuous 
cell growth and uncontrolled proliferation. Cancer cells replace the metabolic 
program that operates in the majority of normal tissues inducing alterations in 
their metabolism, which becomes therefore an attractive target for cancer 
therapy ([1], Figure 1). 
 
 
 
Figure 1. Therapeutic targeting of the Hallmarks of Cancer 
Illustrative examples of drugs that interfere with the acquired capabilities necessary for tumor 
growth and progression [1].  
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1.2 The Warburg effect 
 
During the past century, cancer research has focused on the altered cellular 
metabolism linked to cancer progression. In 1924, Warburg made the first 
discovery that related tumor biology to metabolism. He observed an anomalous 
characteristic of cancer cells: even in the presence of oxygen, they can 
reprogram their glucose metabolism and sustain energy production largely 
through glycolysis pathway rather than through the tricarboxylic acid (TCA) 
cycle [2]. This “aerobic glycolysis”, the so called “Warburg effect”, seems to be 
a general property of highly malignant tumors, regardless of their carcinogenic 
origin [3]. 
Under aerobic conditions, most cells process glucose to pyruvate through 
glycolysis and then completely oxidize most of it to carbon dioxide in the 
mitochondria. The process generates reduced electron carriers (NADH and 
FADH2), reconverted to NAD
+ and FAD through oxidative phosphorylation, 
resulting in the production of 34 molecules of ATP per oxidation of one glucose 
molecule [4]. Cancer cells instead switch to the less-efficient ATP generation 
from aerobic glycolysis. In spite of this, they benefit from the increased 
glycolysis because it leads to elevated glycolytic intermediates, including those 
generating amino acids, nucleotides and lipids required for the biosynthesis of 
macromolecules and organelles and for supporting their high proliferation-rate 
[5]. The reliance on glycolysis has been recently reported to be promoted by 
oncogenes (e.g., RAS,MYC), inhibited by tumor suppressors (e.g., TP53), and 
accentuated under hypoxic conditions by increasing the levels of the HIF1α and 
HIF2α transcription factors, which stimulate the expression of glycolytic 
transporters and enzymes [6].  
In tumor cells, lactate dehydrogenase isoform A (LDHA) preferentially converts 
accumulating pyruvate to lactate, thereby regenerating NAD+ from NADH to 
maintain glycolysis. The ratio of NAD+ to NADH is balanced in favor of NAD+ in 
normal cells, whereas in tumors an increase of NADH relative to NAD+ is 
reported based on the LDHA reaction. The accumulation of lactate implies as 
well the secretion of the excess, which contributes to an extracellular 
environment that promotes tumor progression ([7], Figure 2).  
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Figure 2. The Warburg effect  
Comparison of cell metabolism in normal (left side) and malignant cells (right side). In cancer 
cells, even under normoxic conditions, a high rate of glycolysis and increased glucose uptake is 
observed, that together with the tumor-specific increase of the less active pyruvate kinase M2 
(PKM2) raises the concentrations of glycolytic intermediates. They are mostly diverted into the 
pentose phosphate pathway (PPP) and NADPH is produced to counteract oxidative stress and 
to build up macromolecules including the production of ribose-5-phosphate (Rib-5-P) for nucleic 
acid synthesis [7]. 
 
2. NAD+  
 
2.1 The NAD+ metabolome: a key determinant of cancer cell biology 
 
Since the beginning of the last century, pyridine nucleotides, namely NAD+ and 
its phosphorylated form NADP, have been identified as the major redox carriers 
in all organisms.  
In 1904, sir Arthur Harden inferred the existence of a low molecular coferment 
or ‘cozymase’ required for sugar fermentation in yeast. In subsequent years, 
cozymase was established as a universal factor participating in fermentation, 
respiration and glycolysis in a variety of organisms. In 1920, Hans von Euler-
Chelpin succeeded in its isolation from yeast extracts and determined its 
chemical composition of a sugar, an adenine and a phosphate. The current 
function of NAD+ was established by Otto Warburg in 1936, who discovered its 
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capability to transfer hydrogen from one molecule to another [8]. As the redox 
couple NAD+/NADH, NAD+ plays a crucial role in numerous cellular processes 
acting primarily as electron-shuttling agent involved in supporting the activity of 
enzymes that catalyze oxidation-reduction reactions. However, beyond its 
coenzymatic activity, it has recently been reported to have an unexpectedly 
wide variety of pivotal roles in cellular functions. NAD+ is vital not only for 
energy transduction, but also as a key component of signaling pathways. Thus, 
it has emerged as one of the most important link between regulatory and 
bioenergetic processes and is now regarded as a universal energy and signal-
carrying molecule. Signaling pathways that involve NAD+ and its 
phosphorylated form NADP are many and often undergo crucial changes in 
cancer cells. 
NAD+ serves as substrate for NAD+-dependent enzymes; it is required for three 
major families of enzymes in mammals: ADP-ribose transferases, including 
PARPs, NAD+-dependent protein deacetylases (sirtuins) and cyclic ADP 
(cADP)-ribose synthases (CD38 and CD157) involved in calcium mobilization. 
Endogenous mono-ADP-ribosylation in higher eukaryotes appears to modulate 
immune response, cell adhesion, signal and energy metabolism [9]. NAD+-
dependent enzymes release nicotinamide during their reaction, which needs to 
be recycled to maintain tissue NAD+ levels [10]. Furthermore, NAD+-H regulates 
the transcriptional corepressor CtBP (carboxyl-terminal binding protein) through 
binding. CtBP is involved in transcriptional pathways important for development, 
cell cycle regulation and transformation [11]. 
NAD+ can also be converted to NADP and reduced to NADPH, which is 
necessary for fatty acid synthesis and anti-oxidant defense [12]. 
NAD+-mediated signaling events participate in the regulation of crucial 
biological processes, including transcription, cell cycle progression, DNA repair, 
apoptosis, chromatin dynamics regulation, telomerase activity, circadian 
rhythm, longevity, caloric-restriction response and metabolic regulation. The 
control of such fundamental events has implications in different pathological 
conditions and has been linked to cancer development. 
Therefore, an increased NAD+ demand is present in cancer cells to support 
their altered NAD+-dependent metabolic and signaling pathways [1].  
5 
 
 
2.2 The NAD+ biosynthesis  
 
Unlike metabolic redox reactions, which oxidize or reduce NAD+-H in a 
reversible manner, NAD+-dependent signaling reactions continuously consume 
NAD+ and involve the degradation of the molecule. In fact, the incessant 
regeneration and maintenance of the cellular NAD+ pool is challenging and 
essential to maintain cell proliferation. The necessity of a permanent nucleotide 
resynthesis through different biosynthetic pathways supports the targeting of 
NAD+ metabolism as a new therapeutic concept for cancer treatment [7]. 
In mammals, NAD+ can be synthesized either from the ‘‘de novo pathway” 
starting from tryptophan or from nicotinamide (NAM), nicotinic acid (NA) and 
nicotinamide riboside (NR) [13], representing the ‘‘salvage pathways’’ that allow 
the recycling of metabolites derived from normal cellular catabolism. 
Tryptophan’s role as NAD+ precursor was first suggested by nutritional studies 
on human pellagra in 1945 [14]. In subsequent years, its crucial role has been 
confirmed in most living organism, including mammals [15]. The first, rate-
limiting step in NAD+ biosynthesis is the conversion of tryptophan to N-
formylkynurenine, catalyzed by either indoleamine 2,3-dioxygenase (IDO) or 
tryptophan 2,3-dioxygenase (TDO). TDO is the major hepatic enzyme [16], 
whereas in extrahepatic tissues the cytosolic IDO plays an important role, 
mostly in lung, small intestine, placenta and in the immune system [17]. A 
decrease in TDO activity occurs concomitantly with IDO induction in response 
to inflammatory stimuli (e.g. interferon-gamma), suggesting a coordinate shift in 
tryptophan degradation from the liver to extrahepatic tissues [18]. 
N-formylkynurenine is subsequently converted in four individual steps to the 
unstable α-amino-β-carboxymuconate-ε-semialdehyde (ACMS), which can 
undergo spontaneous cyclization to quinolinic acid. Quinolinic acid is then 
converted to nicotinic acid mononucleotide (NAMN) by a quinolinic acid 
phosphoribosyltransferase (QPRTase) and converges to the Preiss-Handler 
pathway leading to NAD+ ([19], Figure 3).   
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Figure 3. Mammalian de novo NAD
+
 pathway  
The de novo biosynthesis of NAD
+
 starts with the conversion of tryptophan to N-
formylkynurenine catalyzed by either IDO or TDO, which is subsequently converted to the 
unstable ACMS. ACSM is then either converted by ACMSD and directed to total oxidation or 
undergoes nonenzymatic cyclization to quinolinic acid. The final step is comprised of the QPRT-
catalyzed formation of NAMN.  
IDO, indoleamine 2,3-dioxygenase. TDO, tryptophan 2,3-dioxygenase. ACMS, α-amino-β-
carboxymuconate-ε-semialdehyde. ACMSD, ACMS decarboxylase. QPRT, quinolinate 
phosphoribosyltransferase. NAMN, NA mononucleotide [10].  
 
In spite of this well-known and conserved pathway based on tryptophan 
catabolism, the main source of NAD+ in mammals are the salvage pathways, 
which utilize the niacin-derived molecules NA, NAM and NR as precursors. 
Nicotinamide rather than nicotinic acid is thought to be the predominant NAD+ 
precursor in mammals [20] and quantification of its level in human plasma 
revealed a fivefold higher concentration with respect to NA levels [21]. 
Moreover, the cleavage of the ADP-ribose moiety of NAD+ by numerous NAD+-
dependent enzymes, such as sirtuins and PARPs, leads to the concomitant 
release of nicotinamide [10].  
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Nicotinic acid is converted to NAMN as starting point of the Preiss-Handler 
pathway converging with the primary NAD+ biosynthesis from tryptophan [22].  
NAD+ synthesis from nicotinamide in lower organisms, such as bacteria and 
yeast, implies the enzymatic conversion to NA by nicotinamidase (NDase), 
followed by integration in the Preiss-Handler pathway. In contrast, mammals 
convert NAM to NAM mononucleotide (NMN) by NAM 
phosphoribosyltransferase (NAMPT) enzyme, which catalyzes the rate-limiting 
step in the mammalian NAD+ salvage pathway from nicotinamide. NAMPT 
catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-
pyrophosphate to yield nicotinamide mononucleotide. NMN together with ATP 
is further converted to NAD+ by a nicotinamide mononucleotide 
adenylyltransferase (NMNAT) [23]. Three mammalian genes encoding 
adenylyltransferases have been recently identified, with a distinct cellular 
localization (nucleus, cytoplasm, mitochondria), that can use both NMN and 
NAMN as substrate [24], [25]. 
Lastly, the third NAD+ salvage pathway, which was originally known as the only 
NAD+ biosynthesis pathway in certain bacteria, is comprised of the 
phosphorylation of NR to NMN by NR kinase (NRK). The pathway is highly 
conserved in yeast and human for which two NRK enzymes have been 
described ([13], Figure 4).  
 
3. NAMPT 
 
NAD+ synthesis by NAMPT is essential for cellular metabolism, energy 
production, and DNA repair, which are processes deeply impaired during 
malignant transformation. As NAD+ is rapidly consumed in cancer cells, due to 
higher turnover, and converted to nicotinamide, NAMPT is essential for the 
replenishment of the intracellular NAD+ pool. 
Nicotinamide phosphoribosyltransferase (NAMPT) has been originally identified 
as a secreted cytokine-like factor named Pre-B-cell colony enhancing factor 
(PBEF) involved in the maturation of early B-lineage precursor cells [26]. 
Bacterial and murine homologs of NAMPT were later identified as a cytosolic 
nicotinamide phosphoribosyltransferase involved in NAD+ biosynthesis [27]. 
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Figure 4. Mammalian NAD
+
 salvage pathway  
Precursors of NAD
+
 in the salvage pathway are NA, NAM and NR. The initial step in NAD
+
 
synthesis from NA, the so-called Preiss-Handler pathway, is catalyzed by NAPT and results in 
the formation of NAMN, which can also be derived from the de novo NAD
+
 biosynthesis starting 
from tryptophan. NAM is converted by NAMPT forming NMN, which is also the product of 
phosphorylation of NR by NRK. The subsequent conversion of both NAMN and NMN is 
catalyzed by the same enzyme, NMNAT. In the case of NAMN, this reaction is followed by 
amidation by NADS, finally producing NAD
+
. NAPT, NA phosphoribosyltransferase. NAMN, NA 
mononucleotide. NAMPT, NAM phosphoribosyltransferase. NMN, NAM mononucleotide. NRK, 
NR kinase. NMNAT, NMN adenylyltransferase. NADS, NAD
+
 synthase [10].  
 
The crystal structure of the protein revealed its belonging to the dimeric class of 
type II phosphoribosyltransferases and mutagenesis studies showed that 
impaired dimerization exhibits attenuated enzymatic activity and that Asp219 is 
important in defining the substrate specificity [28]. NAMPT can 
autophosphorylate at H247. This modification increases its affinity for 
nicotinamide and its enzymatic activity up to 1000-fold [29]. 
An insulin-mimetic function was also ascribed to NAMPT, which was described 
to be secreted by visceral fat of humans and directly bind the insulin receptor, 
recognized as an adipokine and renamed visfatin [30]. However, this paper was 
retracted  due to  inability  to  find  evidences  to  support  the  actual  binding of  
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NAMPT to the insulin receptor [31]. More recently, NAD+ biosynthesis mediated 
by an extracellular form of NAMPT (eNAMPT) was reported to be involved in 
the secretion of insulin glucose-stimulated in β cells of the pancreas. NAMPT 
haplodeficiency caused defects in insulin secretion in pancreatic islets in vivo 
and in vitro [32].  
“NAMPT” has been approved as the official nomenclature of the protein and the 
gene by both the HUGO Gene Nomenclature Committee (HGNC) and the 
Mouse Genomic Nomenclature Committee (MGNC). 
The human NAMPT gene is located on chromosome 7 and is composed of 11 
exons and 10 introns, encoding for a 491 amino acids polypeptide. The coding 
sequence is highly conserved through evolution and significant sequence 
homology was reported to be shared among prokaryotes, primitive metazoans 
and humans [33]. The crucial role of NAMPT in cell physiology is further 
demonstrated by the fact that the homozygous gene knockout mouse 
(homozygous for a mutant allele enzymatically deficient) is embryonically lethal 
[32].  
NAMPT is expressed in several human organs, tissues and cells including 
heart, brain, placenta, lungs, liver, skeletal muscle, kidney and pancreas [26]. 
NAMPT presents two different forms: intracellular and extracellular (referred as 
iNAMPT and eNAMPT respectively). iNAMPT localizes at the cytoplasm, 
nucleus and mitochondria level [34]. Mitochondrial NAMPT in conjunction with 
the NAD+-dependent deacetylase Sirtuin 3 (SIRT3) promotes cell survival 
following genotoxic stress [35]. NAMPT gene and NAD+ levels display circadian 
oscillations and are regulated by the core clock machinery through binding of 
the circadian transcription factor CLOCK [36]. Sirtuin 1 (SIRT1) is recruited to 
NAMPT promoter and contributes to its circadian synthesis [37]. 
Many functions have been associated with NAMPT, among which the major 
ones are growth factor, cytokine and nicotinamide phosphoribosyltransferase. 
Its dysregulation has been implicated in the susceptibility and pathogenesis of a 
number of human diseases such as obesity, non-alcoholic fatty liver disease, 
type 2 diabetes, aging and cancer. Furthermore, different studies detected an 
elevated NAMPT expression after stimulation with TNFα [38], IL-6 [39] and 
under hypoxic conditions [40]. This could motivate the increased level of 
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NAMPT mRNA reported in states of obesity, insulin resistance in diabetes and 
inflammation. 
In relation to its role as cytokine, NAMPT expression is up-regulated in a variety 
of acute and chronic inflammatory diseases including sepsis [41], acute lung 
injury [42], rheumatoid arthritis [43] and myocardial infarction, where it foams 
cell macrophages within unstable atherosclerotic lesions [44]. NAMPT plays a 
key role in the persistence of inflammation through its capacity to delay 
neutrophil apoptosis [41].  
 
3.1 NAMPT in cancer 
 
NAMPT has been indicated as an attractive diagnostic and drug target for 
cancer therapy by molecular screening, epidemiological survey and 
phamarcological studies.  
NAMPT expression increases in cancer cells, as reported for the first time in 
primary colorectal cancer with respect to normal control by 
using suppression subtractive hybridization (6-fold increase) [45].  
NAMPT implication in cancer pathogenesis may be explained by several 
molecular mechanisms. First of all, NAMPT contributes to tumor evasion of 
apoptosis by synthesizing NAD+ in the salvage pathway. The molecule affects 
cell death through several mechanisms: NAD+ mediates cellular energy 
metabolism, which is a critical factor determining cell death, the NADH/NAD+ 
ratio affects mitochondrial permeability transition (MPT), NAD+ levels mediate 
the activity of caspase-activated DNA Fragmentation Factor 40 (DFF40), a 
nuclease primarily responsible for genomic DNA fragmentation during 
apoptosis, NADPH may mediate cell death by its major effects on oxidative 
stress and NAD+-dependent sirtuins and poly (ADP-ribose) polymerases play a 
role in apoptosis [46].  
Secondly, NAMPT plays a role in new blood vessels formation and 
angiogenesis, supporting tumor growth. It promotes endothelial angiogenesis 
via activation of mitogen-activated protein kinase ERK-dependent pathway and 
PI3K/AKT signaling by inducing vascular endothelial growth factor (VEGF) and 
matrix metalloproteinases (MMP-2, MMP-9) production [47]. The induced 
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angiogenesis is mediated by the up-regulation of the endothelial fibroblast 
growth factor-2 (FGF-2), involving ERK 1/2-dependent gene expression [48].  
Lastly, several different molecular targets have been identified that promote 
carcinogenesis following iNAMPT overexpression, including SIRT1, CtBP, and 
PARP-1. On the other side, a reduced NAMPT expression was found to 
strongly dysregulate cancer biology signaling pathways in a meta-analysis of 
genome-wide expression data [49]. 
Several different human malignant tumors have been demonstrated to 
overexpress iNAMPT including colorectal [45], ovarian [50], breast [51], gastric 
[52], prostate [53], well-differentiated thyroid [54] and endometrial carcinomas 
[55], myeloma [56], melanoma [57], and astrocytomas [58]. Increased iNAMPT 
expression also occurs in malignant lymphomas, including diffuse large B-cell 
lymphoma, follicular B-cell lymphoma, Hodgkin’s lymphoma, and peripheral T-
cell lymphoma [59]. 
In glioblastoma (GBM) samples, NAMPT was reported to be increased and 
identified as a potential malignant astrocytoma serum marker and prognostic 
indicator among GBMs [58]. In breast cancer, NAMPT was demonstrated to up-
regulate Notch1 contributing to tumor growth through the activation of the NF-
κB pathway [60]. 
Although most studies document increased levels of iNAMPT between benign 
and malignant tissues, several others also correlate up-regulated expression 
with specific changes in tumor behavior. Higher NAMPT expression correlated 
with deeper tumor invasion and increased growth, metastases and reduced 
patient survival in gastric cancer, melanoma, endometrial adenocarcinoma and 
astrocytomas. In prostate cancer, NAMPT over-expression along with SIRT1 
increased tumor cells resistance to oxidative stress [53]. In pancreatic cancer, 
NAMPT inhibition reduced overall metabolic activity and prevented tumor 
growth, with a responsiveness modulated by expression level of CD38 [61]. 
Last, several researchers found that iNAMPT expression confers resistance to 
chemotherapeutic agents, including fluorouracil, doxorubicin, paclitaxel, 
etoposide, and phenylethyl isothiocyanate [51], [40], [52], [53]. In addition, 
NAMPT protects cells against genotoxic stress, as reported for the DNA 
12 
 
alkylating agent methylmethane sulfonate (MMS), that is known to hyper-
activate PARP-1 [35]. 
eNAMPT induced the proliferation of the hepatocellular carcinoma HepG2 cell 
line in vitro compared with normal hepatocytes [62] and affected redox adaptive 
responses promoting tumor proliferation in human malignant melanoma cells 
[57]. In breast cancer cells, eNAMPT promotes epithelial-to-mesenchymal 
transition (EMT) through its function as a cytokine secreted into the extracellular 
environment independent of its enzymatic activity. EMT was mediated by 
NAMPT ability to activate the TGFβ signaling pathway via increased TGFβ1 
production [63]. 
 
4. FK866 
 
Targeting NAMPT activity represents a novel therapeutic strategy for human 
cancers. FK866/ WK175/ APO866/ K22.175 was identified as the first low 
molecular weight compound capable of inducing apoptosis by a highly specific 
noncompetitive inhibition of nicotinamide phosphoribosyltransferase. It was 
discovered through a chemical screening performed in HepG2 (human liver 
carcinoma cells) to find new antitumor drugs. Interfering with NAMPT, it 
represents a novel mechanism for induction of tumor cell apoptosis not by cell 
intoxication but by gradually depletion of NAD+ which eventually triggers 
apoptosis [64]. 
The three dimensional structural analysis of the NAMPT–FK866 complex 
revealed that FK866 compound binds at the nicotinamide binding site of 
NAMPT and compete directly with the nicotinamide substrate to inhibit its 
activity. This structural analysis provided a molecular basis for the inhibition of 
FK866 on NAMPT and a starting point for the development of new anticancer 
agents [28], [65]. 
NAMPT inhibition attenuated glycolysis at the glyceraldehyde 3-phosphate 
dehydrogenase step by reducing NAD+ availability to this enzyme. Attenuated 
glycolysis resulted in ATP depletion and perturbed metabolic pathways and led 
to reduced serine biosynthesis and tricarboxylic acid cycle and altered pentose 
phosphate pathway [66].  
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FK866 has been recently reported to interfere with multiple biochemical 
pathways, related to tumor glycolysis, guanylate synthesis, pyridine nucleotide 
pools, and phospholipid metabolism by using 1H-decoupled phosphorus (31P) 
magnetic resonance spectroscopy (MRS). The drug induced an increase in 31P 
MRS signals in the phosphomonoester region and a decrease in NAD+ levels, 
pH, and energetic status in a dose-dependent manner. These metabolic 
changes associated with FK866-induced tumor cell death and enhanced 
radiation sensitivity in a mouse mammary carcinoma [67].  
Although FK866 has been reported to cause selective cancer cell death in a 
variety of models of solid tumors and hematologic malignancies, the 
mechanism of cell death is still debated in the literature. 
FK866 induced the apoptotic cascade in human leukemia cells (THP-1, a 
human acute monocytic leukemia cell line), without any DNA-damaging effects. 
The decreased level of NAD+ initiated the apoptotic death signaling pathway 
leading to disruption of the mitochondrial membrane potential, release of 
cytochrome c from the mitochondria, activation of caspase 3, cleavage of 
caspase 3 and PARP, and DNA degradation with the appearance of a sub-G1 
cell cycle population [68]. FK866-induced delayed cell death by apoptosis in 
hepatocarcinoma cells HepG2 was instead not related to a direct inhibition of 
the mitochondrial respiratory activity, but caused gradual NAD+ depletion [64]. 
In SH-SY5Y neuroblastoma cells, no evidence of apoptosis was assessed by 
immunoblotting for caspase 3 activation fragment and immunostaining for 
cytochrome C and AIF (apoptosis inducing factor) translocation, whereas 
FK866-initiated autophagy was observed with formation of LC3-positive 
vesicles that had fused with lysosomes [69]. Autophagy was confirmed to be 
crucial for FK866-induced cell death in neuroblastoma cells, where the drug 
effects were potentiated by chloroquine and antagonized by 3-methyladenine or 
by down-regulating autophagy-related protein 7 [70]. 
FK866 has been shown to have anti-tumor and anti-metastatic activity and a 
strong anti-angiogenic potency in a murine renal cell carcinoma model 
(RENCA) [71].  
FK866 repressed gastric cancer cell proliferation suppressing cell migration and 
anchorage-independent growth [52].  
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FK866 has been demonstrated to be effective in blood cancer cell lines, where 
it leads to ATP reduction and delayed induction of cell death. 
Against hematological malignancies FK866 was proved to have a potent 
antitumor activity both in a panel of cell lines and primary cells. Most cancer 
cells (acute myeloid leukemia [AML], acute lymphoblastic leukemia [ALL], 
mantle cell lymphoma [MCL], chronic lymphocytic leukemia [CLL], and T-cell 
lymphoma), but not normal hematopoietic progenitor cells, were sensitive to low 
concentrations of the drug. NAD+ depletion and ATP decrease led to cell death 
in a caspase-independent mode, and this was associated with mitochondrial 
dysfunction and autophagy. Further, in vivo administration of FK866 prevented 
and abrogated tumor growth in animal models of human AML, lymphoblastic 
lymphoma, and leukemia without significant toxicity to the animals [72]. FK866 
anti-tumor activity in hematologic malignancies has been recently confirmed by 
a preclinical study [73]. A potent synergistic interaction has been reported 
between FK866 and the apoptosis activator TRAIL (tumor necrosis factor-
related apoptosis-inducing ligand) in human leukemia cell lines and in primary 
B-cell chronic lymphocytic leukemia cells, but not in normal leukocytes, through 
a mechanism involving autophagy. FK866-induced NAD+ depletion, 
mitochondrial transmembrane potential dissipation and massive ATP shortage 
leading to autophagic cell death were synergistically increased. A convergence 
of the two death-inducing stimuli at the mitochondrial level was reported, 
underlying the synergy between TRAIL and FK866, where NAD+ shortage and 
activation of the extrinsic apoptotic cascade (caspase-3) via TRAIL cooperate 
to dissipate the ΔΨm (mitochondrial transmembrane potential) [74]. In primary 
CLL (chronic lymphocytic leukemia) cells apoptosis-mediated death was 
reported by depletion of cellular NAD+ content, followed by a drop in ATP, loss 
of MMP (mitochondrial membrane potential), increase in ROS (reactive oxygen 
species), and induction of apoptotic signaling without up-regulation of the p53-
target p21 also in patients with high-risk features, including del17p13.1 [75]. In 
multiple myeloma (MM) cell lines and patient cells instead, FK866 triggered 
autophagy but no toxicities were reported with normal donor as well as MM 
patients PBMCs. A transcriptional-dependent (TFEB) and independent 
(PI3K/mTORC1) activation of autophagy mediated the cytotoxicity. A significant 
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anti-MM activity was demonstrated in a xenograft-murine MM model, 
associated with down-regulation of ERK1/2 phosphorylation and proteolytic 
cleavage of LC3 ([76], Figure 5). Moreover, FK866-induced NAD+ depletion 
enhanced the proteasome inhibitor bortezomib-induced anti-myeloma activity 
and overcame bortezomib resistance. Synergistic anti-MM cell death was 
associated with activation of caspases (8, 9, 3) and poly (ADP-ribose) 
polymerase, and down-regulation of the anti-apoptotic protein MCL-1, 
enhanced intracellular NAD⁺ depletion, inhibition of nuclear factor κB signaling 
and inhibition of angiogenesis [77]. 
FK866 anti-lymphoma activity was potentiated when used in combination with 
Rituximab (RTX), an anti-CD20 antibody. Human B-lymphoma induced cell 
death was increased by drug combination due to enhancement of autophagy, 
activation of caspase 3 and exacerbation of mitochondrial depolarization. In 
vivo, combined administration in a model of human aggressive lymphoma 
significantly decreased tumor burden and prolonged survival over single-agent 
treatment [78].  
FK866 was safe and well tolerated in a phase I study that included 24 patients 
with various advanced solid tumors that were refractory to standard treatments. 
Thrombocytopenia was the dose-limiting toxicity in this study, suggesting that 
this drug is a good candidate to transition into clinic. Regrettably, no objective 
tumor remission was observed, although a few cases of disease stabilization 
could be recorded [79]. 
NAMPT inhibitors as monotherapy have so far shown limited antitumor activity 
and their benefit should be sought in combination treatments with antineoplastic 
agents, chemotherapy or radiotherapy that might enhance their therapeutic 
efficacy. One plausible explanation for the failure of NAMPT inhibition as a 
single agent anti-cancer therapy could be the action of extracellular NAD+ or 
extracellular NAD+ precursors able to prevent FK866-induced cell death. 
For example, the NAD+-degrading ectoenzyme CD73 reversed cell death 
induced by NAMPT inhibition through the supply of ectocellular NAD+ 
precursors, suggesting the possibility of implementing antitumor therapies 
based on combined inhibition of NAMPT and CD73 [81].   
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Figure 5. FK866-induced autophagic cell death of multiple myeloma (MM) cells 
FK866 depletes NAD
+
 intracellular stores in MM cells, thereby both blocking MAPKs and 
inducing translocation of TFEB from the cytoplasm to the nucleus as well as up-regulating 
autophagy-related genes (transcriptional-dependent mechanism). In parallel, PI3K-mTOR 
activity is directly inhibited (nontranscriptional-dependent mechanism), further inducing 
autophagy in MM cells [80]. 
 
 
5. Metabolic checkpoints: AMPK and mTOR 
 
The liver kinase B1 (LKB1)/ adenosine mono phosphate activated protein 
kinase (AMPK)/ tuberous sclerosis complex (TSC)/ mammalian target of 
rapamycin (mTOR) complex 1 (mTORC1) signaling pathway is central in 
regulating cellular metabolism and cell growth by integrating information 
regarding the intracellular energy and oxygen status, the presence of growth 
factors and nutrient availability. Under circumstances of sufficient energy and 
nutrient sources, this metabolic pathway stimulates cell growth. In cases of 
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stress instead, it induces the adjustment of metabolic processes to restore 
resources in the cell [82]. 
In a recent study published in 2015, FK866-induced delayed energy stress in 
hepatocarcinoma cells has been demonstrated to trigger the activation of 
AMPK and down-regulation of the mTOR signaling which was associated with 
increased cancer cell death [83]. 
 
5.1 LKB1- AMPK 
 
The liver kinase B1 (LKB1, also referred to as serine/threonine kinase 11) is a 
serine/threonine kinase that is ubiquitously expressed in adult and fetal tissues 
[84]. The protein lacks a nuclear export domain and in absence of stimulation is 
therefore retained in the nucleus in its inactive state. Activation of LKB1 is 
associated with its translocation to the cytoplasm, induced upon binding by the 
STE20-related adaptor protein α (STRADα) and scaffolding mouse protein 25 
(MO25) and the consequent formation of a stable heterotrimeric complex that is 
actively exported out of the nucleus [85]. Activated LKB1 phosphorylates and 
activates AMPK (AMP activated protein kinase) in response to energy stress in 
mammalian cells. Activation induced by AMPK-activating drugs did not occur in 
cells lacking LKB1 expression. In vitro studies demonstrated that LKB1 
complexed to STRADα and MO25 activated AMPK by phosphorylating Thr172 
of the α subunit, and that STRADα and MO25 subunits enhanced 
phosphorylation of AMPK by over 100‐fold [86]. 
LKB1-dependent AMPK activation plays a biologically significant role in 
counteracting apoptosis induced by energy stress [87]. Moreover, LKB1 itself 
was reported to act as tumor growth suppressor through its cytoplasmic 
signaling inducing the cyclin-dependent kinase inhibitor p21 in a p53-dependent 
manner [88]. 
AMPK is an highly conserved heterotrimeric serine/threonine kinase comprising 
an α catalytic subunit and two regulatory subunits (β and γ). The AMPK 
cascade is a sensor of cellular energy charge that acts as a 'metabolic master 
switch' regulating physiological processes related to ATP in order to restore the 
energy charge in the cell, by suppressing energy-consuming processes such as 
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glycogen and lipid synthesis on one hand, and enhancing energy-gaining 
pathways such as glycolysis on the other.  
Both catalytic subunit isoforms of AMPK (AMPKα1 and AMPKα2) are activated 
by ATP‐depleting processes and metabolic stress such as glucose deprivation, 
exercise and muscle contraction, ischemia, hypoxia, oxidative stress, osmotic 
and heat shock and hormones including leptin and adiponectin. The fall of ATP 
levels and the rise of cellular AMP, due to the reaction catalysed by adenylate 
kinase, increases the cellular AMP/ATP ratio. This is sensed by AMPK that 
undergoes a conformational change upon binding of AMP. AMPK can be 
phosphorylated by LKB1 and, once activated, restores the energetic balance of 
the cell stimulating ATP production [89].  
AMPKα can also be phosphorylated by calcium/calmodulin-dependent protein 
kinase kinase (CaMKIK), which is triggered through influx of calcium [90].  
LKB1/AMPK signaling monitors energy metabolism through regulation of 
several downstream targets and regulates glucose, lipid and protein 
metabolism. Activated AMPK inhibits through phosphorylation the metabolic 
enzymes acetyl-CoA carboxylases (ACC 1 and 2), which promote fatty acid 
synthesis by production of malonyl-CoA [91]. AMPK was reported to be 
activated by metformin, the most commonly employed drug for the treatment of 
type 2 diabetes, resulting in reduction of ACC activity, induction of fatty acid 
oxidation and suppressed expression of lipogenic enzymes [92].  
Inactivation of AMPK has been implicated in tumor progression based on the 
over-expression of hypoxia-inducible factor-1α (HIF-1α), thereby promoting the 
Warburg effect by increasing aerobic glycolysis and lactate production [93]. In 
hepatocellular carcinoma, loss of AMPK promoted carcinogenesis by 
destabilizing p53 in a SIRT1-dependent manner [94]. 
One of the downstream effectors of AMPK is the tumor suppressor tuberous 
sclerosis complex 2 (TSC2), that is activated by phosphorylation (Thr1227 and 
Ser1345) under energy starvation condition and inhibits mTORC1 complex and 
mTOR signaling [95]. TSC2 is a GTPase-activating protein (GAP) which inhibits  
mTOR through inhibition of its activator Rheb, a small Ras family GTPase [96]. 
TSC2 forms a stable heterodimeric complex with TSC1, which prevents its 
ubiquitin-mediated degradation and stabilizes its intracellular expression levels 
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[97]. In contrast to stress-induced activation of TSC1:TSC2 complex, various 
growth factors and cytokines inhibit the complex by inhibitory phosphorylation of 
TSC2 through different kinases including PI3K/PKB (also known as AKT), 
resulting in dissociation of the TSC1:TSC2 complex, followed by its 
degradation. Moreover, AKT was proved to be a negative regulator of AMPK. 
AKT activates mTOR through full inhibition of TSC2 and by inhibition of AMPK-
mediated activating phosphorylation of TSC2 [98]. Finally, the critical mTOR 
binding partner raptor (regulatory-associated protein of mTOR) was shown to 
be a direct substrate of phosphorylation by AMPK, a crucial step required for 
suppression of mTORC1 activity by energy stress [99]. 
 
5.2 mTOR 
 
mTOR (mammalian target of rapamycin) is a highly conserved serine/threonine 
kinase, nutrient-responsive regulator of cell growth and proliferation found in all 
eukaryotes, active under nutrient-rich conditions in response to glucose, amino 
acids and growth factors [100]. mTOR is found in two biochemically and 
functionally distinct signaling complexes: mTORC1 and mTORC2 complex. 
mTORC1 is nutrient-sensitive, acutely inhibited by the drug rapamycin, and 
functions as a master regulator of cell growth, angiogenesis, and metabolism. 
Specifically, this complex is regulated by sensing intracellular as well as 
extracellular stimuli, such as stress, nutrients, energy, oxygen levels and growth 
factors. In contrast, mTORC2 is less sensitive to nutrients but more sensitive to 
growth factors, interacts with RICTOR (rapamycin-insensitive companion of 
mTOR) and controls actin cytoskeleton [101].  
Rheb (Ras homologue enriched in brain) GTPase promotes mTORC1 activity 
when GTP-bound [102]. The mTORC1 complex consists of mTOR, mLST8/Gbl 
(mammalian lethal with SEC13 protein 8), raptor (regulatory-associated protein 
of mTOR) and the recently identified PRAS40 and DEPTOR [103]. Raptor acts 
as a scaffold to recruit downstream substrates such as the eukaryotic 
translation initiation factor 4E binding protein 1 (4EBP1) and p70 ribosomal S6 
kinase (p70S6K), to the mTORC1 complex.  
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Upon activation, the mTORC1 controls cell growth by regulating protein 
translation and cell metabolism through directly phosphorylating and activating 
p70S6K and through the inhibition of the translation inhibitor 4EBP1 [104]. 
Phosphorylated 4EBP1 is released from eukaryotic translation initiation factor 
4E (EIF4E), which is now free to join the eukaryotic translation initiation factor 
4G (EIF4G) and the eukaryotic translation initiation factor 4A (EIF4A) and start 
cap-dependent protein translation through binding to the 5' cap of mRNAs. 
Recently, it has been shown that mTORC1 directly phosphorylates the 
phosphoprotein MAF1, a key repressor of RNA polymerase III transcription 
after various stresses, leading to increased protein translation [105]. In addition, 
activated mTORC1 stimulates angiogenesis by inducing hypoxia-inducible 
factor 1a (HIF1a), which increases the expression of vascular endothelial 
growth factor (VEGF) [106]. Furthermore, mTORC1 activity inhibits autophagy 
via phosphorylation of ATG13 and ULK1/2 ([107], Figure 6). 
NAMPT over-expression reduced mTOR activation during cerebral ischemia 
where NAMPT promoted neuronal survival through inducing autophagy via 
regulating TSC2-mTOR-p70S6K signaling pathway in a SIRT1-dependent 
manner [108].  
Deregulation of the mTOR signaling pathway is one of the most commonly 
observed pathological alterations in human cancers. The phosphatidylinositol 3-
kinase (PI3K)/AKT kinase cascade signalling pathway plays a crucial role in 
regulating mTOR and has a cardinal role in cancer cell metabolism promoting 
cell proliferation, growth and survival. To counteract PI3K, cells contain 
phosphatase and tensin homologue deleted on chromosome 10 (PTEN). 
Somatic inactivating mutations in the tumor suppressor gene PTEN are 
frequently detected in glioblastomas, melanomas, and in prostate and 
endometrial cancers. Aberrant activation of the PI3K/AKT signaling by genetic 
alterations in PTEN or AKT result in hyper-activation of mTORC1 signaling and 
are associated with different types of human cancer [109]. 
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Figure 6. mTORC1 signaling  
The mTOR complex 1 (mTORC1), consisting of mTOR, raptor and mLST8, controls cell growth 
mainly through the regulation of protein translation. Activated TSC1:TSC2 complex induces 
conversion of active GTP-bound Rheb to inactive GDP-bound Rheb. Active Rheb promotes 
mTORC1 activation, controlling protein translation by activating the ribosomal protein S6 kinase 
(S6K), inhibiting inhibition eukaryotic initiation factor 4E binding proteins (4E-BP) and the RNA 
polymerase III (PolIII) repressor MAF1. In addition, mTORC1 induces angiogenesis through 
induction of hypoxia-inducible factor 1a (HIF1a)-dependent expression of vascular endothelial 
growth factor (VEGF), and inhibits autophagy by phosphorylating ATG13 and ULK1/2. In 
addition to TSC-dependent regulation of mTORC1 activity, the complex is directly activated by 
sufficient levels of energy (ATP) and nutrients (amino acids), as well as through 
phosphorylation of mTOR by PKB/AKT and of raptor by AMPK [82]. 
 
6. Cell fate determinants in response to stress: phospo-EIF2A and the 
UPR 
 
The endoplasmic reticulum (ER) is a multi-functional organelle responsible for 
many fundamental cellular processes, including calcium storage, lipid 
biosynthesis and folding and assembly of proteins targeted to a transmembrane 
or secretory pathway [110]. Different endogenous and exogenous stimuli, such 
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as pharmacological treatments, viral infections, metabolic demands but also 
differentiation, may impair, directly or indirectly, the ER functions, possibly 
resulting in an accumulation of misfolded proteins inside the ER lumen [111]. 
This might lead to presenting wrongly folded proteins on the cell membrane, 
affecting the ability of the cell to interact with the extracellular environment and 
possibly contributing to the insurgence of pathological conditions such as 
cancer, diabetes and neurodegenerative disorders [112]. In response to this 
accumulation and in the attempt to maintain cellular homeostasis, the ER 
activates three different pathways, giving rise to the Unfolded Protein Response 
(UPR). The first two phases of the counteract are rectifying and consist in 
decreasing the protein load entering the ER, by globally lowering protein 
synthesis and translocation into the ER, and strengthening the ER-protein 
folding machinery, by up-regulating the expression of specific UPR target 
genes. If these two actions do not succeed in reestablishing cellular 
homeostasis, a third mechanism, namely cell death, is activated [113].  
The UPR is triggered by three transmembrane receptors, PKR-like ER kinase 
(PERK), inositol-requiring enzyme 1 (IRE1), and activating transcription factor 6 
(ATF6), which are all activated by GRP78/BiP, an anti-apoptotic ER chaperone 
capable of sensing changes in the concentration of unfolded proteins in the ER 
lumen [114]. GRP78 is physiologically present at high concentrations inside the 
ER and is found both soluble and constitutively bound to the luminal domain of 
UPR receptors. As chaperone, it temporary binds all the proteins entering the 
ER, promoting the correct folding and remaining attached to misfolded proteins. 
When the density of unfolded proteins exceeds the ER chaperone and 
degradation capacity, GRP78 detaches from the UPR receptors, triggering their 
activation. Beyond acting as a stress sensor and a chaperone, GRP78 
regulates calcium homeostasis, translocates newly synthesized polypeptides 
across the ER membrane and targets misfolded proteins for ER-associated 
degradation (ERAD) [115], [116]. Among the effects induced by the activation of 
the UPR, inhibition of general translation is the most conditioning for the cell. It 
is achieved through the dissociation of GRP78 from the luminal domain of 
PERK, which promotes its oligomerization and autophosphorylation on the 
cytosolic domain.  
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The main effect of the activated form of PERK is the phosphorylation of the α-
subunit of eukaryotic translation initiation factor-2 (EIF2A) at Ser51. EIF-2, a 
translation initiation factor coupled with GTP in the active form, is involved in 
the ribosomal selection of the start codon and delivers the starting methyonil-
tRNA to the initiating translation machinery. After exerting its function, the GTP 
complexed-EIF-2 is hydrolized to the inactive EIF-2-GDP form and is released 
from the ribosomal complex. The restoration of the active GTP-bound EIF-2 is 
performed by the pentameric guanine nucleotide exchange factor EIF2B. 
Phosphorylation of the α subunit of EIF-2 at Ser51 leads to the inhibition of EIF-
2B activity, reducing guanine nucleotide exchange. This decrease in active form 
of EIF2 results in a global decrease of translation initiation, consequently 
lowering the amount of newly synthesized proteins, many of which would be 
targeted to the ER for secretion and post translational modification [117]. 
However, EIF2A phosphorylation also promotes the expression of specific 
genes of which mRNAs are inefficiently processed in absence of stress, like, for 
example, the transcriptional regulator Activating Transcription Factor 4 (ATF4) 
enhancing the translation of select mRNAs encoding for proteins that control 
cell adaptation to stress. Increased levels of ATF4 induce a cascade of 
transcriptional factors including CHOP/GADD153, contributing to the 
expression of stress-related genes, important for cellular metabolism, the redox 
status of the cell and apoptosis ([118], Figure 7).  
Affecting cell metabolism so deeply, the phosphorylation of EIF2A, and 
consequently its tandem interaction with ATF4, does not occur only in case of 
ER stress but is common to responses to different types of stress, such as for 
example nutrient deprivation and viral infections [111]. On the other hand, 
phenomena leading to an inhibition of phosphorylation of EIF2A may lead to 
pathological conditions, as it has been documented in different forms of cancer. 
In recent years, it has become evident that phosphorylation of the alpha subunit 
of EIF2 at serine 51(EIF2A-S51P) is an important determinant of cell fate in 
response to stress playing a role in the balance between cell survival and 
death. 
A family of protein kinases phosphorylate EIF2A in response to different cellular 
stress conditions. Besides PERK, the family includes the double-stranded RNA 
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(ds-RNA)-dependent kinase (PKR), the heme-regulated inhibitor kinase (HRI) 
and the general control non-derepressible-2 (GCN2), which is activated by 
uncharged tRNA caused by amino acid deficiency. Short-term induction of p-
EIF2A has been associated with cell survival whereas long-term induction with 
cell death [119]–[121]. 
 
 
 
Figure 7. The unfolded protein response  
Cellular stress conditions disrupt the proper function of the ER and initiates cell stress 
response. UPR is characterized by the activation of three ER transmembrane effector proteins: 
PKR-like ER kinase (PERK), inositol requiring enzyme 1 (IRE1) and the activating transcription 
factor-6 (ATF6). PERK phosphorylates eIF2a attenuating mRNA translation, but inducing the 
transcription factors ATF4 and CHOP, which will regulate the expression of genes involved in 
the restoration of the homeostasis and GADD34, an inhibitor of eIF2a, attenuating the 
response. PERK also phosphorylates and activates the transcription factor NRF2, which 
induces antioxidant responses. This eIF2a/ATF4/CHOP response is also known as the 
integrated stress response (ISR). IRE1 is a kinase and an endonuclease that regulates the 
splicing of the transcription factor XBP1, resulting in the transcription of genes involved in 
restoring the ER folding capacity. ATF6 is translocated into the Golgi where it is cleaved to 
release the transcription factor that regulates chaperones expression and ER-associated 
degradation (ERAD) genes. ATF4, activating transcription factor 4. CHOP, C/EBP-homologous 
protein. GADD34, protein phosphatase 1 regulatory subunit 15A. NRF2, nuclear factor, 
erythroid 2 like 2. XBP1, X box-binding protein 1 [122].  
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AIM of THE THESIS 
 
My PhD work was funded by the Italian Ministry of Health grant GR-2008-
1135635 coordinated by Dr. Alessio Nencioni (University of Genoa) and my 
research was in the frame of a project aimed at the preclinical evaluation of the 
NAMPT inhibitor FK866 for the treatment of autoimmunity and lymphoblastic 
leukemia. 
Specific task of the laboratory of Genomic Screening was to perform 
experiments in T-ALL cell lines (mainly Jurkat cells) and primary T-ALL cells, to 
assess the effect of FK866 at metabolic and molecular level. Application of 
gene expression analysis using microarrays aimed at determining changes of 
key pathways that are influenced by FK866-induced NAD+ depletion and 
identifying the multi-level gene expression regulation exerted by the drug. 
We were interested to find differentially expressed genes, in the early phase of 
cell response to FK866, which can explain the mechanism of cell death induced 
by the compound.  
Our ultimate aim was to define the mechanisms underlying the FK866 
resistance phenotype. 
Therefore, the aims of my thesis were (1) to investigate the molecular 
mechanisms of FK866, a specific and potent NAMPT inhibitor, in Jurkat cells; 
(2) to address the impact of a pharmacological NAMPT inhibition resulting in 
intracellular NAD+ reduction on the energy metabolism and to investigate the 
pathways activated in response to the insult; and (3) to investigate drug 
resistance by isolating Jurkat-derived resistant cells and by characterization of 
the mechanism of resistance. 
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METHODS 
 
The complete description of the Materials and Methods can be found in the 
manuscripts (see page 88 and 102). The Methods section reported here 
includes methods used in unpublished experiments or additional details for 
specific protocols. 
 
Cell lines 
 
Jurkat human T acute lymphoblastic leukemia (T-ALL) cell line was purchased 
from the InterLab Cell Line Collection bank (ICLC HTL01002, Genoa, Italy).  
MEC.1 human chronic B cell leukemia and OCI/AML3 human acute myeloid 
leukemia cell lines were purchased from DSMZ (ACC 497 and ACC 582). 
Human lung carcinoma A594 (CCL-185) and H460 (HTB-177) cells were 
purchased from ATCC. These cells were transduced with retroviral vectors 
encoding either LKB1 cDNA (pBABE-LKB1) or the pBABE control vector. 
Cell lines were grown in complete RPMI 1640 (Gibco Life Technologies) 
supplemented with 10% fetal bovine serum (FBS, Lonza), 2 mM L-glutamine, 
100 U/ml penicillin-streptomycin (Lonza) at 37° C under 5% CO2. 
 
Determination of NAD+/NADH and ATP levels 
 
To determine the content of NAD+/NADH cells were harvested after 48 h of 
treatment and analyzed with NAD+/NADH Quantification Kit (BioVision) 
according to the manufacturer’s protocol. Samples were measured using a 
Tecan Infinite 200 Reader at OD450 nm. 
To evaluate the content of intracellular ATP after the treatment, Cell titer Glo 
Luminescent Cell Viability Assay (Promega) was used following the 
manufacturer’s instructions. Luminescence was measured after 48 h of drug 
treatment. NAD+/NADH and ATP values were normalized to viable cells 
(Trypan Blue Stain, Lonza).  
 
Annexin V/7AAD and PI Flow Cytometry Analysis 
 
In order to calculate dose-response curve, FITC Annexin V Apoptosis Detection 
Kit I and 7AAD Staining Solution (BD Pharmingen) were used to stain Jurkat 
cells treated with FK866 for 48 h, 72 h and 120 h (drug concentration range: 0.1 
-100 nM), according to manufacturer’s protocol. EC50 values were determined 
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by nonlinear regression analysis of viable cells (Prism software v 5.01, 
GraphPad) by comparison with Mock condition (DMSO). To evaluate cell death, 
Propidium Iodide Staining Solution from BD Pharmingen was used and 
analyzed by FACS. 
 
Click-iT Labeling Kits 
 
Click-iT RNA Alexa Fluor 488 Imaging Kit (Invitrogen) was used to quantify by 
FACS analysis the level of global RNA synthesis. Click-iT RNA assays employ 
an alkyne-modified nucleoside, EU (5-ethynyl uridine), that is fed to cells and 
incorporated into nascent RNA. Detection utilizes the chemoselective ligation or 
“click" reaction between an azide and an alkyne, in which the modified RNA is 
detected with a corresponding azide-containig dye. 
 3*10^6 Jurkat cells were treated for 45 h with FK866 (or DMSO only in the 
Mock condition) and incubated for 3 h with 1X EU working solution without 
removing the drug-containing media. EU detection by FITC signal was 
performed following manufacturer’s protocol after cell fixation and 
permeabilization. 7AAD Staining Solution (0.25 µg/sample) allowed the 
exclusion of nonviable cells in flow cytometric assay. 3 h of treatment with 
Actinomycin D (Sigma) 5 µM was used as positive control of transcriptional 
inhibition.  
Click-iT AHA Alexa Fluor 488 Protein Synthesis HCS Assay employs an amino 
acid analog of methionine containing an azido moiety (AHA) that is incorporated 
into proteins during active protein synthesis detected with an AHA Alexa Fluor 
488 alkyne. Cells (3*10^6 cells) were treated for 45 h with FK866, centrifuged 
and co-incubated for 3 h with Click-iT AHA diluted in L-methionine-free medium 
(RPMI Medium 1640, Sigma) for a final 50 μM concentration and the drug 
(DMSO for Mock condition). After fixation and permeabilization, AHA was 
detected by FACS analysis according to manufacturer’s instructions. For gating, 
cells were treated for 3 h with cycloheximide 350 µM (Sigma) in order to block 
translation. 
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Western blotting and sub-cellular fractionation 
 
After the treatment cells were washed once in PBS and lysed in RIPA lysis 
buffer (Tris 50 mM pH 7.4, NaCl 150 mM, Igepal CA-630 1%, EDTA 1 mM, Na 
deoxycholate 0.5%, SDS 0.1%) containing Protease Inhibitor Cocktail (Sigma-
Aldrich) for 5 min on ice. After sonication (2 pulses of 7 sec, amplitude 80) and 
centrifugation at 4°C for 30 min at maximum speed, the supernatants were 
diluted in SDS-PAGE protein sample buffer and boiled for 5 min. Equal 
concentration of proteins (quantified with Bradford Reagent, Sigma) was 
separated on SDS–polyacrylamide gel electrophoresis (SDS-PAGE) and 
processed following standard procedures. The PVDF membrane (Immobilon-P 
Membrane, Millipore) signals were detected by chemiluminescence using ECL 
Western Blotting Detection Reagents (GE Healthcare).  
For sub-cellular fractionation, cells were lysed in cold cytosolic lysis buffer (10 
mM HEPES pH 7.0, 10 mM KCl, 1 mM EDTA, 0.5% NP-40, 1 mM DTT, and 
Protease inhibitor cocktail). The supernatant containing cytosolic fraction was 
collected by centrifugation at 3000 x g for 5 minutes at 4°C. Nuclear pellets 
were then re-suspended in cold nuclear lysis buffer (10 mM HEPES pH 7.0, 
400 mM NaCl, 1 mM EDTA, 25% Glycerol, 1 mM DTT, and Protease inhibitor 
cocktail). The nuclear extract was harvested by centrifugation at 12000 x g for 
15 minutes at 4°C. Then, equal quantities of proteins were separated by 
electrophoresis on SDS-page gels. Tubulin and nucleolin served as the loading 
control for the cytosolic and nuclear fraction, respectively. 
Desitometric analysis were performed by using the ImageJ software. 
 
Polysomal RNA extraction  
 
For polysomal RNA extraction 30*10^6 Jurkat cells/ml were seeded and treated 
for 48 h. Cells were harvested and treated with cycloheximide (Sigma) for 5 min 
at 37°C in order to stabilize the polysomes (final concentration 100 μg/ml). After 
washing cells twice with cold phosphate buffer saline (PBS + cycloheximide 10 
μg/ml), 1 ml of lysis buffer was added [10 mM NaCl, 10 mM MgCl2, 10 mM 
Tris–HCl pH 7.5, 1% Triton X-100, 1% sodium deoxycholate, 0.2 U/μl RNase 
inhibitor (Fermentas), cycloheximide 10 μg/ml and 1 mM dithiothreitol]. Lysates 
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were transferred to Eppendorf tubes, incubated on ice for 2 min and centrifuged 
for 5 min at 12000 g at 4°C. The supernatant was loaded directly onto a 15-
50% linear sucrose gradient containing 30 mM Tris-HCl pH 7.5, 100 mM NaCl, 
10 mM MgCl2, and centrifuged at 4°C in a SW41 rotor for 110 min at 180000 g. 
Subpolysomal and polysomal fractions were collected using a Teledine ISCO 
gradient maker with automated fraction collector monitoring the absorbance at 
254nm. For RNA extraction, the fractions were treated with proteinase K (100 
μg/ml) in 1% SDS for 3 h at 37°C. After phenol–chloroform extraction and 
isopropanol precipitation, the recovered RNA pellets were resuspended in 30 μl 
of RNase-free water. RNA quality was assessed by the Agilent 2100 
Bioanalyzer platform. 
RNAs extracted from fractions were pooled for microarray analysis 
(subpolysomal RNA: fraction 2-7; polysomal RNA: fraction 8-11; total: fraction 
2-11). 
 
Microarray analyses 
 
Total, polysomal and subpolysomal RNA were hybridized in quadruplicate on 
the Agilent Human GE 4x44K v2 Microarray (G2519F-026652) following the 
manufacturer’s protocol. Hybridized microarray slides were scanned with an 
Agilent DNA Microarray Scanner G2505C. μm resolution with the 
manufacturer’s software (Agilent ScanControl 8.1.3). The scanned TIFF images 
were analyzed numerically and background corrected using the Agilent Feature 
Extraction Software version 10.7.7.1 according to the Agilent standard protocol 
GE1_107_Sep09. 
The output of Feature Extraction was analyzed with the R software environment 
for statistical computing (http://www.r-project.org/) and the Bioconductor library 
of biostatistical packages (http://www.bioconductor.org/). Low signal Agilent 
probes, distinguished by a repeated “not detected” flag across the majority of 
the arrays in every condition, were filtered out from the analysis. Signal 
intensities across arrays were normalized with the quantile normalization 
algorithm.  
Polysomal RNA and total RNA DEGs were determined adopting a double 
threshold based on 1) the magnitude of the change (log2 fold change >1 and <-
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1 for induced and repressed genes, respectively); 2) the statistical significance 
of the change, measured with a moderated t-test (p-value <0.05) implemented 
in the Bioconductor Limma package. 
Translational efficiency (TE) was calculated as the ratio between polysomal and 
sub-polysomal  signals. Genes  with  significant  differences  in  TE  after  the  
treatment with FK866 were selected adopting a double threshold based on 1) 
the magnitude of the change in TE (log2 change of TE >1 and <-1 for genes 
with increased and decreased TE, respectively); 2) the statistical significance of 
the polysomal fold change, measured with a moderated t-test (p-value <0.05) 
implemented in the Bioconductor Limma package. 
Translatome DEGs were analyzed with the Ingenuity Pathway Analysis (IPA), 
using the “Canonical Pathways” analysis (http://www.ingenuity.com/). 
Enrichment was tested with the Fisher exact test. The significance of over-
representation is determined at a 0.05 p-value threshold. 
Total RNA extracted from resistant cells was hybridized in quadruplicate on the 
Agilent Human GE 4x44K v2 Microarray (G2519F-026652) and compared with 
total RNA from parental cells. After quantile normalization and removal of low 
signals, differentially expressed genes were selected according to a double 
threshold on log2 FC (absolute value > 0.75) and moderated t-test p-value 
(<0.05) calculated with the Limma package. The DAVID resource was used for 
functional annotation enrichment analysis of the resulting lists of DEGs, using 
annotations from Gene Ontology (http://www.thegeneontology.org), KEGG 
(http://www.genome.jp/kegg/), PFAM (http://pfam.sanger.ac.uk/). The 
significance of over-representation was determined using a p-value threshold of 
0.05. Gene Ontology terms with more than 500 associated genes were filtered 
out for being too general. 
  
Real-time PCR 
 
For Real-time PCR, 1μg of total, polysomal and subpolysomal RNA was 
DNAse-treated and cDNA was synthesized using RevertAid First Strand cDNA 
Synthesis Kit (Fermentas), following the manufacturer’s recommendation. Real-
time  PCR  reactions  were carried  out using the KAPA PROBE or SYBR FAST  
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Universal qPCR Kit on a CFX96 Real-Time PCR Detection System (BioRad). 
Relative mRNA quantification was obtained with the ΔCt method, taking into 
account the efficiency of cDNA synthesis by the quantification of the ACTB 
housekeeping gene from the same cDNA. TaqMan probes for Gene Expression 
Assays were obtained from Applied and used for quantification of NAMPT 
(Hs00237184_m1) normalized to the levels of ACTB (Hs99999903_m1).  
Primers’ sequences used for SYBR Green Real-time PCR are reported as 
follows: 
 
Gene Primer Forward Primer Reverse 
ACTB CTGGAACGGTGAAGGTGACA AGGGACTTCCTGTAACAATGCA 
HSP90AA1 CTGCTTATTTGGTTGCTGAG CCCATAGGTTCACCTGTGTCTG 
MYSM1 ACAGCCAGGAAGTGGTGAAA CCAAGGTCCAAGGAATAAGGC 
PRKAA1/AMPK ACCAAGGTGTAAGGAAAGCA ACAACCTTCCATTCATAATCCA 
STK11/LKB1 GAGCTGATGTCGGTGGGTATG CACCTTGCCGTAAGAGCCT 
BiP/Grp78 TGTTCAACCAATTATCAGCAAACTC TTCTGCTGTATCCTCTTCACCAGT 
 
Sequencing 
 
We checked for presence of mutations in the NAMPT gene by sequencing its 
coding sequence in resistant and parental cells. NAMPT gene was amplified by 
using specific primers designed on the coding region including the ATG and the 
stop codon (highlighted in bold in the primer sequence). Sequencing was 
performed by an external sequencing service (BMR-Genomics, Padova, Italy).  
To sequence the whole coding region, an additional primer pair was designed 
(NAMPT-seq). 
 
Gene Primer Forward Primer Reverse 
NAMPT AGATGAATCCTGCGGCAGAA CCTAATGATGTGCTGCTTCC 
NAMPT-seq TTATGGAACGAAAGATCCTG CAAAAGCATCTTTTTCATGGTC 
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Lentiviral transductions 
 
Lentiviral vector stocks were produced by co-transfection in 293T cells (ATCC 
CRL-11268) of the packaging plasmid pCMV-deltaR8.91, the VSV-envelope 
coding plasmid pMD2.G (kind gift of Didier Trono, EPFL, Lausanne) and the 
transfer vectors. 48 h post transfection vector containing supernatants were 
collected and viral titers were determined using a qPCR based RT-assay [123]. 
Half a million Jurkat cells were transduced using a total of 2-4 RTUs of viral 
vectors. To maximize the transduction efficiency cells were centrifuged at 25°C 
for 2 h at 1600 g in the presence of vectors and then incubated overnight at 
37°C before changing medium. After a recovery period of approximately 48 h 
cells were seeded and treated as needed. 
 
Drug sensitivity and resistance testing (DSRT) 
 
The DSRT platform is based on an oncology compound collection that covers 
the active substances from the majority of U.S. Food and Drug 
Administration/European Medicines Agency (FDA/EMA)–approved anticancer 
drugs (n = 123), as well as emerging investigational and preclinical compounds 
(n = 64) covering a wide range of molecular targets [124]. The compounds were 
obtained from the National Cancer Institute Drug Testing Program (NCI DTP) 
and commercial chemical vendors: Active Biochem, Axon Medchem, Cayman 
Chemical Company, ChemieTek, Enzo Life Sciences, LC Laboratories, Santa 
Cruz Biotechnology, Selleck, Sequoia Research Products, Sigma-Aldrich, and 
Tocris Biosciences. 
Compounds were dissolved in 100% dimethylsulfoxide (DMSO) and dispensed 
on tissue culture–treated 384-well plates, plated in five different concentrations 
in 10-fold dilutions covering a 10000-fold concentration range (e.g., 1–10000 
nmol/L), using an acoustic liquid handling device (Echo 550 from Labcyte Inc.). 
The predrugged plates were kept in pressurized StoragePods (Roylan 
Developments Ltd.) under inert nitrogen gas until needed. During the screening, 
compounds were initially dissolved with 5 μL of medium while shaking for 30 
minutes. Twenty microliters of single-cell suspension (4000 cells) were then 
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transferred to each well using a Multi Drop Combi (Thermo Scientific) peristaltic 
dispenser. After 72 h cell viability was measured using CellTiter-Glo 
luminescent assay (Promega) with a PHERAstar FS (BMG Labtech) plate 
reader. The data were normalized to negative control (DMSO only) and positive 
control wells (containing 100 μmol/L benzethonium chloride, effectively killing all 
cells). For each drug tested a dose-response curve was generated. Drug 
responses were compared across the samples by calculation of the Drug 
sensitivity scoring (DSS), using the method described by Yadav B et al. [125]. 
 
Drug combination analysis 
 
Combination index (CI) was calculated using CompuSyn software V1.0 by the 
method of Chou and Talalay [126]. Strong synergistic effect has been 
considered if CI <0.1. 
 
Statistical analysis 
 
Experiments were performed in biological triplicates. T-test was used to 
calculate final p-values, without assuming variances to be equal (Welch's t-
test). P-value <0.05 was considered statistically significant. 
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RESULTS 
 
1. Investigating the mechanism of action of FK866 
 
This section presents an extended summary of the results included in the 
accompanying manuscripts. For clarity some of the Figures of the manuscripts 
are also reproduced here. Unpublished data supporting the results will be 
included. 
Results in the thesis body reflect my personal contribution to the work.  
With respect to the first paper (page 88, Zucal C et al.), I was not involved in 
microarray analysis (performed by TT) and in preparing pLKO.1 transfer vectors 
for LKB1 silencing by cloning annealed oligos coding for shRNAs (AC). VDA 
was involved in the polysomal RNA extraction and in flow-cytometric analysis. I 
did all the other experiments described here and in the paper. 
With respect to the second one (page 102, Cagnetta A et al), this section 
presents my personal contribution in the results included in the accompanying 
manuscript. Specifically, I was involved in the investigation of ER-stress related 
markers in leukemia cell lines (MEC.1 and OCI/AML3). 
 
 
The primary aim of my thesis was to investigate the molecular mechanisms of 
the specific NAMPT inhibitor FK866 in Jurkat cells, addressing the impact of a 
pharmacological inhibition resulting in intracellular NAD+ reduction on the 
energy metabolism and investigating the pathways activated in response to the 
insult. 
In order to characterize the effects of FK866 on Jurkat cells in the early phases 
of cell response to stress, a pre-toxic dose of the drug was determined.  
Cell viability was quantified through Annexin V/7AAD staining after 48, 72 and 
120 hours of FK866 treatment, resulting in a complete cell death in the latter 
case. As shown in Figure 8a, the drug did not highly impact on cell viability at 
48 hours, as both the Annexin V and 7AAD positive populations at this time 
point were low for the tested doses. Calculated EC50 at 48 hours was 5 nM, 
dose that was afterwards used in all the performed experiments. In addition, 
100 nM concentration of FK866 was chosen since, failing to substantially 
compromise Jurkat cell viability at 48 hours but providing a stronger NAMPT 
inhibition, allowed us to study cell signaling in the absence of an ongoing 
apoptotic response (Figure 8a). The absence of caspase 3 and 7 activation 
further confirmed that apoptosis was not started yet (Figure 8b). 
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On the contrary, the metabolic effect of NAMPT inhibition, namely NAD+ and 
ATP intracellular decrease, was clearly present with the selected doses at 48 
hours (Figure 8c). 
 
 
Figure 8. FK866 induces cell death and metabolic stress in Jurkat cells 
A, Flow-cytometric quantification of cell viability at 48, 72 and 120 h performed with AnnexinV 
and 7AAD staining. Mock, 5 nM FK866 and 100 nM FK866 are shown as representative 
samples (left panel). B, Caspase 3/7 activity was measured in Jurkat cells treated with FK866 
for 48 h. Alternatively, cells were exposed to 5 μM of Camptothecin for 4 h as a positive control. 
C, Jurkat cells were treated with FK866 for 48 h. Thereafter, intracellular NAD
+
(H) and ATP 
levels were evaluated in comparison with control cells. RLUs were normalized to number of 
viable cells. B-C mean±SD of three experiments, * and # indicates p-value <0.05. 
In order to better characterize the global effects of NAD+ depletion inside the 
cell, we evaluated the rate of transcription and translation upon treatment. We 
applied a technique based on Click-it reaction, which allows quantification of the 
ongoing RNA and protein synthesis. Regarding the first, the percentage of 
incorporation of the uridine-analog EU in the treated samples did not reveal a 
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highly compromised level of transcription (Figure 9a). In contrast, the 
translational rate, detected by AHA (L-azidohomoalaine), was strongly affected 
by FK866 (Figure 9b).  
 
 
 
Figure 9. Macromolecular synthesis is inhibited by FK866 
A, RNA synthesis was determined by monitoring EU incorporation with Click-it chemistry after 
48 h of treatment with FK866 or 5 μM Actinomycin D, an RNA synthesis blocking agent (3 h). 
The histogram quantifies the dose-dependent transcription inhibition induced by FK866 in the 
viable cell population. B, Protein synthesis was monitored by AHA incorporation after 48 h of 
treatment with FK866 or 350 μM Cycloheximide, a protein synthesis inhibitor (3 h). The 
histogram quantifies FK866 induced protein synthesis arrest in the viable cell population. 
 
 
To assess if this translational inhibition was specific for defined classes of 
genes underlying the cell response to FK866, we performed polysomal mRNA 
profiles and gene expression analyses on total mRNA levels and on polysome-
associated mRNAs. The analysis allowed a ‘bidimensional’ transcriptomic 
approach, namely a genome-wide measure not only of the level of cellular 
mRNAs but also of the degree of their engagement in the translation machinery 
at polysomes.   
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We observed a marked but not complete depletion of the polysomal mRNAs 
fractions with respect to the sub-polysomal fractions (representative of mRNPs 
and mRNAs bound to ribosomal subunits or un-translating monosomes) in 
Jurkat cells after a 48 hours treatment with 5 nM of FK866, highlighting the 
interference with the mRNA translation process (Figure 10a). 
We used single color microarray hybridization to compare total, sub-polysomal 
and polysomal mRNAs. After data preprocessing, normalization and quality 
check (Supplementary Table S1), 569 differentially expressed genes (DEGs) 
were detected in total mRNA and 1267 in polysomal mRNA fractions 
(Supplementary Table S2). After comparison of the two lists of DEGs, the 
expression of 338 genes showed to change in the same direction amongst the 
two pools (homodirectional DEGs), reflecting a significant concordance 
between total and polysomal RNA expression (Spearman correlation of 0.76). 
Noticeably, no DEGs showed opposite regulation and 918 DEGs (73% of all 
translatome) presented significant changes only at the polysomal level, 
whereas 227 DEGs (40% of transcriptome) changed significantly only in total 
RNA (Figure 10b). 
Therefore, we concluded that FK866 had a strong effect in shifting specific 
mRNAs into polysomes (translatome level) in order to cope with the NAD+ 
shortage-induced metabolic stress.  
Successively, we measured the Translational Efficiency (TE) of each gene, 
defined as the ratio between polysomal and sub-polysomal RNA signals.This 
parameter allows to exclude genes whose expression in the polysome-
associated mRNA pool relies on a very strong (or very weak) transcription and 
to select genes reflecting a proper functional relocalization upon treatment 
[127]. Distribution of genes with significant differences in TE after treatment with 
FK866 is shown in Figure 10c. Among candidate genes positively regulated at 
the translational level in response to FK866 (Supplementary Table S3), 
MYSM1, HSP90AA1, and PRKAA1 (AMPK) were also validated by qRT-PCR 
and confirmed to be significantly up-regulated in the polysomal mRNA fraction 
(Figure 10d).  
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Figure 10. Multi-level RNA regulation in response to FK866 treatment 
A, Representative profile of RNA fractionation of Jurkat cells treated with DMSO or 5 nM FK866 
for 48 h, obtained after centrifugation of cytoplasmic lysates on sucrose gradient. Fractions 2 to 
7 correspond to sub-polysomal RNA, while fractions 8 through 11 to polysomal RNA. Polysomal 
profiling was performed four times. Total, sub-polysomal, and polysomal mRNAs extracted from 
5 nM FK866-treated and control Jurkat cells were subjected to single color microarray 
hybridization. B, Scatterplot showing genome-wide transcriptional and translational response to 
FK866 treatment. Transcriptome (total) and translatome (polysomal) variations are mildly 
correlated (0.5 Spearman value), DEGs are more correlated (0.76 Spearman value). Different 
classes of DEGs are highlighted according to the legend. C, Scatterplot showing the genome-
wide subpolysomal and polysomal response to FK866 treatment. Genes with statistically 
significant variations in translational efficiency (TE), characterized by an increased or 
decreased access to the translating compartment of the cells, are highlighted. D, qPCR 
validation for three candidate genes with significant increases in translational efficiency. 
Statistical significance was calculated with t-test (* indicates p-value <0.05). 
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To find key mRNA targets whose translation is essential and strongly promoted 
to survive to FK866-induced stress, we performed an over-representation 
analysis of the signaling pathways of the entire set of genes regulated at 
polysomal level by using Ingenuity Pathway Analysis software (IPA). 
 
 
Figure 11. IPA of the transaltome following FK866 treatment 
Significantly enriched pathways among translatome (polysomal) DEGs, detected by Ingenuity 
“Classical Pathway Analysis”. Bars display the percentage of down-regulated and up-regulated 
DEGs contributing to the enrichment of each pathway. 
 
The Glucocorticoid Receptor (GR) Signaling pathway was the top ranked theme 
and the significant enrichment (p=1.42E-06) was caused by the over-
representation of 34 differentially regulated genes out of the 277 belonging to 
this ontology. Analyzing the components of the GR Signaling pathway, we 
found different factors with regulated polysomal loading that might be possible 
drug targets. Among them, we found heat shock protein HSP90, signaling 
kinases as JAKs and MAPKs, the AMP dependent protein kinase PRKAA1 
(AMPK) and, interestingly, the NR3C1 (Glucocorticoid Receptor) gene. 
In the first ten significantly over-represented pathways, many themes 
suggested a modulation of the ubiquitination process (druggable protein gene 
PSMD1) and the production of reactive oxygen species by the interferon 
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gamma signaling pathway (druggable protein gene IFNGR1). Notably, the 
modulation of many eukaryotic initiation factors (EIF2A, EIF2B, EIF3C, EIF4A2, 
EIF4G2, EIF4G3) strongly suggested a role for pathways related to the 
translation process and connected to the regulation of EIF4E and p70S6K 
signaling. Finally, the AMPK signaling was identified as a top hit, driven by the 
presence of the HSP90 and PRKAA1 (AMPK) genes (Figure 11 and 
Supplementary Table S4). 
Taken all the results together, since global translation was observed to be 
deeply inhibited in the “Click-it” experiment and members of translational control 
pathways were found to be affected in the IPA analysis, we focused on the 
investigation of possible impact of FK866 on master regulators of translation. In 
particular, we mainly explored factors involved in the initiation phase of cap-
dependent translation, which is considered the limiting step of translation strictly 
regulated in the cell. Multiple associated proteins, each designated as EIFs 
(eukaryotic initiation factors), are required to assemble a translationally 
competent 80S ribosome, which is recruited in the cytoplasm by the 5′ cap 
structure of the mRNAs. 
Specifically, mRNAs are bound by EIF4F, consisting of the EIF4E subunit that 
binds to the cap, the helicase EIF4A, and scaffolding protein EIF4G. During 
conditions of low nutrient availability, EIF4E can be sequestered by the EIF4E-
binding protein (4EBP1), thus limiting assembly of the EIF4F complex. 
mTORC1 signaling enhances protein synthesis by phosphorylating 4EBP1, 
preventing its binding to EIF4E. 
The next step of translation involves the recruitment of a 43S preinitiation 
complex (PIC) composed of the 40S ribosomal subunit bound to EIF3, EIF1, 
EIF1A, EIF5, and the EIF2-GTP-Met-tRNAi ternary complex. Therefore, the 
initiation factor EIF2A plays an important role in the initiation phase of 
translation. Its phosphorylated form at serine 51 decreases global protein 
synthesis [128]. 
We evaluated the impact on protein translation by detecting the phosphorylation 
status of mTOR, its target 4EBP1, and EIF2A.  
In T-ALL cells, FK866 inhibited mTOR signaling resulting in de-phosphorylation 
of 4EBP1 in a dose-dependent manner. Furthermore, EIF2A was 
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phosphorylated upon treatment, indicating an impairment in the initiation phase 
of translation (Figure 12). 
 
 
Figure 12. FK866 blocks translation through mTOR/4EBP1 and EIF2A 
Jurkat cells were treated for 48 h with FK866 and levels of the indicated proteins were detected 
by immunoblotting. The panel represents one experiment out of at least three biological 
replicates. β-actin was used as loading control. 
 
AMPK is a cellular energy sensor and a metabolic checkpoint, promptly 
activated in response to energetic stress. In particular, the kinase inhibits 
energy-consuming pathways when the intracellular ATP content is low. Among 
several regulated pathways, AMPK impacts on mTOR signaling affecting 
protein metabolism. Based on the metabolic impact of FK866, resulting in NAD+ 
and ATP depletion, we investigated the possible role of AMPK in responding to 
the drug-induced stress. 
We demonstrated AMPK activation upon FK866 in Jurkat cells, by detecting the 
increase in its phosphorylated form at threonine 172 and the inhibition of its 
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target ACC (Acetyl-CoA carboxylase). Its activity was also involved in the 
response to FK866 in T-ALL patient’s derived samples. Importantly, in drug-
responsive primary cells, we reported both the activation of AMPK and the 
inhibition of EIF2A (Figure 13). 
 
 
 
Figure 13. FK866 activates AMPK 
A, Western blot analysis of the indicated proteins after 48 h treatment. One representative 
experiment out of three biological replicates. B, WB of PD T-ALL 12 as representative of T-ALL 
xenografts samples. Cells were treated with FK866 for 48 h. Histogram shows the densitometric 
analysis of p-AMPK and p-EIF2A in the three T-ALL xenografts (PD T-ALL 12, 19 and 25). 
 
In order to link the observed inhibition of protein translation with the activation of 
a cell death program related to NAD+ depletion, we evaluated the effect of 
FK866 on the BCL-2 family of apoptosis regulator proteins. In particular, we 
checked the level of expression of B-cell lymphoma 2 (BCL-2), which is 
considered an important anti-apoptotic factor and was not affected by the 
treatment. By contrast, we observed a strong down-regulation of MCL1 
(Induced myeloid leukemia cell differentiation protein). FK866 induced MCL1 
down-regulation was dependent on proteasome activation as demonstrated by 
the rescue of its expression level by co-treatment with the proteasome inhibitor 
MG132 (Figure 14). 
Previous studies have shown that inhibition of the mTOR/4EBP1 pathway lead 
to a reduction in the levels of this anti-apoptotic protein, with important 
implications for chemosensitivity in leukemia cells [129]. Moreover, stress-
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induced phosphorylation of EIF2A was reported to be both essential and 
sufficient for the translational repression of MCL1 protein [130]. Notably, down-
regulation of MCL1 through inhibition of translation has also been shown to 
occur as a consequence of AMPK activation in tumor cells [131].  
 
 
 
 
Figure 14. FK866 down-regulates MCL1  
A, WB analysis of the anti-apoptotic proteins BCL-2 and MCL1 after 48 h of FK866 treatment. 
B, WB analysis of MCL1 in Jurkat cells treated with FK866 for 48 h and with the proteasome 
inhibitor MG132 (MG) 1 μM for 24 h. MG132 was added after 24 h of FK866 treatment. A and B 
represent one experiment out of three biological replicates. 
 
Taken together, these data indicate that AMPK might play a crucial role in the 
FK866-induced inhibition of translation and in cell fate determination through 
the modulation of an important member of the BCL-2 family of anti-apoptotic 
factors.  
To verify AMPK implication in the observed protein synthesis inhibition and in 
the down-regulation of MCL1 level, we modulated its activity by using its 
inhibitor Compound C (CC). Co-treatment with FK866 and CC blocked AMPK 
activation and abolished EIF2A phosphorylation and 4EBP1 dephosphorylation. 
Therefore, interference with AMPK activation impacted on the translational 
block induced by FK866. Consequently, MCL1 level was rescued in the FK866-
treated sample in which AMPK was blocked by Compound C (Figure 15a). The 
link between AMPK and the inhibition of translation via EIF2A phosphorylation 
at serine 51 in response to FK866 treatment was further confirmed by silencing 
both the alpha1 and the alpha2 catalytic isoforms of the kinase (Figure 15b). 
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Figure 15. AMPK is involved in FK866-induced translational inhibition  
A, Jurkat cells were treated with or without FK866 at the indicated doses in presence or 
absence of 5 μM Compound C for 48 h. Thereafter, cells were lysed and protein levels were 
revealed by immunoblotting. Histogram shows the densitometric analysis of p-AMPK and p-
EIF2A. B, Cells were transduced with lentiviral particles containing scramble or shAMPK 
(targeting the α1 and the α2 subunit) and treated for 48 h with or without 5 nM FK866. WB 
analysis indicated 40% of AMPK silencing (p-value<0.05) and densitometric analysis shows the 
significant decrease of p-EIF2A in shAMPK Jurkat cells (p-value<0.03). A and B, mean and SD 
of a biological triplicate. 
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To sum up this first part of the results, FK866 was shown to be effective in 
blocking NAMPT activity in Jurkat cells and led to a decrease in NAD+ and ATP 
cellular content. The induced stress activated the energetic sensor AMPK which 
in turn blocked protein synthesis and impacted above all on the initiation factor 
EIF2A, which readily responded to the metabolic insult. 
 
 
 
Figure 16. NAMPT inhibition and genetic ablation induce translational arrest  
A, Jurkat cells were transduced with lentiviral particles expressing two NAMPT-silencing 
shRNAs (shNAMPT-1 and -2), resulting in 50% of NAMPT silencing (p<0.001). WB analysis of 
proteins compared to scramble condition together with densitometric analysis of the bands. B, 
Jurkat cells were treated for 48 h with CHS-828. The levels of total and phosporylated proteins 
were evaluated by WB. Histogram shows the densitometric analysis. A and B, mean±SD of a 
biological triplicate. (* indicates p-value <0.05). 
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The close relationship between NAD+ depletion based on blocking its 
biosynthesis from nicotinamide due to NAMPT inhibition and the 
aforementioned molecular effects was proved by genetic ablation of the 
enzyme-coding gene. In NAMPT silenced Jurkat cells we observed again the 
activation of AMPK, the inhibition of EIF2A and the decreased level of 
expression of MCL1 (Figure 16a). Further support of the link between NAMPT 
inhibition and protein synthesis arrest came from experiments with CHS-828, a 
NAMPT inhibitor structurally different from FK866. Testing pre-toxic doses of 
the drug we reported an impaired translation, highlighted by the 
phosphorylation status of 4EBP1 and EIF2A (Figure 16b). 
Thus, cells were reported to cope with the energetic stress connected to 
NAMPT inhibition and consequent NAD+ decrease by blocking energy-
consuming pathways, primarily protein synthesis. In our model, AMPK played a 
major role in tuning the molecular response. 
To test our hypothesis, we evaluated the effect on cell viability of impairing 
AMPK ability to sense metabolic fluctuations. This was performed by 
modulating the level of its upstream activator LKB1 (liver kinase B1). Jurkat 
cells were silenced for LKB1 by using two different short hairpin RNAs 
(shRNAs) expression vectors against its coding sequence. Silenced cells were 
more sensitive to FK866, proving that activation of AMPK mediated by LKB1 
was protective against the metabolic stress (Figure 17a). The reliance on 
LKB1-AMPK pathway to resist the stress was further clarified through the use of  
two LKB1-deficient lung carcinoma cell lines, A549 and H460. We assessed 
cell viability after FK866 treatment, comparing cells stably expressing LKB1 due 
to retroviral vectors with those expressing the empty vector. Cells with a 
functional LKB1 were significantly more resistant to FK866. Furthermore, only 
these cells exhibited AMPK activation and EIF2A inactivation after treatment, 
linking the molecular mechanism which leads to protein translation arrest with 
cell survival (Figure 17b). 
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Figure 17. LKB1 activates AMPK protecting cell from FK866-induced metabolic stress 
A, Jurkat cells were transduced for 72 h with shRNAs expressing the control sequence 
(scramble) or two LKB1-silencing shRNAs (shLKB1-A and –B) and then treated with FK866 for 
48 h. Viability was measured by MTT assay in comparison with Mock (DMSO) condition (left). 
Expression level of LKB1 mRNA, evaluated through qPCR in Jurkat cells after 120 h of lentiviral 
transduction (right). B, A549 and H460 cells expressing LKB1 (LKB1 WT) or an empty vector 
(pBABE) were treated with FK866 for 48 h and cell viability was evaluated by MTT assay (upper 
part). WB analysis of A549 and H460 cells treated or not (Mock) with 100 nM FK866 for 48 h 
(lower part). A and B, mean and SD of a biological triplicate (*, p-value<0.05). 
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In our model of cell response to stress, both AMPK and EIF2A play crucial roles 
in sensing metabolic alterations and readily respond to them to ensure cell 
survival. Importantly, we demonstrated for the first time that EIF2A inhibition 
was a specific hallmark of FK866, strictly related to its mechanism of action. We 
tested the effect of some traditional chemotherapeutic agents such as 
doxorubicin, dexamethasone, cisplatin and the mTOR inhibitor rapamycin on 
protein synthesis inhibition, by evaluating the phosphorylation status of EIF2A 
and 4EBP1. By comparing sub-lethal doses of the drugs, we reported that 
among all FK866 was the only compound effective on both EIF2A inhibition and 
4EBP1 activation (Figure 18a). EIF2A acted as an early master regulator of cell 
fate in response to NAMPT inhibition, as suggested by its inhibitory 
phosphorylation at serine 51 after FK866 treatment. 
To investigate the role of EIF2A inhibition with respect to cell viability, we 
compared FK866-treated cells expressing the wild type protein, a 
nonphosphorylatable mutant (S51A) and a phosphomimetic mutant (S51D). 
Cells expressing the nonphosphorylatable mutant exhibited a stronger cell 
death response, indicating that the phosphorylation of EIF2A is protective 
against the induced metabolic stress (Figure 18b). For this reason, we 
investigated more deeply EIF2A-dependent processes, which acquire 
fundamental relevance in explaining the mechanism of action of NAMPT 
inhibitors. Among them, we checked for the activation of the unfolded protein 
response (UPR) and specifically we evaluated the level of BiP, a chaperone 
protein and a master regulator for ER stress able to control the activation of 
UPR signaling. After FK866 treatment mRNA level of BiP gene was increased 
(Figure 18c). 
 
In conclusion, we reported that leukemia cells activated a specific molecular 
response to contrast NAD+-depletion via NAMPT inhibition. Major players of the 
response are AMPK, which inhibits protein translation, and EIF2A that is 
involved in the determination of cell fate and strictly related to the stress 
response. 
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Figure 18. EIF2A inhibition by FK866 results in protective effects against stress 
A, Jurkat cells were treated for 48 h with FK866, Rapamycin (RAPA), Doxorubicin (DOXO), 
Cisplatin (CIS) and Dexamethasone (DEXA). The level of p-EIF2A and p-4EBP1 was 
evaluated. Histogram shows the densitometric analysis of p-EIF2A (*indicates p-value <0.05). 
B, A549 cells viability after 48 h of treatment with FK866 100 nM in un-transfected (NTC) cells 
and transfected with EIF2A wild type, EIF2A-S51A, EIF2A-S51D (p-value<0.05). C, Expression 
level of BiP mRNA evaluated in Jurkat cells after 48 h of treatment with FK866 5 nM (*, p-
value<0.0005). A-C, mean and SD of a biological triplicate. 
 
 
Importantly, we further confirmed a key role for ER stress in the mechanism of 
action of FK866 and for the activation of UPR in response to the metabolic 
stress induced by NAMPT inhibition by testing the drug in combination with 
efflux pump inhibitors.  
Indeed, FK866 was frequently reported to exhibit limited cytotoxicity against 
primary leukemia cells. Therefore, its applicability as a single agent is limited. 
Common cause of treatment failure is the insurgence of multidrug resistance 
(MDR), which is strictly related to over-expression of membrane transport 
proteins. Among them, P-glycoprotein 1 (Pgp, encoded by MDR-1/ABCB1 
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gene) is one of the key factors involved in extruding drugs across the plasma 
membrane thus reducing their intracellular concentration and their efficacy 
[132]. High level of PgP has been frequently observed in hematological 
malignancies and the expression correlated with poor clinical outcome in Acute 
Myeloid Leukemia [133]. Therefore, PgP inhibitors represent an attractive 
approach for cancer treatment. Natural and synthetic identified inhibitors 
include calcium channel blockers (verapamil and nifedipine), indole alkaloids 
(reserpine), steroids (progesterone and tamoxifen), the immunosuppressive 
agents cyclosporin A (CsA), and rapamycin and the second-generation Pgp 
inhibitor PSC-833 (valspodar). 
In our work, we tested the combination of FK866 and PgP inhibitors in leukemia 
cells, in order to provide a biological rationale for exploiting this approach in the 
treatment of hematological malignancies.  
Firstly, we demonstrated that PgP inhibitors such as CsA and verapamil 
synergistically potentiated FK866-induced cytotoxicity in leukemia cells, 
whereas normal CD34+ hematopoietic progenitor cells and healthy leukocytes 
were not affected. FK866 was demonstrated to be a PgP substrate, which 
decreased the drug intracellular concentration. Testing metabolic effects of the 
combination of FK866 and PgP inhibitors, we reported the exacerbation of cell 
demise induced by NAMPT inhibition. Drug combination enhanced NAD+ 
depletion, ATP shortage and induced ΔΨm dissipation (mitochondrial 
transmembrane potential).  
The mechanism underlying the interaction between FK866 and PgP inhibitors, 
which sensitized leukemia cells to NAMPT inhibition, was further investigated. 
Interestingly, we reported the involvement of ER stress and UPR in this 
synergy, confirming that FK866 negatively affects endoplasmic reticulum (ER) 
physiology. 
ER stress inhibition with the chemical chaperone 4-phenyl butyric acid (4-BPA) 
significantly reduced the cytotoxic effects of FK866, CsA, and of the two 
combined agents in OCI/AML3 and MEC.1 cells, as well as in primary B-CLL 
cells (Figure 19a). 
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Figure 19. CsA plus FK866 antileukemic effect is mediated by ER stress–dependent UPR 
signaling 
A, OCI/AML3, MEC.1 or primary B-CLL cells were preincubated for 2 h with or without 4-phenyl 
butyric acid (4-BPA). Thereafter, leukemia cells were treated with FK866 (3 nmol/L) for 48 h; 
CsA (1 µmol/L) was then added for additional 48 h followed by cell death analysis using PI 
staining and FACS analysis. Data represent mean and SD of triplicate samples (*,p < 0.01; **, 
p< 0.002; ***p < 0.0002; ****, p< 0.0001). B, OCI/AML3 or MEC.1 cells were pretreated with or 
without FK866 (3 nmol/L) for 24 h, and then CsA (1 µmol/L) was added for additional 24 h. WB 
analysis of cellular fractions was performed using anti-BIP, anti-IRE1α, anti-CHOP and anti-
tubulin or anti-nucleolin antibodies as fraction specific loading controls. C, B-CLL primary cells 
were treated with FK866 (10–100 nmol/L), CsA (0.3–1 µmol/L), or combined therapy for 48 h. 
Cell lysates were subjected to Western blot analysis, using anti-BIP and anti-tubulin antibodies. 
Blots shown are representative of three independent experiments and histogram shows the 
densitometric analysis (mean±SD).  
 
 
Moreover, by investigating ER stress related markers we observed an increase 
of IRE1α, C/EBP-homologous protein (CHOP) and BIP levels. In cells that were 
cotreated with FK866 and CsA increase was much stronger as compared with 
the single-agent treatments (Figure 19b). A marked increase in the master 
regulator of the UPR BIP was also detected in primary B-CLL cells treated with 
FK866 and CsA (Figure 19c).  
These findings confirmed a key role for ER stress in the mechanism of action of 
FK866 and indicated a novel role for UPR in mediating the antitumor activity of 
FK866 in combination with Pgp inhibitors in leukemia cells. 
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2. Drug resistance to FK866 
 
Insurgence of drug resistance during chemotherapy is a common occurrence 
and is a major cause of cancer relapse and consequent failure of therapy. It can 
occur as either de novo or acquired resistance following therapy. For several 
targeted therapies the development of target-specific drug resistance has been 
described. 
2.1 Drug resistance to NAMPT inhibitors 
 
Regarding NAMPT inhibitors, pharmacoresistance was reported in HCT-116 
colon cancer cell line for GMX1778. A resistant clone presenting an acquired 
drug resistance was derived through serial selection with increasing sublethal 
concentrations of the drug. Sequencing of the NAMPT gene in the GMX1778- 
resistant cell line revealed a single point mutation of amino acid 217, which is 
located near the active site of NAMPT, from glycine to arginine (G217R). The 
mutation resulted in an IC50 value 2500-fold higher than the one calculated in 
parental cells and was not directly related to changes in NAMPT expression 
levels. Over-expression of mutated NAMPT (G217R) in HEK-293-T cells 
increased intracellular NAD+ levels by 80%, inducing resistance to GMX1778 
cytotoxicity [134]. 
Additionally, mutations in the NAMPT gene (mapped to H191R, D93del and 
Q388R) conferring drug resistance to other NAMPT inhibitors, including FK866 
and CHS-828, were reported in resistant cell lines developed from HCT-116 
and in NYH, human small cell lung carcinoma cell line. Specifically, these 
mutations structurally modified the inhibitor-binding pocket (G217R and 
H191R), dumping drug efficacy. The resistant cell lines showed tumorigenicity 
in xenograft mouse models and in vivo resistance [135]. 
More recently, six mutations in the NAMPT gene have been reported in GNE-
618 resistant cells derived from RD (rhabdosarcoma), MiaPaCa-2 (pancreatic 
cancer) and NCIH460 (non-small cell lung cancer) cell lines. In addition to the 
previously identified G217R and D93del mutations, G217A, G217V, S165F and 
S165Y were reported as novel. Resistant cell lines were observed to be 10 to 
1000-fold less sensitive to the NAMPT inhibitor GNE-618 with respect to 
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parental ones. However, no cross resistance to GMX1778 and FK866 was 
detected, suggesting a molecule specific NAMPT resistance.  
Interestingly, tumor xenografts established from NCI-H460 cells presenting the 
S165Y mutation were resistant to high doses of GNE-618 [136].  
To date, tumor cell resistance to NAMPT inhibitors has been ascribed to point 
mutations either proximal or distal to the enzyme substrate binding sites and a 
reactivation or over-expression of alternative NAD+ biosynthesis pathways has 
never been reported. 
 
2.2 Development of FK866-resistant Jurkat cell line 
 
The development of drug-resistant cancer cell lines is an helpful approach for 
investigating the mechanisms of cytotoxicity and resistance to antitumor agents. 
Acquired resistance can be studied by inducing resistance in vitro growing cells 
in the presence of increasing concentrations of drug. 
We have developed FK866-resistant models from Jurkat cells, by using a 
stepwise increase in treatment dose [137]. The surviving daughter resistant 
cells were then compared to the parental sensitive cells assessing cell viability 
and defining EC50. Calculated EC50 after 48 hours of treatment with FK866 was 
9.8 µM for the resistant cells, whereas an EC50 of 5.4 nM could be estimated for 
parental ones (2000-fold lower). Moreover, resistant cells were also insensitive 
to long-term (5-day) treatment with 500 nM of FK866 (Figure 20a).  
In FK866-resistant cells, the levels of intracellular NAD+ and ATP were 
estimated after treatment in comparison with the parental cells, in order to 
assess the efficacy of the drug and to evaluate the induced metabolic stress. 
NAD+ levels in the resistant cells were measured as 50% of the untreated 
sample in the parental cell line. On the contrary, however, FK866 treatment did 
not heavily impact on NAD+ content in the resistant model (Figure 20b). With 
respect to ATP, intracellular levels were comparable to the untreated sample in 
the parental cells and completely recovered also upon treatment with FK866 
(Figure 20c). 
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Figure 20. Isolation and metabolic characterization of FK866-resistant cells  
A, Evaluation of Jurkat cells viability in parental and resistant cells during long-term treatment 
with FK866. Calculation is based on Trypan blue exclusion of dead cells. B and C, NAD
+
-NADH 
and ATP intracellular levels were measured in parental and resistant Jurkat cells after drug 
treatment. Values are normalized to untreated parental cells (Mock). Mean and SD of three 
independent experiments (*, p-value<0.0001). 
 
 
As already mentioned, in reported examples from the literature FK866 
resistance is due to mutations of NAMPT gene dumping drug efficacy.  
In our case, exclusion of mutations in NAMPT gene was performed by 
sequencing its coding region in resistant and parental cells. Interestingly, Jurkat 
cells have thus developed different mechanism to elicit FK866 
pharmacoresistance. 
Importantly, we observed that NAMPT gene expression was significantly down-
regulated by 50% in the resistant model (Figure 21a). Moreover, the acquired 
mechanism of resistance mutation-independent conferred cross-resistance to 
another NAMPT inhibitor, CHS-828 (Figure 21b).   
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Figure 21. NAMPT mRNA level in resistant cells and cross-resistance to CHS-828 
A, Basal expression level of NAMPT revealing a 50% decrease in FK866-resistant cells 
compared with parental cells. Mean and SD of three independent experiments (*, p-
value<0.0001). B, Viability assessment through MTT assay of parental and FK866-resistant 
cells in response to a 48 h CHS-828 treatment. 
 
 
2.2 Characterization of the resistant model: translational control   
 
In order to elucidate the stress response of our resistant model in response to 
FK866, we checked markers of translational arrest that represents the early 
response in the parental cells. In Jurkat parental cells we identified a general 
arrest of translation after FK866 treatment, which involves the activation of 
AMPK probably due to the decrease in ATP intracellular content. In the 
resistant model drug treatment did not activate AMPK and no inhibition of 
translation mediated by mTOR/4EBP1 or EIF2A was reported (Figure 22a).  
The status of phosphorylation of these key pathways involved in translation was 
a clear indication that protein synthesis resumed, as revealed also by detection 
of AHA incorporation in the nascent proteins after FK866 treatment of resistant 
cells (Figure 22b). 
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Figure 22. Protein translation resumed in resistant cells 
A, Western Blot analysis of parental and resistant cells after treatment with FK866 for 48 h. 
Representative panel of three independent experiments B, Protein synthesis was monitored in 
parental and resistant Jurkat cells by AHA incorporation after 48 h of treatment with FK866. The 
histogram quantifies protein synthesis in the viable cell population. 
 
2.3 Drug sensitivity and resistance testing (DSRT) 
 
Isolated FK866-resistant Jurkat cells are in summary able to recover NAD+ and 
ATP levels and to restart translation and are insensitive to drug treatment. 
However, acquired resistance could confer sensitivity to other drugs and we 
searched for new drug vulnerabilities and druggable targets through an high-
throughput screening.  
For this purpose, I spent a period abroad in Helsinki at FIMM (Institute for 
Molecular Medicine Finland) in the Laboratory of Individualized Systems 
Medicine under the supervision of Olli Kallioniemi. 
During my visit I performed high throughput drug sensitivity and resistance 
testing (DSRT) with FK866-resistant Jurkat cell line models that we have 
established. In particular, I tested parental cells in comparison with 3 different 
FK866-resistant models previously derived by treating Jurkat cells with 
increasing doses of the drug: 10, 40 and 100 nM FK866 resistant.  
The DSRT platform is based on an oncology compound collection, that covers 
the active substances from the majority of FDA/EMA–approved anticancer 
drugs (n = 123), as well as emerging investigational and preclinical compounds 
(n = 64) covering a wide range of molecular targets (Supplementary Table 
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S5). Briefly, drugs were pre-plated in 384-well plates in five different 
concentrations in a 10 000-fold concentration range, where  
Jurkat cells were added and then incubated for 72 h. After measuring cell 
viability, dose-response curves were generated on the basis of the viability 
readouts and drug responses were compared across the samples by 
calculation of the Drug sensitivity scoring (DSS), (see methods and [125] for 
details). 
Parental cells were screened and compared with FK866-resistant models in 
order to identify new drug vulnerabilities and co-resistance. DSRT aimed at 
discovery of drugs able to kill resistant cells and identification of co-resistance. 
Different concentrations of Jurkat parental cells and the 3 resistant models were 
initially seeded in 384-well plate to determine the number that ensures each 
sample to be in growth phase at the end of the assay. Cell viability was 
assessed after 72 hours and by generated growth curves we selected the 
optimal seeding density, which was determined as 4000 cells/well (Figure 23a). 
DSRT was then performed on parental and resistant cells. Following the drug 
testing experiment, we assessed the quality of the screening by measuring Z' 
factors and strictly standardized mean differences (SSMD). Z' values lied 
between 0.5 and 1, indicating that the screening performance was good. Curve 
fitting algorithm was thereafter applied and DSS was calculated.  
X-Y plots (Figure 23b) represent the correlation of the DSRT results of Jurkat 
parental and resistant 10 nM, 40 nM and 100 nM. DSS of FK866 decreased in 
the 3 models as expected (Figure 23c). Plots illustrate that resistant cells 
gained sensitivity to Bryostatin 1 among more than 300 compounds tested, a 
protein kinase C (PKC) activator.  
Resistant 10 nM lost sensitivity to danusertib, an Aurora kinase inhibitor, 
whereas resistant 40 and 100 nM acquired resistance to the synthetic 
glucocorticoids (GCs) dexamethasone and methylprednisolone (Figure 23c).  
Because of the low number of identified cross-resistant drugs, we can possibly 
exclude insurgence of multidrug resistance (MDR) in the FK866-resistant 
model. 
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Figure 23. Growth curves and drug sensitivity scoring (DSS) of resistant cells  
A, Growth curves of Jurkat parental and FK866-resistant models. Cells were seeded in 384-well 
plate and cell viability was measured after 72 hours using CellTiter Glo. B, Correlation of the 
DSRT results of Jurkat parental and resistant 10 nM, 40 nM and 100 nM. Drugs for which the 
DSS decreased greater than 10 from parental cells are marked in green, drugs for which the 
DSS increased greater than 10 in resistant cells are marked in blue. C, DSS (Drug Sensitivity 
Scoring) of FK866, Bryostatin 1 and Dexamethasone in the 4 screened samples. 
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The identified co-resistance to dexamethasone and methylprednisolone are of 
particular interest because these drugs are immunomodulatory reagents, 
related to GR (Glucocorticoid Receptor) and glucocorticoid resistance is a 
major driver of therapeutic failure in T cell acute lymphoblastic leukemia (T-
ALL). Notably, induced myeloid leukemia cell differentiation protein MCL-1 
over-expression was involved in conferring resistance to glucocorticoids in ALL 
cells. Over-expression of MCL1 sequestered the BH3-only protein BIM and thus 
rendered cells unable to activate the pro apoptotic signaling and resistant to 
GC-induced apoptosis [138]. In addition, inhibition of translation through the 
mTOR/4EBP1 pathway was reported to reduce the levels of the anti-apoptotic 
protein MCL1 [129]. 
In Jurkat cells we identified a translational arrest and reported a decrease in the 
level of expression of MCL1 (Figure 14). Our FK866-resistant model was able 
to restart translation and treated cells expressed MCL1 at the level of the 
untreated control (Figure 24a). Based on this, we hypothesized that 
dexamethasone cross-resistance could be strictly related to the observed levels 
of the anti-apoptotic protein MCL1, as already reported in ALL cells, and could 
depend on the re-activation of mTOR signaling.  
Finally, in contrast to the identified cross-resistance to dexamethasone in 
resistant models, Jurkat parental cells were sensitive to the drug with a 
calculated EC50 of 50 nM at 48 hours.  
From genome-wide gene expression analyses we observed that the GR 
signaling pathway was affected by FK866 administration (Figure 11), therefore 
we investigated how FK866 could possibly affect GR-regulated homeostasis. 
We evaluated whether FK866 could increase the activity of dexamethasone in 
Jurkat cells and exacerbate its apoptotic function. In fact, dexamethasone is a 
well-known activator of the Glucocorticoid Receptor and an inducer of T-ALL 
cells death [139].  
By exposing Jurkat cells to single or combined equipotent concentrations of 
FK866 and dexamethasone (nanomolar ratio 1:5), we observed that combined 
drug treatment resulted in a strong synergistic interaction causing cell death 
(Figure 24b) with a Combination Index (CI) value of 0.00270 for cytotoxicity on 
50% of cells, as estimated by the Chou and Talalay statistics [126].  
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Figure 24. FK866 shows a strong synergistic interaction with Dexamethasone 
A, Western Blot analysis of MCL-1 levels in parental and resistant cells after a 48 h treatment 
with FK866. Representative panel of three independent biological replicates. B, Jurkat cells 
were treated for 48 h, alone or in drug combination, with equipotent doses of FK866 and 
Dexamethasone and viability was determined by PI staining and flow-cytometry. Dose-
response curves were analyzed by CompuSyn software V1.0 following the Chou and Talalay 
statistics. The combination showed a significant synergistic interaction with a CI value of 
0.00270 for cytotoxicity on 50% of cells.  
 
2.4 Characterization of the resistant model: transcriptional regulation   
 
Genetic and epigenetic changes, resulting in gene expression reprogramming, 
play a major role in allowing adaptation to the presence of anticancer drugs. 
Modifications might occur at DNA or RNA level.  
We performed gene expression microarray analysis on RNA extracted from 
resistant and parental cells treated or not with the drug. Comparing the number 
of DEGs, FK866 treatment induced little variations on resistant cells at 
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transcriptional level. DEGs in parental cells were 4 times more. Interestingly, 
the expression level of thousands of genes were different in resistant cells with 
respect to parental (Figure 25a).  
 
 
 
 
Figure 25. Gene expression analysis in FK866-treated resistant cells  
A, Histogram shows the number of differentially expressed genes selected according to a 
double threshold on log2 FC (absolute value > 0.75) and moderated t-test p-value (<0.05). On 
the right, box whisker plots of pairwise gene expression comparisons, based on log2 Fold 
changes. Comparing the sparseness of the distributions, variations induced by FK866 on 
resistant cells have less magnitude than variations induced by FK866 on normal cells. B, 
Barplots displaying the top 5 enriched Gene Ontology terms for the resistant versus parental 
comparison. Enrichments are scored according to Fisher Benjamini-Hochberg corrected p-
value, displayed in the x axis. Enrichment significance threshold is displayed as a vertical 
dashed line. The number of DEGs associated to each term is specified next to the 
corresponding bar, between round brackets. 
 
Among these 5000 genes differentially expressed (DEGs) in parental vs 
resistant cells, we performed bioinformatics analyses (Gene Ontology) that in 
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the future will be crossed with their biological function in order to select targets 
for validation (by real-time PCR, Western blotting). Top 5 enriched Gene 
Ontology terms related to the comparison between parental and resistant cells 
highlighted a possible correlation between FK866-resistance and nuclear DNA 
organization, particularly influencing the nucleosome assembly. Notably, an 
enriched term in the molecular function ontology referred to histone 
demethylation. Taking together, these data suggest that resistance to FK866 
might involve a different global transcriptional regulation, allowing cells to 
survive the metabolic stress (Figure 25b). 
Interestingly, in FK866-resistant models Indoleamine 2,3-dioxygenase (IDO1) 
gene expression was found to be up-regulated (abs log2 FC >3). IDO1 is the 
first and rate-limiting enzyme of tryptophan catabolism through kynurenine 
pathway, which might support an alternative NAMPT-independent pathway of 
NAD+ synthesis. 
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DISCUSSION 
 
Alterations in NAD+ levels have a powerful metabolic impact on cells, especially 
on cancer cells. During malignant transformation in fact their cellular 
metabolism undergoes multiple molecular and metabolic adaptations to support 
aberrant cell growth and survival, resulting in a significantly higher energy 
demand and NAD+ turnover that sustain rapid proliferation, relative genomic 
instability, continuous DNA repair, increased aerobic glycolysis and increased 
activity of NAD+-dependent enzymes. NAD+ is therefore a key metabolite 
required as redox co-factor and as substrate for NAD+-dependent enzymes, 
such as poly (ADP-ribose) polymerases (PARPs), ADP-ribosyl cyclases/CD38 
and sirtuins, which continuously consume NAD+ and release nicotinamide. 
In mammals, the nicotinamide phosphoribosyltransferase NAMPT is a main 
regulator of the intracellular NAD+ pool, constantly recycling NAD+ from 
nicotinamide [27]. Because of its relevance in NAD+ maintenance, it is often 
over-expressed in tumor cells.  
In hematological malignancies, higher NAMPT expression levels were reported 
in a wide range of cell lines and patient samples [75], [76], [140], [141]. An 
array-based comparative genomic hybridization analysis of a dataset of 
hematological cancer cells (derived from the Cancer Cell Line Encyclopedia 
database, [142]) showed focal amplification of the NAMPT locus (mapping on 
7q22.3) and NAMPT transcript levels were found to correlate with the DNA 
copy number. Moreover, high NAMPT expression in hematologic malignancies 
was significantly associated with poor overall survival and adverse prognosis 
[143]. 
Thus, altogether, these data support the notion that NAMPT plays an important 
role in the pathophysiology of hematologic malignancies and that it represents 
an attractive therapeutic target.  
Notably, NAMPT inhibitors FK866 and CHS-828 (or GMX1777, a pro-drug of 
GMX1778) showed potent antitumor activity in several preclinical models of 
solid and hematologic cancers [64], [134], [144] because NAMPT inhibition led 
to ATP shortage and to consequent cell death [64]. Moreover, NAMPT inhibition 
was found to increase the efficacy of standard chemotherapeutics: histone 
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deacetylase inhibitors [145], tumor necrosis factor-related apoptosis-inducing 
ligand [140], and poly(ADP-ribose) polymerase inhibitors [146].  
Regrettably, clinical trials applying NAMPT inhibitors as monotherapy have so 
far been less promising. The main forms of reported toxicity for FK866 and 
CHS-828 were thrombocytopenia, gastrointestinal symptoms (especially for 
CHS-828), and lymphopenia (for FK866) but no objective tumor remission was 
observed, although a few cases of disease stabilization could be recorded with 
FK866 [79], [147]. Understanding cellular mechanisms of response to FK866 
can help the development of new analogues that exhibit less toxicity and more 
efficacy. In our study, we reported an activation of a signaling network in which 
the AMPK-EIF2A axis was responsible for the early cellular response to FK866-
induced metabolic stress. AMPK was activated in response to NAD+ and ATP 
depletion and impaired mTOR signaling resulting in protein synthesis arrest, 
which had a protective role conferring temporary resistance to the FK866-
induced energetic stress. We reported that activation of LKB1/AMPK pathway 
was protective against FK866, suggesting the utilization of this drug as a 
metabolism-based cancer therapeutic to selectively target LKB1-deficient 
tumors (sporadic lung, cervical, and endometrial cancers often carry LKB1 
deficiency), which are unable to sense energetic stresses and activate 
mechanisms to restore energy homeostasis [148]. In an experimental condition 
preceding cell death characterized by high energetic demand, EIF2A acted as 
an early master regulator of cell fate, blocking anabolic processes and, at the 
same time, modulating cell death and adaptive pathways. Related to this, we 
also reported a reduction in the levels of the anti-apoptotic protein MCL1, which 
has been clearly associated with enhanced lethality in Jurkat cells and could 
provide a molecular explanation for the anti-leukemic activity of NAMPT 
inhibitors [149].  
According to this observation and with the aim to potentiate FK866 efficacy, we 
evaluated Cyclosporine-A induced inhibition of P-glycoprotein 1 (Pgp), a key 
factor mediating multidrug resistance, in combination with FK866. The results 
indicated that Pgp inhibition increased the cytotoxic effects of FK866 in 
leukemia cells, not affecting healthy leukocytes and hematopoietic progenitor 
cells, specifically by increasing the intracellular concentration of the drug and 
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thereby exacerbating ATP shortage and endoplasmic reticulum stress, which 
was reported to be a specific response to FK866-induced stress [143].   
The relevance of FK866 antileukemic activity in combined therapy was also 
assessed by using NAD+-dependent histone deacetylases (sirtuins) inhibitors 
alone and in combination with traditional HDAC (NAD+-independent 
deacetylases) inhibitors, in primary leukemia cells and cell lines. Sirtuin 
inhibitors and FK866 synergistically enhanced HDAC inhibitor activity in 
leukemia cells and induced the up-regulation of Bax, a pro-apoptotic Bcl2 
family-member whose translocation to mitochondria is normally prevented by 
SIRT1 [145]. 
One possible explanation for the failure of NAMPT inhibition as an anti-cancer 
therapy could be the fact that supply of extracellular NAD+ or extracellular NAD+ 
precursors, including nicotinic acid, nicotinamide mononucleotide (NMN) and 
nicotinamide riboside (NR), can prevent the induced cell death by overcoming 
blockade of NAD+ biosynthesis from nicotinamide. The ectoenzyme CD38 
degrades NMN and generates nicotinamide (NAM), which can cross the plasma 
membrane and sustain NAMPT-dependent NAD+ [150]. Recently, the 
ectoenzyme CD73 has also been demonstrated to contribute to NAD+ synthesis 
by dephosphorylating NMN to produce NR, which crosses the plasma 
membrane [151]. Both CD38 and CD73 might therefore be involved in 
modulating cell susceptibility to FK866 and NAMPT inhibition. Specifically, it 
was demonstrated that CD73 enabled the utilization of extracellular NMN as a 
precursor for intracellular NAD+ biosynthesis in human cells and reversed the 
FK866-induced cell death bypassing NAMPT inhibition. This work highlighted 
the possibility of implementing antitumor therapies based on combined 
inhibition of NAMPT and CD73 holding promise for treatments aimed at 
inhibiting NAD+ pathways starting from NAM or NMN [81]. High level of CD73 
has been observed in several types of cancer and tumor microenvironment 
contains factors modulating its expression, which is currently believed to 
promote cancer cell survival and associated with poor prognosis and 
metastasis [152]. 
On the contrary, higher expression of CD38, which degrades NAD+ and NMN to 
nicotinamide, impaired the efficacy of NAD+ and NMN-mediated rescue from 
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FK866-induced cell death because NAM utilization in these cells is blocked by 
NAMPT inhibition. Thus, CD38 expression by tumor cells could account for their 
inability to overcome NAMPT inhibition, when they are supplemented with 
NAM-containing precursors. Interestingly, preclinical and clinical studies 
revealed a sensitivity of normal lymphocytes to FK866, as inferred from the 
observed lymphopenia in response to this drug [79] that might be related to the 
high CD38 expression in lymphocytes [153]. 
In order to potentiate the efficacy of NAMPT inhibitors, work has been done to 
define predictive biomarkers of drug sensitivity that may be used for clinical 
testing. In a panel of 25 tumor cell lines an inverse correlation between NAMPT 
mRNA expression levels and GMX1778 cytotoxicity was reported [134]. These 
results were also confirmed at the protein level in three non-small-cell lung 
carcinoma (NSCLC) cell lines less sensitive to GMX1778, which expressed 
relatively higher levels of NAMPT when compared to a sub-set of small-cell 
lung carcinoma (SCLC) cells. Moreover, in a panel of 53 NSCLC cell lines 
NAMPT mRNA and protein levels inversely correlated with sensitivity to the 
NAMPT inhibitor GNE-618 [154]. Thus, NAMPT itself may serve as predictive 
biomarker for NAMPT inhibitor sensitivity.  
The Preiss-Handler pathway leading to NAD+ synthesis starting from nicotinic 
acid (NA) is frequently found to be inactive in cancer cells due to lack of 
expression of the rate-limiting enzyme nicotinic acid phosphoribosyltransferase 
(NAPRT1), thus making them more dependent on NAMPT for NAD+ generation 
and cell survival and more susceptible to the cytotoxic effects of NAMPT 
inhibitors [134]. In NAPRT1-deficient tumors, addition of nicotinic acid to the 
media was not sufficient to mitigate the cytotoxic effects of NAMPT inhibition. 
Loss of NAPRT1 expression was reported to be caused not by the presence of 
NAPRT1 mutations or loss of heterozygosity but by tumor-specific promoter 
methylation, which provides a novel predictive biomarker for NAMPT inhibitors. 
NA rescue status was evaluated in a panel of more than 400 cancer cell lines. 
A subset of cell lines representing a range of tumor types was found to be 
NAPRT1-deficient (approximately 10-20% of colorectal, ovarian, non-small cell 
carcinoma and glioblastoma cell lines analyzed) or expressed undetectable 
NAPRT1 levels. Tumor-specific promoter hypermethylation of a CpG island that 
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overlaps with the NAPRT1 gene transcription start site inactivated this NAD+ 
salvage pathways, resulting in synthetic lethality with the co-administration of a 
NAMPT inhibitor [155].  
Finally, as for several other targeted therapies, also for NAMPT inhibition the 
development of target-specific drug resistance has been described.  
We developed a model of FK866 resistance derived from Jurkat T-ALL cells, 
which was independent from NAMPT mutations but able to survive drug 
treatment maintaining a sufficient NAD+ pool, restoring ATP intracellular content 
and resuming translation. In the resistant cells, NAMPT mRNA levels were 
reduced up to 50% with respect to parental cells whereas NAD+ levels after 
treatment with the drug were restored up to 50% (in parental cells they were 
almost completely abolished). 
The molecular mechanism of drug resistance has not been fully understood yet. 
However, NAMPT reduced levels have to be counterbalanced to support NAD+ 
synthesis and cell survival, possibly by activation of NAMPT-independent 
pathways of NAD+ synthesis. A major candidate for restoring NAD+ is the de 
novo pathway, which is based on the transport of tryptophan within the cells by 
the L-type amino acid transporter 1 (LAT1) [156]. Tryptophan is then 
catabolized by the rate-limiting enzyme IDO1, which catalyzes the conversion 
of tryptophan to kynurenine and NAD+ [157]. In FK866-resistant models, IDO1 
gene expression was found to be up-regulated and might support the 
alternative pathway of NAD+ synthesis. Therefore, we will investigate the 
involvement of tryptophan in the mechanism of resistance. Moreover, the 
requirement of LAT1-mediated tryptophan transportation in FK866-resistant 
models to support de novo NAD+ biosynthesis will be tested by checking the 
response to JPH203, a LAT1 selective inhibitor [158], and by tryptophan 
deprivation through removal from culture media. LAT1 over-expression in T-
ALL cancer cells was reported to reflect an addiction towards increased 
nutrients uptake for mTOR and AKT activation and reprogrammed metabolism 
[158]. 
NAD+ synthesis based on the de novo pathway relying on tryptophan transport 
seems to be therefore the most promising pathway to be worth of investigation. 
In addition, we will evaluate the activity of ectoenzymes such as CD73, which 
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enables the utilization of extracellular NMN as precursor for intracellular NAD+ 
biosynthesis bypassing NAMPT inhibition, and CD38, which degrades NMN 
and generates nicotinamide.  
In addition, the level of the rate-limiting enzyme in NAD+ synthesis from 
nicotinic acid, nicotinic acid phosphoribosyltransferase (NAPRT1), will be 
evaluated. NAPRT1 activity constitutes a possible rescue mechanism able to 
mitigate the cytotoxic effects of NAMPT inhibition. 
In conclusion, understanding the molecular mechanism of FK866 resistance will 
provide insights in the regulation of NAD+ content in cancer cells, contributing to 
the development of new specific and effective combinatorial drug therapies.  
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Abstract
Background: Nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in NAD+ biosynthesis
from nicotinamide, is one of the major factors regulating cancer cells metabolism and is considered a promising
target for treating cancer. The prototypical NAMPT inhibitor FK866 effectively lowers NAD+ levels in cancer cells,
reducing the activity of NAD+-dependent enzymes, lowering intracellular ATP, and promoting cell death.
Results: We show that FK866 induces a translational arrest in leukemia cells through inhibition of MTOR/4EBP1
signaling and of the initiation factors EIF4E and EIF2A. Specifically, treatment with FK866 is shown to induce
5′AMP-activated protein kinase (AMPK) activation, which, together with EIF2A phosphorylation, is responsible for the
inhibition of protein synthesis. Notably, such an effect was also observed in patients’ derived primary leukemia cells
including T-cell Acute Lymphoblastic Leukemia. Jurkat cells in which AMPK or LKB1 expression was silenced or in
which a non-phosphorylatable EIF2A mutant was ectopically expressed showed enhanced sensitivity to the NAMPT
inhibitor, confirming a key role for the LKB1-AMPK-EIF2A axis in cell fate determination in response to energetic
stress via NAD+ depletion.
Conclusions: We identified EIF2A phosphorylation as a novel early molecular event occurring in response to
NAMPT inhibition and mediating protein synthesis arrest. In addition, our data suggest that tumors exhibiting an
impaired LBK1- AMPK- EIF2A response may be especially susceptible to NAMPT inhibitors and thus become an
elective indication for this type of agents.
Keywords: NAMPT, EIF2A, AMPK, Energetic stress, Translation arrest, UPR
Background
Aberrant activation of metabolic pathways has emerged as
an hallmark of proliferating cancer cells and pharmaceut-
ical approaches targeting cell metabolism hold potential
for treating cancer [1]. Nicotinamide adenine dinucleotide
(NAD+) plays a key role in different biochemical processes,
acting as a coenzyme in redox reactions or as a substrate
for NAD+ degrading enzymes, such as poly(ADP-ribose)
polymerases (PARPs), cluster of differentiation 38
(CD38), and sirtuins. Intracellular NAD+ is continuously
replenished utilizing either tryptophan, nicotinamide, nico-
tinic acid or nicotinamide riboside as a substrate [2], and
nicotinamide phosphoribosyltransferase, NAMPT, is the
rate-limiting enzyme for NAD+ biosynthesis from nicotina-
mide in mammalian cells [3]. High NAMPT levels, whose
activity appears to be also important in the differentiation
of myeloid cells [4], were shown to be required to support
cancer cell growth, survival and epithelial-mesenchymal
transition (EMT) transition [5, 6], and have been reported
in different types of tumors [7, 8]. In line with these no-
tions, several studies have highlighted a strong activity of
NAMPT inhibitors in preclinical models of inflammatory
and malignant disorders, including leukemia [2, 9–11].
FK866, a prototypical NAMPT inhibitor, was found to
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promote cell death in both lymphoid- and myeloid-derived
hematological malignancies and its activity clearly resulted
from intracellular NAD+ depletion [12–14]. Notably,
opposite to cancer cells, activated immune cells [10], along
with many other types of healthy cells, such as
hematopoietic stem cells [12], appear unaffected by
NAMPT inhibitors, and consistently, agents such as FK866
or CHS-828 are well tolerated in patients [15, 16].
The molecular consequences upon NAMPT inhibition
are only partially understood. The induced NAD+ deple-
tion clearly affects intracellular ATP levels resulting in
mitochondrial dysfunction and activation of cell death
pathways: reactive oxygen species generation and activa-
tion of the apoptotic cascade have both been involved in
cell demise in response to NAMPT inhibitors [17]. ATP
depletion has been related to the loss of plasma mem-
brane homeostasis invariably leading to oncosis cell death
[18]. Different groups have suggested a role for autophagic
cell death in the cytotoxic activity of these drugs [10, 12,
13, 19]. In particular, Cea and colleagues proposed that
FK866 would induce autophagy via activation of
transcription factor EB (TFEB), a master regulator of
the lysosomal-autophagic pathway [20], and through
MTORC1/AKT and ERK1/2 pathway inhibition [21].
There is also evidence that AMP-activated protein kinase
(AMPK), an important coordinator of metabolic pathways
in response to energetic fluctuations [22], is activated by
FK866 in prostate cancer cells affecting lipogenesis [23]
and in hepatocarcinoma cells with impact on MTOR/
4EBP1 signaling [24]. Moreover, NAMPT-dependent
AMPK activation associated with deacetylation of liver
kinase B1 (LKB1), an upstream kinase of AMPK, has been
linked with modulation of NAD levels and with significant
impact on neuron cell survival [25]. Translation inhibition
is often observed during cell stress [26] and this event
often involves a re-programming of translation leading to
differential regulation of mRNAs, occurring also via alter-
native mechanisms, aimed at reorganizing cell physiology
to respond to the insult.
In this study, we focused on the pre-toxic molecular
events induced by FK866 in acute lymphoblastic leukemia
cells, known to be sensitive to the drug [10], in order to
define the molecular mechanism favoring cell death or cell
survival. A marked global protein synthesis inhibition rep-
resented an early cellular response associated with the
FK866-induced energetic stress and here we show that
AMPK-EIF2A is a central hub in mediating this effect and
is responsible for cell fate decisions.
Methods
Cell lines, primary B-CLL cell and T-ALL PDX isolation
Human Jurkat T-cell acute lymphoblastic leukemia (T-
ALL) cells were purchased from the InterLab Cell Line
Collection bank (ICLC HTL01002). SUP-T1 cells were
purchased from ATCC (CRL-1942) and Molt-4 Clone 8
from NIH AIDS Reagent Program (Catalog #: 175).
Human lung carcinoma A594 (CCL-185) and H460
(HTB-177) cells were purchased from ATCC. These cells
were transduced with retroviral vectors encoding either
LKB1 cDNA (pBABE-LKB1) or the pBABE control vec-
tor. Cell lines were grown in complete RPMI 1640
(Gibco Life Technologies) supplemented with 10 % fetal
bovine serum (FBS, Lonza), 2 mM L-glutamine, 100 U/
ml penicillin-streptomycin (Lonza). All cell lines were
grown at 37 °C under 5 % CO2 and regularly tested for
mycoplasma contamination. For primary B-CLL cell iso-
lation, a 5 ml blood sample was obtained from patients
presenting with marked lymphocytosis (>20000/μl) ac-
cording to a protocol that was approved by the Ethics
Committee of the Hospital IRCCS AOU San Martino
IST in Genoa (#840, February 18th 2011). Patients’ writ-
ten informed consent was collected. B-CLL cells were
isolated by density gradient centrifugation on Ficoll-
Hypaque (Biotest). The phenotype of the obtained cell
preparations was confirmed by immunostaining with
anti-CD19, anti-CD5, and anti-CD23 (Immunotech), and
subsequent flow cytometric analysis. T-ALL xenografts
(PD T-ALL) were established from BM (bone marrow) of
newly diagnosed ALL pediatric patients, according to a
protocol approved by the ethics committee of the Univer-
sity of Padova (Project number 16B/2013). The PD T-ALL
cells used in this study have been published elsewhere
[27]. At time of PD T-ALL establishment, written in-
formed consent was obtained from the parents of the chil-
dren. In vitro studies were performed with T-ALL cultures
established from the spleen of the xenografts. Purity of the
cultures (in terms of percentage of human CD5+ cells)
was checked by flow cytometry and was always >85 %. Re-
search carried out on human material was in compliance
with the Helsinki Declaration.
Chemicals
FK866 (sc-205325) was bought from Santa Cruz, Com-
pound C (P5499), Nicotinic acid (N0761), Actinomycin
D (A9415), (S)-(+)-Camptothecin (C9911), Cyclohexi-
mide (C1988), MG-132 (M7449), Doxorubicin hydro-
chloride (D1515) and Dexamethasone (D4902) were
bought from Sigma-Aldrich, CHS-828 (200484-11-3)
from Cayman chemical, Torin 1 (S2827) and Rapamycin
(S1039) from Selleck Chemicals, Cisplatin (ALX-400-
040) from Enzo Life Sciences and Propidium Iodide
Staining Solution from BD Pharmingen. Jurkat cells were
treated with drugs dissolved in DMSO at the same cell
density (5X105 cells/ml).
Viability assays
Cell viability was assessed with the Annexin V-FITC
Apoptosis Detection Kit I and 7-Aminoactinomycin D
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(7-AAD) Staining Solution (BD Pharmingen) according
to manufacturer’s instruction. EC50 values of FK866 were
determined by nonlinear regression analysis (GraphPad
Prism software v5.01,) vs viable cells in mock conditions
(DMSO).
Jurkat, A549 and H460 cell lines were grown and
treated in 96 well-plate for 48 h. Cells were then assayed
for viability using Thiazolyl blue tetrazolium bromide
(MTT) M5655 (Sigma). In brief, MTT (5 mg/ml) at
10 % volume of culture media was added to each well
and cells were further incubated for 2 h at 37 °C. Then
100 μl of DMSO was used to dissolve formazan. Absorb-
ance was then determined at 565 nm by microplate
reader. Cell survival was calculated and EC50 values were
determined.
Determination of NAD+-NADH and ATP levels and
caspase/protease activity
Intracellular NAD+-NADH content was assessed with a
NAD+-NADH Quantification Kit (BioVision) according to
the manufacturer’s protocol. Intracellular ATP content
was determined using Cell titer Glo Luminescent Cell Via-
bility Assay (Promega). NAD+-NADH and ATP values
were normalized to the number of viable cells as deter-
mined using Trypan Blue (Lonza). EnzChek Protease
Assay Kit, containing a casein derivative labeled with
green-fluorescent BODIPY FL (Life Technologies), was
used to determine protease activity after treatment of
2x106 cells. Cells were washed once with PBS and lysed in
500 μl of 1X digestion buffer, sonicated and centrifuged
for 5 min at maximum speed. One μl of the BODIPY ca-
sein 100X was added to 100 μl of the supernatant and in-
cubated for 1 h protected from light. Fluorescence was
measured and normalized to protein concentration in the
cell lysates (Bradford Reagent, Sigma). Caspase-Glo 3/7
Assay (Promega) was used to quantify caspase activity.
RNA and protein click-iT labeling kits
Click-iT RNA Alexa Fluor 488 Imaging Kit (Life Tech-
nologies) was used to quantify the level of global RNA
synthesis by flow-cytometry. Jurkat cells (3x106/sample)
were treated for 45 h with FK866 (or DMSO) and then
incubated for 3 h with 1X EU working solution without
removing the drug-containing media. EU detection was
performed following the manufacturer’s protocol after
cell fixation and permeabilization. Click-iT AHA Alexa
Fluor 488 Protein Synthesis Assay (Life Technologies)
was used to measure the rate of translation. Cells
(3x106/sample) were treated for 45 h with FK866, centri-
fuged and incubated for 3 h with 50 μM AHA in L-
methionine-free medium (RPMI Medium 1640,
Sigma-Aldrich) containing the drug (or DMSO). After
fixation and permeabilization, AHA incorporation was
assessed by flow cytometry. 7-AAD Staining Solution
(0.25 μg/sample) allowed the exclusion of non-viable cells.
Western blotting, antibody list and plasmids
Cells were lysed for 5 min on ice in RIPA lysis buffer
supplemented with Protease Inhibitor Cocktail (Sigma-
Aldrich). After sonication and clarification, equal amounts
of proteins were separated by SDS–PAGE and blotted
onto PVDF membranes (Immobilon-P, Millipore), as in
[28]. The antibodies used were: 4EBP1 (sc-6936), p-4EBP1
(Ser 65/Thr 70; sc-12884), EIF4E (sc-9976), p-EIF4E (Ser
209; sc-12885), AKT1/2/3 (sc-8312), p-AKT1/2/3 (Ser
473; sc-7985), MTOR (sc-8319), BCL-2 (sc-509), NAMPT
(sc-130058) from Santa Cruz; EIF2S1 (ab26197), p-EIF2S1
(Ser 51; ab32157), and p-MTOR (Ser 2448; ab1093) from
Abcam; AMPKα (2603), p-AMPKα (Thr 172; 2531), ACC
(3676) and p-ACC (Ser 79; 3661) and MCL1 (4572) from
Cell Signaling. A mouse anti-β-actin antibody (3700, Cell
Signaling) was used as a protein loading control. eIF2a 1
(Addgene plasmid # 21807), eIF2a 2 (Addgene plasmid #
21808) and eIF2a 3 (Addgene plasmid # 21809) were a gift
from David Ron. A549 cells were transfected using Lipo-
fectamine 3000 Reagent from Life Technologies. Cells
were plated in 6 well and transfected at 70 % confluence
for 24 h with 1 μg of DNA. Jurkat cells were transfected
for 48 h with 1 μg of DNA in 24- well plate.
Real-time PCR
Total RNA was extracted with Quick-RNA MiniPrep kit
(Zymo Research) and treated with DNAse. cDNA was
synthesized using RevertAid First Strand cDNA Synthe-
sis Kit (Fermentas) following the manufacturer’s recom-
mendation. Real-time PCR reactions were performed
using the KAPA SYBR FAST Universal qPCR Kit on a
CFX96 Real-Time PCR Detection System (BioRad). Rela-
tive mRNA quantification was obtained with the ΔCq
method using β-actin (ACTB) as housekeeping gene.
Primers’ sequences are reported as follows: BiP/Grp78
(Fw: TGTTCAACCAATTATCAGCAAACTC Rev: TTC
TGCTGTATCCTCTTCACCAGT) ACTB (Fw: CTGGA
ACGGTGAAGGTGACA Rev: AGGGACTTCCTGTAA
CAATGCA) STK11/LKB1 (Fw: GAGCTGATGTCGGT
GGGTATG Rev: CACCTTGCCGTAAGAGCCT).
Lentiviral particles production and luciferase assay
Lentiviral particles were produced using the pHR-SIN-R-
Myc-F, pHR-SIN-F-HCV-R and pHR-SIN-F-CrPV-R
transfer vectors [29], coding for reporter genes controlled
by a cMyc-5′UTR, HCV or CrPV IRESes regulated trans-
lation, by co-transfection of 293 T cells with the packaging
plasmid pCMV-deltaR8.91 and the VSV envelope-coding
plasmid pMD2.G. Five thousand Jurkat cells/sample were
transduced. After treatment with FK866, luciferase activity
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was measured using the Dual-Glo Luciferase Assay Sys-
tem (Promega) and normalized for protein concentration.
Silencing with shRNAs
The pLKO.1-based lentiviral plasmids containing AMPKa1
shRNA (TRCN0000000859), AMPKa2 shRNA (TRCN0000
002169) or NAMPT shRNA expression cassette (TRCN
0000116180) and (TRCN0000116181) were purchased
from Sigma-Aldrich. Scramble shRNA (Addgene plas-
mid #1864 [30]) was used as a control. Vectors were
produced in 293 T cells by cotransfection of the dif-
ferent transfer vectors with the packaging plasmid
pCMV-deltaR8.91 and the VSV envelope-coding plas-
mid pMD2.G. 1 million of Jurkat cells were trans-
duced with lentiviral particles expressing the control
(shSCR) or NAMPT-silencing short hairpin RNA
(shNAMPT) by spinning them down with vector-con-
taining supernatants for 2 h at 1600xg at room
temperature and leaving them incubate overnight at 37 °C
without replacing the transduction supernatant. After
changing the medium, the cells were further incubated for
72 h before collection for WB.
For AMPK silencing experiments, Jurkat cells were
first transduced with the shRNA vector targeting the α1
subunit (shAMPKα1) as reported before. After 24 h
from the first transduction the cells were then trans-
duced again, following the same protocol, with the lenti-
viral vector coding for the shRNA targeting the AMPK
α2 subunit (shAMPKα2). After changing the medium
the next morning, the cells were further incubated for
48 h and then treated for additional 48 h with or without
(DMSO) 5 nM of FK866.
To obtain LKB1 silencing, pLKO.1 transfer vectors
were prepared by cloning annealed oligos coding for
shRNAs (clone TRCN0000000408 for LKB1-A and clone
TRCN0000000409 for LKB1-B) into the TRC cloning
vector (Addgene plasmid #10878 [31] according to the
TRC standard protocol. Cells were transduced by spin-
ning them down with vector-containing supernatants
and leaving them incubate overnight. After changing the
medium, the cells were incubated for 72 h and then
treated for additional 48 h with or without FK866.
Statistical analysis
Experiments were performed in biological triplicates. T-
test was used to calculate final p-values, without assum-
ing variances to be equal (Welch’s t-test). P-value <0.05
was considered statistically significant.
Results
Sensitivity of leukemia cells to the NAMPT inhibitor
FK866
FK866 was previously shown to have cytotoxic activity
at nanomolar concentrations against different types of
hematological malignancies, including myeloid and
lymphoid leukemias and multiple myeloma [12, 21]. We
monitored FK866-induced cell death in Jurkat cells by
quantifying early and late apoptosis with 7AAD and
Annexin V staining. In line with previous reports, FK866
cytotoxic activity started to become evident between 48
and 72 h of exposure with approximately 74 and 47 % of
viable cells left at these time points when cells are
treated with FK866 100 nM (Fig. 1a), respectively. This
suggests the existence of a lag phase through which cells
can cope with the energetic shortage. Starting from a
concentration of 10 nM, FK866 cytotoxic activity
reached a plateau and an EC50 of 5.3 nM could be esti-
mated after 48 h of exposure (Fig. 1a). Indeed, at 120 h
we measured an effective IC50 of 10 nM, highlighting
the inability of these cells to compensate for the ener-
getic stress induced by FK866 in long term treatment
(Fig. 1a). Cell cycle analysis of FK866-treated cells, at
48 h, showed a non-significant accumulation of cells in
G2/M phase, while, as predicted, serum starvation re-
sulted in accumulation of cells in G0/G1 phase (Fig. 1b
and Additional file 1A). Forty-eight hours treatment
with FK866 led to approximately 25 % of cell death, but
did not lead to massive protease or caspase activation
(Fig. 1c and d). However, 5 nM FK866 was sufficient to
effectively reduce NAD+(H) and ATP levels in Jurkat
cells, representing a pre-toxic experimental condition to
apply for further experiments (Fig. 1e).
FK866 and NAMPT ablation blocks cap-dependent
translation, but not gene transcription, through MTOR/
4EBP1, EIF4E, and EIF2A inhibition in cancer cells
We assessed the impact of FK866 on global transcrip-
tional and translational efficiencies in Jurkat cells. Global
RNA transcription and translation were monitored using
the Click-it chemistry and flow-cytometry by the incorp-
oration of the nucleoside analog 5‑ethynyl uridine (EU)
and of an aminoacid analog (AHA), respectively. In the
viable Jurkat cell population, FK866 caused a reduction
in the incorporation of EU in a dose–dependent manner,
with 70 and 55 % of transcriptionally active cells in the
presence of 5 and 100 nM FK866, respectively. Thus,
despite NAD+ and ATP depletion, cells treated with
FK866 for 48 h essentially retained their ability to per-
form RNA transcription. By contrast, even 5 nM FK866
determined a striking reduction (up to 30 %) of the frac-
tion of viable cells showing active protein synthesis
(Fig. 2a and Additional file 1B). The utilization of bicis-
tronic reporter assays to test the efficacy of cap or IRES
(Internal Ribosome Entry Site) dependent translation
confirmed that FK866 induced a strong translation arrest
with a major impact on cap-dependent translation in
Jurkat cells (Additional file 2).
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Since the initiation phase is considered the limiting
step of translation [32], we evaluated the activation of
three signaling pathways regulating the canonical cap-
dependent translation process. The Mammalian Target
of Rapamycin (MTOR) kinase regulates the p70 riboso-
mal S6 kinase (p70-S6K) and the eukaryotic translation
initiation factor 4E-binding protein 4EBP1, whose phos-
phorylation determines EIF4E availability for its interact-
ing partner EIF4G, which is involved in mRNA
recruitment to the ribosomes for protein translation
[32]. It has been recently shown that FK866 induces
MTOR de-phosphorylation [24], thereby inducing au-
tophagic cell death in multiple myeloma cells [21, 33].
As shown in Fig. 2b, Jurkat cells treated with FK866
indeed showed a marked de-phosphorylation of MTOR
and 4EBP1. Enhanced AKT phosphorylation at Ser-473
was also observed (Fig. 2b), which is in line with the
paradoxical activation of AKT by MTORC2 complex fol-
lowing inhibition of MTOR as reported with different
MTOR inhibitors in multiple myeloma cells [34]. Not-
ably, treatment with FK866 led to a previously unappre-
ciated de-phosphorylation of EIF4E on serine 209,
suggesting that the MAP Kinase Interacting Serine/
Threonine Kinase (MNK)-dependent pathway is also af-
fected [35] (Fig. 2c), and to an increased phosphorylation
on Ser-51 of EIF2A, an initiation factor that transfers
methionyl-initiator tRNA (Met) to the small ribosomal
subunit. When phosphorylated (Fig. 2c), EIF2A loses its
Fig. 1 FK866 affects NAD+(H) and ATP levels in Jurkat cells leading to cell death. a Flow-cytometric quantification of cell viability with AnnexinV
(FITC) and 7AAD (PerCP-Cy5-5-A) staining. Jurkat cells were treated with FK866 for 48,72 and 120 h. Mock, 5 nM FK866 and 100 nM FK866 (at 48
and 72 h) are shown as representative samples. Flow-cytometry experiments were carried out on two biological replicates and statistics were
based on the acquisition of 10000 events/sample. b Cell-cycle analysis with PI staining of the nuclei after 48 h of treatment. Overnight serum
starvation is shown as positive control of induced cell cycle synchronization in G0/G1 phase. Histograms quantify the cell cycle phase distribution.
Flow-cytometry experiments were carried out on two biological replicates and statistics were based on acquisition of 30000 events/sample. Cell
cycle phase analysis was done using ModFit LT 3.2 software and the Sync Wizard model. c Jurkat cells were treated with FK866 for 48 h. Alternatively,
cells were exposed to 5 μM of Camptothecin for 4 h as a positive control. Protease activity in cell extracts was assessed with a commercially available
kit and values were normalized to the protein concentration in the same extracts. d Caspase 3/7 activity was measured in Jurkat cells treated as in c. e
Jurkat cells were treated with FK866 for 48 h. Thereafter, intracellular NAD+(H) and ATP levels were evaluated in comparison with control Jurkat cells.
RLUs were normalized to number of viable cells. In c-e the means with SD of at least three independent experiments are shown. Statistical significance
was calculated with t-test (* and # indicates p-value <0.05)
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ability to exchange GDP and GTP, impairing the forma-
tion of a complex with the EIF2B subunit and thus pre-
venting translation initiation [36]. Analogously, SUP-T1
and Molt-4 Clone 8 T-ALL cell lines presented the same
FK866-induced inhibition of the activation of 4EBP1,
supporting the existence of a general mechanism under-
lying the FK866-induced translational arrest in leukemia
cells (Fig. 2d, e). These effects were also observed using
another inhibitor of NAMPT enzymatic activity, CHS-
828 (Additional file 3A), but not with other commonly
used chemotherapeutics as cisplatin, doxorubicin, dexa-
methasone and rapamycin, at equivalent pre-toxic doses.
Indeed, FK866 induced a stronger protein synthesis ar-
rest than the MTOR inhibitor rapamycin suggesting that
this event is a molecular hallmark of FK866. Addition-
ally, FK886 concomitantly induced EIF2A phosphoryl-
ation and 4EBP1 de-phosphorylation, uniquely among
all the other drugs, thus mechanistically supporting the
strong protein synthesis arrest. The other drugs tested
were ineffective (Additional file 3B, C, D). In conclusion,
these experiments show the modulation of several hubs
of the signaling apparatus controlling translation initi-
ation in response to FK866, providing a robust
explanation for the marked protein synthesis inhibition
observed after drug treatment.
FK866 induces AMPK and EIF2A phosphorylation in Jurkat
and primary leukemia cells
In view of the strong translation inhibition and consider-
ing its energy-sensing activity in controlling translation
[37], we investigated in Jurkat cells the impact of FK866
and CHS-828 on the phosphorylation status of AMPK,
whose activation has been previously shown to be induced
by FK866 in prostate and hepatic cancer cells [23, 24].
FK866 caused a partial reduction in total AMPK levels at
the highest dose used, but, at a same time, a parallel dose-
dependent increase of the phosphorylation of its Thr-172
and of its bona fide target ACC (Acetyl-CoA Carboxylase)
(Fig. 3a), indicating a significant activation of AMPK. We
evaluated the effect of FK866 on two important antiapop-
totic factors, MCL1 (Myeloid Cell Leukemia 1) and BCL-2
(B-Cell Lymphoma 2). BCL-2 protein levels were essen-
tially not affected by FK866 treatment as compared to the
strong down-regulation of MCL1 (Fig. 3a). Notably, nico-
tinic acid (NA) supplementation, which blocks FK866
cytotoxic activity by allowing NAD+ biosynthesis through
Fig. 2 FK866 inhibits the signaling cascades controlling protein synthesis in T-ALL cell lines. a RNA synthesis was determined by monitoring EU
incorporation with Click-it chemistry. Jurkat cells were treated for 48 h with or without (Mock) the indicated concentration of FK866 or for 3 h with
5 μM Actinomycin D, an RNA synthesis blocking agent. The histogram quantifies the dose-dependent transcription inhibition induced by FK866
in the viable cell population. In the lower part, Click-it chemistry based on the incorporation of an aminoacid analog (AHA) was used to monitor
protein synthesis. Jurkat cells were treated for 48 h with or without (Mock) the indicated concentration of FK866 or for 3 h with 350 μM Cycloheximide,
as a positive control for protein synthesis inhibition. The histogram quantifies FK866-induced protein synthesis arrest in the viable cell population.
Flow-cytometry experiments were carried out on two biological replicates and statistics were based on acquisition of 50000 events/sample. b Jurkat cells
were treated for 48 h with or without (Mock) the indicated concentration of FK866. Thereafter, cells were lysed and the levels of total and p-Akt (Ser-473),
total and p-MTOR (Ser-2448), total and p-4EBP1 (Ser-65 and Thr-70), c) total and p-EIF4E (Ser-209), total and p-EIF2A (Ser-51) were detected by
immunoblotting. d Molt-4 cells were treated with FK866 for 48 h and the levels of total 4EBP1 and p-4EBP1 were evaluated. e Western blot analysis as
in d in SupT1 cells. b-e, one representative experiment out of at least three biological replicates is presented and β-actin was used as loading control
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an alternative pathway (via nicotinic acid phosphoribosyl-
transferase, NAPRT1), completely prevented AMPK phos-
phorylation in primary B-CLL (Fig. 3b, Additional file 3E),
confirming that NAD+ depletion is responsible for AMPK
activation. In patient-derived T-ALL xenografts (PD T-
ALL) the drug induced cell death and activated AMPK as
well as EIF2A phosphorylation (Fig. 3c and d), demon-
strating that this molecular event is not limited to cell line
models but is also present in primary leukemia cells.
EIF2A phosphorylation precedes 4EBP1 de-
phosphorylation in Jurkat cells
NAMPT expression level during FK866 treatment
remained unchanged as expected (Fig. 4a). Genetic abla-
tion of NAMPT by lentiviral transduction in Jurkat cells
(Fig. 4b) lowered NAD+(H) level to 75 % of the control
while ATP level was not significantly decreased thus in-
ducing an intermediate condition of energetic stress
compared to the one obtained with 5 nM FK866
administration (Fig. 4c). In these conditions of mild
stress, AMPK was marginally activated but, nevertheless,
we observed a significant phosphorylation of EIF2A but
not the de-phosphorylation of 4EBP1, suggesting that
the first event precedes the second one (Fig. 4d). Import-
antly, we observed a clear down-regulation of MCL1, as
observed with FK866 treatment (Fig. 3a), suggesting that
EIF2A activation is an early response to NAD+(H)
shortage.
FK866-induced AMPK activation regulates EIF2A
phosphorylation
To formally assess the role of AMPK in FK866-induced
translational arrest, we pharmacologically blocked
AMPK with Compound C, a small molecule inhibitor of
this enzyme, although not selective [38]. In addition, we
down-regulated AMPK using lentiviral transduction of
shRNAs. Compound C administration to Jurkat cells
treated with FK866 abrogated AMPK phosphorylation,
Fig. 3 FK866 induces AMPK and EIF2A phosphorylation in primary leukemia cells. a Jurkat cells were treated for 48 h with or without (Mock) the
indicated concentration of FK866. Thereafter, cells were lysed and the levels of total and p-AMPK (Thr-172), ACC and p-ACC, BCL-2, MCL1 and
β-actin as loading control were detected by immunoblotting. One representative experiment out of three biological replicates. b primary B-CLL
cells (source: peripheral blood; RAI stage III, 86 years, CD38-pos) were treated for 48 h with or without FK866 in the presence or absence of 1 mM
NA. Thereafter, protein lysates were immunoblotted for AMPK and p-AMPK. c Cell viability with respect to Mock condition, measured by CellTiter
Glo, of three different T-ALL xenografts (PD T-ALL 12, 19 and 25) after treatment with FK866 5nM for 48 h. d WB of PD T-ALL 12 as representative
of T-ALL xenografts samples. Cells were treated with 5 and 50 nM FK866 for 48 h. Histogram shows the densitometric analysis of p-AMPK and
p-EIF2A in the three T-ALL xenografts (PD T-ALL 12, 19 and 25)
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reactivated the MTOR/4EBP1 pathway and restored
EIF2A in its un-phosphorylated state (Fig. 5a). Rescue
experiments with Compound C did not show any down-
regulation of MCL1 protein level with no change in
BCL2 expression (Fig. 5a). Co-treatment with Com-
pound C partially reverted FK866-induced ATP loss but
activated the apoptotic response (Fig. 5b). Down-
regulation of AMPK was achieved by targeting both
AMPKα1 and AMPKα2 isoforms (shAMPK cells). We
then exposed silenced and control (scramble) cells to 5
nM of FK866 for 48 h (Fig. 5c). In shAMPK cells we ob-
served a significant decrease of EIF2A phosphorylation
but not of 4EBP1 de-phosphorylation. This supports the
notion that FK866-induced AMPK activation is primar-
ily involved in the regulation of EIF2A phosphorylation
and subsequently in 4EBP1 de-phosphorylation (Fig. 5c).
Importantly, shAMPK Jurkat cells showed an increased
sensitivity to FK866 with respect to control cells, as re-
vealed by PI staining and flow-cytometry (Fig. 5d),
pointing out the protective effect of AMPK in FK866-
induced stress conditions.
EIF2A mediates the AMPK pro-survival effect during
FK866 treatment
Given the protective role of AMPK in a context of
FK866-sensitive cancer cell, we hypothesized that the
liver kinase B1 (LKB1), a well-established AMPK regula-
tor, can also exert the same protective effect. Indeed,
genetic ablation of LKB1 in Jurkat cells led to an in-
crease toxicity of FK866 treatment (Fig. 6a). Accordingly,
we used two lung adenocarcinoma cell lines (H460 and
A549), bearing genetic inactivation of LKB1 to prove the
dependency of FK866 efficacy on the activation of the
LKB1/AMPK pathway. These results provide a rationale
for the utilization of NAMPT inhibitors in cancers with
this type of genetic background. The cells were stably
transduced with retroviral vectors encoding parental
LKB1 cDNA (LKB1 WT) or with a control vector
Fig. 4 NAMPT genetic ablation induces EIF2A phosphorylation and MCL1 down-regulation. a Expression levels of NAMPT. Jurkat cells were treated
with 5 and 100 nM FK866 for 48 h. One representative experiment out of three biological replicates is presented. b WB analysis indicated 50 % of
NAMPT silencing (p < 0.001) in Jurkat cells by using lentiviral particles expressing two NAMPT-silencing shRNAs (shNAMPT-1 and −2). c Intracellular
NAD+(H) and ATP levels in shNAMPT cells (transduced with shNAMPT-1 and −2) were evaluated in comparison with scramble Jurkat cells. Thirty
percent reduction of NAD+(H) levels was observed in shNAMPT cells (p-value < 0.01). RLUs were normalized to number of viable cells. Mean and SD of
a biological triplicate. d WB analysis of AMPK, p-AMPK, EIF2A, p-EIF2A, p-4EBP1 and MCL1 in shNAMPT (transduced with shNAMPT-1 and −2) cells.
Histogram shows the densitometric analysis of p-AMPK, p-EIF2A and MCL1 (* indicates p-value <0.05). Mean and SD of a biological triplicate
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Fig. 5 AMPK regulates EIF2A phosphorylation and is a pro-survival factor in Jurkat cells. a Jurkat cells were treated with or without FK866 at the
indicated concentrations in the presence or absence of Compound C 5 μM for 48 h. Thereafter, cells were lysed and the levels of p-AMPK (Thr-172),
p-MTOR, 4EBP1, p-4EBP1, BCL-2, MCL1, EIF2A and p-EIF2A were revealed by immunoblotting. Histogram shows the densitometric analysis of p-AMPK
and p-EIF2A. b In the same samples, caspase 3/7 activity was quantified and relative ATP levels were determined and then normalized to the number
of viable cells (* indicates p-value <0.05). a and b are representative of a biological triplicate (mean and SD). c Jurkat cells were transduced with
lentiviral particles containing scramble or shAMPK (targeting the α1 and the α2 subunit), then treated for 48 h with or without 5 nM FK866. Cell lysates
were used for total AMPK, EIF2A, p-EIF2A, 4EBP1, p-4EBP1 and β-actin immunoblotting. WB analysis indicated 40 % of AMPK silencing (p-value < 0.05)
and densitometric analysis shows the significant decrease of p-EIF2A in shAMPK Jurkat cells (p-value < 0.03). Mean and SD of a biological triplicate. d
Jurkat scramble and shAMPK cells were treated for 48 h with the indicated doses of FK866. Cell viability was determined by PI staining and flow-
cytometry (two biological replicates and statistics based on the acquisition of 10000 events/sample)
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(pBABE). FK866 treatment induced AMPK and EIF2A
phosphorylation in addition to 4EBP1 de-phosphorylation
only when LKB1 was active. On the other hand, albeit to a
different extent among the two cell lines, FK866 was not
able to activate AMPK or EIF2A but was still effective in
de-phosphorylating 4EBP1 when LKB1 was inactive. Via-
bility assays indicated an increased sensitivity of LKB1
negative, EIF2A un-phosphorylated cells to FK866 com-
pared to LKB1 expressing cells (Fig. 6b and Additional file
4A). Finally, in order to assess the relevance of EIF2A in
mediating the AMPK induced protection from FK866, we
treated with the drug A549 and Jurkat cells transfected
with EIF2A, its phosphomimetic mutant S51D or with the
non-phosphorylatable mutant S51A. In the context of in-
active LKB1, the overexpression of EIF2A and the EIF2A-
S51D isoform led to a protective effect, while the alanine
mutant induced an increase of cell toxicity (Fig. 6c). The
same trend was observed also in Jurkat cells (Additional
file 4B). Therefore, these data indicate that the translation
arrest induced by EIF2A mediates the protective effect of
AMPK from FK866 induced stress.
EIF2A balances pro-survival and pro-death pathways
EIF2A is a key factor regulating the translation machin-
ery in response to a myriad of factors including nutrient
depletion, presence of exogenous mRNA and the Un-
folded Protein Response (UPR) following the induction
of Endoplasmic Reticulum (ER) stress [39]. Indeed,
FK866 induced the overexpression of BiP/Grp78 mRNA,
coding for a chaperone involved in the folding of ER
proteins (Fig. 6d), thus indicating UPR activation in
Jurkat cells after 48 h treatment. Moreover, FK866 in-
duced MCL1 down-regulation was dependent on prote-
asome activation as demonstrated by the rescue of its
expression level by MG132 treatment in Jurkat cells
(Fig. 6e) [40]. In conclusion, FK866 induces an AMPK-
Fig. 6 Protective role of EIF2A and FK866 induced UPR. a Expression level of LKB1 mRNA, evaluated in Jurkat cells after 120 h of lentiviral
transduction with shRNAs expressing the control sequence (scramble) or two LKB1-silencing shRNAs (shLKB1-a and –b), in the upper panel. Cells
were transduced for 72 h and then treated with FK866 for 48 h. Viability was measured by MTT assay in comparison with Mock (DMSO) condition,
in the lower panel. Mean and SD of a biological triplicate (*, p-value < 0.05). b WB analysis indicated the levels of AMPK, p-AMPK, p-EIF2A, p-4EBP1
in A594 cells expressing LKB1 (LKB1 WT) or transduced with an empty vector (pBABE) treated or not (Mock) with 100 nM FK866 for 48 h, left
panel. A549 cells were treated with indicated concentration of FK866 for 48 h and cell viability as shown in dose–response curve was evaluated
by MTT assay, right panel. Mean and SD of three biological replicates. c A549 viability after 48 h of treatment with FK866 100 nM in un-transfected
(NTC) cells and transfected with EIF2A wild type, EIF2A-S51A, EIF2A-S51D (mean and SD of three experiments,*, p-value < 0.05). d Expression level of
BiP mRNA, evaluated in Jurkat cells after 48 h of treatment with FK866 5nM (*, p-value < 0.0005). Mean and SD of a biological triplicate. e WB analysis
of MCL1 in Jurkat cells treated with FK866 for 48 h and with the proteasome inhibitor MG132 1 μM for 24 h. MG132 was added after 24 h of FK866
treatment. One representative experiment out of three biological replicates
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EIF2A mediated translational arrest, which is responsible
for MCL1 down-regulation and the activation of the
UPR response, that is a strategic pausing step necessary
to protect cells from FK866-induced energetic stress.
Discussion
We investigated the link between NAD+(H) depletion
and cell death using a T-ALL cell model after induc-
tion of the primary effects of NAMPT inhibition,
namely NAD+(H) and ATP depletion, while nearly
preserving total cell viability. The functional conse-
quences of NAD+(H) depletion upon FK866 treatment
resulted in a marked inhibition of the three major
pathways regulating the translation process and in a
striking arrest of protein synthesis. Interestingly,
FK866 efficacy in blocking protein synthesis was
higher than all the other chemotherapeutics tested
and even higher than the MTOR inhibitor rapamycin,
suggesting that this is a crucial event in the cell re-
sponse to FK866. This phenomenon is general be-
cause it was observed in primary leukemic samples,
coming both from B-CLL and T-ALL patients, and in
T-ALL derived cancer cell lines. Nicotinic acid rescue
experiments, treatment with the FK866 analog CHS-
828 and NAMPT genetic ablation showed that trans-
lation arrest was dependent on the shortage of ATP
and NAD+(H) induced by the inhibition of the
NAMPT catalytic function and not by unspecific
FK866 effects. FK866 has been shown to have con-
trasting effects on AMPK. In neuronal cells FK866
decreased AMPK activation and was detrimental for
neuronal survival [25], however in cancer cells that
have a dysregulated metabolic demand, it has been
observed the opposite. In prostate cancer cells, FK866
treatment reduced fatty acid and phospholipid synthe-
sis, partly via AMPK activation [23]. FK866 induced
activation of AMPK and subsequent decreased phos-
phorylation of 4EBP1 by MTOR has been observed in
hepatocarcinoma cells. Given the importance of
MTOR in sustaining cancer cell growth, this event
was proposed as an effective mechanism to target
cancer cells [23]. By evaluating the early molecular effects
of FK866 treatment on protein synthesis, we observed the
involvement of the same pathway but, in addition, we
showed a protective role for AMPK and EIF2A. In our ex-
perimental conditions, the inactivation of MTOR by
AMPK and consequent protein synthesis arrest had a pro-
tective effect conferring temporary resistance to the
FK866-induced energetic stress. Additionally, we deter-
mined that AMPK-induced hyper-phosphorylation of
EIF2A is regulated by the fluctuations of NAD availability
at the intracellular level. This molecular mechanism, lead-
ing to inhibition of translation initiation, followed AMPK
activation. In fact, genetic AMPK down-regulation of both
isoforms of the α catalytic subunit rescued the FK866 in-
duced hyper-phosphorylation of EIF2A. As a further con-
firmation, the same results were obtained by AMPK
functional ablation using the inhibitor Compound C or by
inactivation of its upstream regulator LKB1. Indeed, res-
cue of 4EBP1 phosphorylation levels was observed only
after Compound C administration, suggesting that EIF2A
is a preferential target of the AMPK signaling cascade, at
least in the initial phase of cell response to FK866. Inter-
estingly, in our cell model and at the doses we used, we
did not observe Compound C-induced phosphorylation of
EIF2A as recently reported in different cancer cells [41].
Our cell model resembles the AICAR-induced AMPK ac-
tivation that leads to EIF2A phosphorylation in adipocytes,
an event shown to be crucial for AMPK-induced apoptosis
[42], and supports the idea that FK866 induced activation
of the AMPK-EIF2A axis can be a novel pathway to be in-
vestigated to elucidate the pharmacology of FK866.
Many types of cancer, as sporadic lung, cervical, and
endometrial cancers, carry LKB1 deficiency that can be
exploited with metabolic drugs since these cells are un-
able to appropriately respond to metabolic stress [43].
Given the protective role of LKB1/AMPK pathway
against FK866, our study suggests the utilization of
FK866 as a metabolism-based cancer therapeutic to se-
lectively target LKB1-deficient tumors. Indeed in cells
lacking a functional LKB1 pathway, metabolic stress has
been demonstrated to result in rapid apoptosis as the
cells are unable to sense energetic stresses and activate
mechanisms to restore energy homeostasis [44].
Previous studies have shown that inhibition of the
MTOR/4EBP1 pathway in leukemia cells leads to a re-
duction in the levels of the anti-apoptotic protein
MCL1, with important implications for chemosensitivity
[45]. Down-regulation of MCL1 through inhibition of
translation has been clearly associated with enhanced le-
thality in Jurkat cells [46]. Importantly, FK866 adminis-
tration led to smooth death [40] via EIF2A-dependent
MCL1 down-regulation consequent to translation arrest
and simultaneous proteasome activation. Indeed, MCL1
intracellular levels were shown to be strictly dependent
on the activation of EIF2A [47] and AMPK [48], and to
the subsequent translation arrest. This could provide a
molecular explanation for the anti-leukemic activity of
NAMPT inhibitors. Notably, the ectopic expression of
the non-phosphorylatable mutant EIF2A-S51A increased
FK866 toxicity. Therefore the activation of the AMPK-
EIF2A axis is essential for the tumor cell to adapt to the
shortage of NAD+(H). For example, the increased ex-
pression level of BiP mRNA is a specific adaptive re-
sponse observed in the integrated stress response (ISR)
and translational repression [49]. The exacerbation of
proteasome inhibition with bortezomib has been shown
to potentiate FK866 efficacy through the activation of
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the caspases’ cascade [40]. Here we show the relevance
of EIF2A activation in this mechanism. Additionally, the
synergistic effect of FK866 with cyclosporine in leukemia
cells has been ascribed to the activation of the UPR [50].
This suggests that the exacerbation of the UPR, which is
dependent on EIF2A, can be thought as a relevant strat-
egy to potentiate the effect of FK866 in conditions in
which activation of the EIF2A-dependent UPR is desir-
able, i.e., diabetes, atherosclerosis, or neurodegenerative
disorders [51]. Indeed, FK866 effects on translation re-
semble the ones induced by metformin, a well-known
AMPK activator with antidiabetic and antitumoral prop-
erties [52, 53]. Finally, de-phosphorylation of EIF4E,
never linked to NAMPT inhibitors or AMPK activation
before, completes the general picture of a global inhib-
ition of the translation process, even though the mech-
anism leading to upstream MNK activation has not been
investigated yet.
Conclusions
In conclusion, this work describes the activation of a
complex signaling network in which the AMPK-EIF2A
axis is responsible for the early cellular response to the
metabolic stress produced by FK866. In an experimental
condition in which catastrophic proteolytic cascades are
not yet started but the energetic demand is high, EIF2A
acts as an early master regulator of cell fate, blocking
anabolic processes and, at the same time, modulating
cell death and adaptive pathways. Therefore EIF2A-
dependent processes, such as protein synthesis and UPR,
acquire fundamental relevance in explaining the mech-
anism of action of NAMPT inhibitors.
Additional files
Additional file 1: Cell-cycle analysis and Click-iT detection of RNA
and Protein synthesis. A) Cell-cycle analysis with PI staining of the
nuclei after 48 h of treatment. Overnight serum starvation is shown as a
positive control of induced cell cycle synchronization in G0/G1 phase. Cell
phase analysis was done with ModFit LT 3.2 software by using the Sync
Wizard model (30000 cells/sample in biological duplicate). B) Jurkat cells
were treated for 48 h with or without (Mock) the indicated concentration
of FK866 or for 3 h with 5 μM Actinomycin D, an RNA synthesis blocking
agent, then subjected to Click-it biochemistry and flow-cytometry
analyses including 7-AAD to identify living cells. C) Jurkat cells were
treated for 48 h with or without (Mock) the indicated concentration of
FK866 or for 3 h with 350 μM Cycloheximide, as a positive control for
protein synthesis inhibition, then stained as in B. In B and C. Experiments
were carried out on two biological replicates (50000 events/sample).
(PDF 1562 kb)
Additional file 2: Luciferase assays. A) Light units, normalized to
protein concentration, of RLuc-cMyc 5′UTR IRES-FLuc reporter vector
transduced in Jurkat cells with lentiviral particles after 48 h of treatment
with or without (Mock) the indicated concentration of FK866. Two hour
treatment with 250 nM of Torin 1 served as a positive control for IRES-
dependent protein translation (p-value <0.05). B) Light units, normalized
to protein concentration, of FLuc-HCV-RLuc and FLuc-CrPV-RLuc reporter
vectors transduced in Jurkat cells with lentiviral particles. Cap-dependent
translation (FLuc) was strongly reduced with 5 nM and 100 nM FK866
(48 h) in comparison to Mock condition (p-value <0.0001). RLuc signal is
not shown because of its low level and its variability between technical
and biological replicates. Cells transduced with the pHR-SIN-F-HCV-R were
serum starved for 5 h as a positive control of IRES activation, as shown in
the graph (p-value <0.05). In A and B data are represented as mean and
SD of three independent experiments. (PDF 584 kb)
Additional file 3: Effects of CHS-828 and chemotherapeutics on
protein translation. A) Jurkat cells were treated for 48 h with or without
(Mock) the indicated concentration of CHS-828. Caspase 3/7 activity was
quantified (using 5 μM of Camptothecin for 4 h as a positive control of
apoptosis) and relative ATP levels were determined and then normalized
to the number of viable cells. The levels of total AMPK, p-AMPK, total
EIF2A and p-EIF2A, total 4EBP1, p-4EBP1 were evaluated by WB. Histogram
shows the densitometric analysis of p-AMPK and p-EIF2A (* indicates p-value
<0.05). Mean and SD of a biological triplicate. B) Jurkat cells were treated with
the indicated concentration of drugs for 48 h and cell viability was measured
by Cell Titer Glo. Data are represented as mean and SD of three independent
experiments. C) Click-it chemistry based on the incorporation of an aminoacid
analog (AHA) was used to monitor protein synthesis. Jurkat cells were treated
for 48 h with or without (Mock) the indicated concentration of FK866,
Rapamycin (RAPA), Doxorubicin (DOXO), Cisplatin (CIS) and Dexamethasone
(DEXA). The histogram quantifies the % of AHA positive cells (active protein-
synthesizing cells) in the viable cell population. Flow-cytometry experiments
were carried out on two biological replicates and statistics were based on
acquisition of 20000 events/sample. D) Jurkat cells were treated as in C and
the level of p-EIF2A and p-4EBP1 was evaluated. Histogram shows the
densitometric analysis of p-EIF2A (* indicates p-value <0.05). Mean and SD of
a biological triplicate. E) Primary B-CLL cells were treated for 48 h with or
without 30 nM FK866 in the presence or absence of 1 mM NA. Histogram
shows the densitometric analysis of p-AMPK/AMPK. (PDF 691 kb)
Additional file 4: Protective role of EIF2A. A) WB analysis indicated
the levels of AMPK, p-AMPK, p-EIF2A, p-4EBP1 in H460 cells expressing
LKB1 (LKB1 WT) or transduced with an empty vector (pBABE) treated or
not (Mock) with 100 nM FK866 for 48 h, left panel. H460 cells were
treated with indicated concentration of FK866 for 48 h and cell viability
as shown in dose–response curve was evaluated by MTT assay, right
panel. Mean and SD of three biological replicates. B) Jurkat viability after
48 h of treatment with FK866 5nM in un-transfected (NTC) cells and
transfected with EIF2A wild type, EIF2A-S51A, EIF2A-S51D (mean and SD
of three experiments,§, p-value < 0.1). (PDF 274 kb)
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Abstract
Purpose: The nicotinamide phosphoribosyltransferase
(NAMPT) inhibitor, APO866, has been previously shown to
have antileukemic activity in preclinical models, but its cyto-
toxicity in primary leukemia cells is frequently limited. The
success of current antileukemic treatments is reduced by the
occurrence of multidrug resistance, which, in turn, is mediated
by membrane transport proteins, such as P-glycoprotein-1
(Pgp). Here, we evaluated the antileukemic effects of APO866
in combination with Pgp inhibitors and studied the mechan-
isms underlying the interaction between these two types of
agents.
Experimental Design: The effects of APO866 with or
without Pgp inhibitors were tested on the viability of
leukemia cell lines, primary leukemia cells (AML, n ¼ 6;
B-CLL, n ¼ 19), and healthy leukocytes. Intracellular nic-
otinamide adenine dinucleotide (NADþ) and ATP levels,
mitochondrial transmembrane potential (Dcm), markers of
apoptosis and of endoplasmic reticulum (ER) stress were
evaluated.
Results: The combination of APO866 with Pgp inhibitors
resulted in a synergistic cytotoxic effect in leukemia cells, while
sparing normal CD34þ progenitor cells and peripheral blood
mononuclear cells. Combining Pgp inhibitors with APO866 led
to increased intracellular APO866 levels, compoundedNADþ and
ATP shortage, and induced Dcm dissipation. Notably, APO866,
Pgp inhibitors and, to a much higher extent, their combination
induced ER stress and ER stress inhibition strongly reduced the
activity of these treatments.
Conclusions: APO866 and Pgp inhibitors show a strong syn-
ergistic cooperation in leukemia cells, including acute myeloge-
nous leukemia (AML) and B-cell chronic lymphocytic leukemia
(B-CLL) samples. Further evaluations of the combination of
these agents in clinical setting should be considered. Clin Cancer
Res; 21(17); 3934–45. !2015 AACR.
Introduction
Intracellular nicotinamide adenine dinucleotide (NADþ)
is essential for several cellular processes, acting either as
a coenzyme in redox reactions or as a substrate for
NADþ-degrading enzymes. Cancer cells are highly dependent
on NADþ to face increased metabolic demands and high
proliferation rates (1). Tryptophan, nicotinic acid (NA), nic-
otinamide (NAM), and nicotinamide ribose are the main
NADþ precursors in mammals. Speciﬁcally, NADþ production
from NAM via nicotinamide phosphoribosyltransferase
(NAMPT) appears to play a major role in lymphocytes and
hematopoietic cells and to be further upregulated in leukemia
cells, justifying their susceptibility to NAMPT inhibitors such
as APO866 (formerly known as FK866 or WK175; refs. 2–9).
On the basis of its promising preclinical activity, APO866
was proposed as novel drug for different hematologic malig-
nancies (4, 7, 10, 11). Nevertheless, this agent exhibits var-
iable and frequently limited cytotoxicity against primary
leukemia cells, which limits its applicability as a single agent.
In the attempt to obviate to such limitation, APO866 has
been combined with TRAIL (12), DNA-damaging agents (dau-
norubicin, cisplatin, Ara-C, and melphalan; refs. 13, 14),
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ionizing radiations (15), rituximab (16), and proteasome
inhibitors (17), frequently achieving remarkable anticancer
effects.
Multidrug resistance (MDR) limits the beneﬁt of different types
of anticancer agents (18). Its etiology is multifactorial, but over-
expression of membrane transport proteins, such as 170-kDa
P-glycoprotein-1 (Pgp), represents a leading cause (19). By extrud-
ing drugs across the plasma membrane, Pgp reduces their intra-
cellular concentration and, thus, their efﬁcacy (20–25). Consis-
tent with this biologic function, high levels of Pgp are frequently
observed in hematologic (lymphomas, multiple myeloma, and
leukemia; refs. 26, 27), aswell as in solid (neuroblastoma and soft
tissue sarcoma) tumors (28) and Pgp overexpression has been
frequently associated with a poor prognosis. Several natural and
synthetic Pgp inhibitors have been identiﬁed, including drugs in
clinical use, such as calcium channel blockers (verapamil and
nifedipine), indole alkaloids (reserpine), steroids (progesterone
and tamoxifen) and the immunosuppressive agents cyclosporin A
and rapamycin (29). A recent clinical study evaluated PSC-833
(valspodar), a second-generation Pgp inhibitor, in combination
with chemotherapy in patients with acutemyelogenous leukemia
(AML; ref. 30). Disappointingly, this trial failed to show any
clinical advantage from the use of the Pgp inhibitor, suggesting
that the clinical settings and the anticancer treatments that are
going to beneﬁt the most from the use of Pgp inhibitors may still
have to be identiﬁed.
Here, we demonstrate that Pgp inhibitors, such as cyclosporin
A (CsA), verapamil, and PGP-4008, synergistically increase the
antileukemic activity of APO866. This effect is shown to reﬂect
an increased intracellular concentration of APO866, which, in
turn, increases its ability to block growth- and survival-promot-
ing pathways in leukemia cells.
Materials and Methods
Cell lines and reagents
The leukemia (OCI/AML2, OCI/AML3, HL-60, HEL, KG1a,
SET1, MV4-11, MEC.1, MEC.2, and LAMA-84 imatinib sensitive
or resistant) multiple myeloma (RPMI-8226 and Dox40) and
lymphoma (Daudi, U937, Raji, and SU-DHL1) cell lines were
provided by collaborators or purchased from ATCC or DSMZ
(Braunschweig, Germany). All cell lines were grown in RPMI-
1640–based medium supplemented with 10% FBS (GIBCO;
Life Technologies), 2 mmol/L L-glutamine, 100 U/mL penicillin,
and 100 mg/mL streptomycin (GIBCO; Life Technologies).
Nilotinib was supplied by Novartis and was stored at 10
mmol/L in DMSO at #20$C. CsA, verapamil, melphalan,
doxorubicin, ﬂudarabine, and velcade were obtained from the
pharmacy of the S. Martino Hospital in Genoa, Italy. PGP-4008
was purchased from Alexis Biochemicals (Plymouth Meeting).
Tetramethylrhodamine ethyl ester (TMRE), 4-PBA, NAM, and
NA were obtained from Sigma-Aldrich (Sigma-Aldrich Italia).
APO866 was generously provided by the NIMH Chemical
Synthesis and Drug Supply Program.
Primary cell isolation from patient samples
Following written consent obtainment, peripheral blood
samples were obtained from a cohort of 25 patients (19 B-CLL
and 6 AML) and healthy donors (n ¼ 3) at the Department of
Internal Medicine of the University of Genova (Genova, Italy),
according to the Declaration of Helsinki. The clinical and
laboratory features of B-cell chronic lymphocytic leukemia
(B-CLL) and AML patients are summarized in Tables 1 and 2,
respectively. For B-CLL cell isolation, peripheral blood mono-
nuclear cells (PBMC) were isolated by density gradient centri-
fugation on Ficoll-Hypaque (Biotest). The B-CLL phenotype of
the obtained cell preparations was conﬁrmed by immunostain-
ing with anti-CD19, anti-CD5, and anti-CD23 (Immunotech),
followed by the ﬂow cytometric analysis. The purity of the
isolated B-CLL cells was typically >85%. AML blasts were
isolated by adding a 6% dextran solution (Fresenius Kabi) to
the blood specimens at a ratio of 4:5, followed by a 1-hour
incubation at room temperature. Thereafter, the leukocytes-
enriched supernatants were transferred to a 50 mL conical
centrifuge tube and centrifuged at 300 % g for 10 minutes.
Residual red blood cells were lysed by suspending the cell
pellets in 4 mL 0.2% NaCl for 30 seconds followed by addition
of 4 mL 1.6%NaCl and immediate centrifugation at 300% g for
10 minutes. Normal PBMCs were isolated from healthy donor
blood samples by density gradient centrifugation on Ficoll-
Hypaque. Cells were either used immediately for viability
assays or for mRNA isolation, or stored at #80$C in medium
containing 20% FBS and 10% DMSO. CD34þ peripheral blood
precursor cells (PBPC) were obtained from the excess PBPC
concentrates (1–2 mL) of G-CSF–mobilized patients undergo-
ing autologous PBPC transplantation (n ¼ 3), after obtaining
informed consent according to the Declaration of Helsinki.
CD34þ cells were puriﬁed using the CD34 MicroBead Kit from
Miltenyi Biotec (Bergisch Gladbach) according to the manu-
facturer's instructions. Using this method, CD34þ cells were
typically >80% pure and >80% viable as detected by propidium
iodide (PI) staining and ﬂow cytometry (see below).
Viability assays
A total of 2% 105 cells per well (primary leukemia cells, PBMCs
andPBPCs)or 5%104 cells perwell (OCI/AML3andMEC.1)were
plated in 96-well plates in aﬁnal volumeof 200mL in the presence
or absence of the indicated stimuli. Dead cells were quantiﬁed
Translational Relevance
The rate-limiting enzyme in nicotinamide adenine dinu-
cleotide (NADþ) biosynthesis from nicotinamide, NAMPT
(nicotinamide phosphoribosyltransferase), regulates
growth and metastatic potential of tumor cells. Leukemic
cells show a higher NADþ turnover rate than normal cells,
suggesting that NADþ biosynthesis could be critically
required in hematologic malignancies, too. Here, we show
that the NAMPT inhibitor APO866 is active, but only
achieves a partial cell killing in primary leukemia cells.
Inhibition of P-glycoprotein 1 (Pgp), which is one of the
key factors mediating multidrug resistance, is shown to
potentiate the cytotoxic effects of APO866 in leukemia
cells, but not in healthy leukocytes and hematopoietic
progenitor cells, by increasing intracellular APO866 con-
centration and thereby exacerbating ATP shortage and
endoplasmic reticulum stress. Our data indicate a possible,
new, safe, and widely applicable approach for treating
hematologic malignancies.
Mechanism of Synergy between APO866 and Cyclosporin-A
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96 hours later by PI staining (2 mg/mL) and ﬂow cytometry (FACS
Calibur; Becton Dickinson). Speciﬁc death was calculated as
follows: [(% experimental death # % spontaneous death)/
(100#% spontaneous death)]% 100. For Annexin-V/PI staining
3 % 106 leukemic cells were plated in 1 mL medium in 24-well
plates in thepresence of the indicated stimuli and for the indicated
amounts of time. Afterwards, cells were washed, stained with
Annexin-V-FITC (Becton Dickinson) and PI and analyzed by
ﬂow cytometry. For the detection of hypodiploid cell nuclei, cell
pellets were suspended in a buffer containing 0.1% sodium
citrate, 0.1% Triton-X 100, and 50 mg/mL PI. Thereafter, cells
were analyzed by ﬂow cytometry.
Mitochondrial transmembrane potential (Dcm)
determination
Dcm was determined as previously described (4, 17). Brieﬂy,
cells were harvested, washed and incubated in the presence of
50 nmol/L TMRE in regular RPMI-based medium for 150 at 37$C.
Thereafter, cells were analyzed by ﬂow cytometry.
Immunoblotting
Whole-cell lysates and cell fractions were prepared as previ-
ously described (4, 17). Protein concentrations were determined
by Bradford assay (Bio-Rad) and 10 to 50 mg proteins
were subjected to SDSPAGE, transferred to polyvinylidene
diﬂuoride membranes, and detected with the following antibo-
dies: anti-NAMPT (Bethyl Laboratories, Inc.), anti-BIP, -IRE1a,
-ubiquitin, -CHOP, -MDR1/ABCB1 (Cell Signaling Technology),
anti–g-tubulin (mouse monoclonal; Sigma Aldrich) and anti-
nucleolin (Santa Cruz Biotechnology). Standard enhanced
chemiluminescence (ECL by Thermo Fisher Scientiﬁc) was used
for protein bands detection.
Determination of NADþ and ATP levels
Intracellular NAD(H) content was determined with an NAD
(H) Quantiﬁcation Kit by BioVision following the instructions of
the manufacturer. Intracellular ATP content was determined with
Cell titer Glo Luminescent Cell Viability Assay (Promega). NADþ
and ATP values were normalized to the number of viable cells as
determined with Trypan Blue (Lonza).
Intracellular APO866 measurement
A total of 20 % 106 primary B-CLL cells were plated in 6-well
plates and treated for 24hourswith 3nmol/L APO866 in presence
or absence of CsA 0.3 mmol/L. Thereafter, cells were harvested and
lysed in water. The extracted material was analyzed on an Agilent
1100 capillary chromatography system, equipped with a diode
array detector and coupled to a mass spectrometer Agilent 1100
series LC/MSD Trap, equipped with an orthogonal geometry
electrospray ion source and an ion-trap analyzer. HPLC separa-
tion was performed on a Waters Atlantis TM dC18 column
(150 % 1 mm; particle size, 3 mm) at a ﬂow rate of 30 ml/min;
eluent A was 0.1% formic acid in water, eluent B was acetonitrile
containing 0.1% formic acid, and the applied gradient was as
follows: during the ﬁrst 5 minutes eluent B was maintained at
5%. Subsequently, between 5 and 35minutes, eluent B was prog-
ressively increased to 100%. Detection wavelength was set at
220 and 260 nm. MS spectra were acquired in positive ion mode
in the m/z range, 100 to 400. APO866 concentration values were
normalized to a protein concentration.
Immunohistochemistry
Sections of bone marrow (BM) samples from patients diag-
nosed with hematologic malignancies at the IRCCS AOU San
Martino-IST were stained with anti-NAMPT (clone H-300;
sc-67020; Santa Cruz Biotechnology; ref. 31). IHCwas performed
using the Ventana BenchMark XT automated immunostainer.
Tissue sections were deparafﬁnized and rehydrated. After antigen
Table 1. Clinical and laboratory features of B-CLL patients
Patient no. Sex Age, y Cytogenetics RAI stage IgVH Zap70 CD38
#1& M 71 Nor RAI 0 Mutated Neg Neg
#2& F 67 13q- RAI IV Mutated Pos Pos
#3& F 68 Nor RAI IV Mutated Neg Neg
#4 M 74 17p- RAI 0 Unmutated Pos Neg
#5 M 76 Nor RAI II Mutated Neg Neg
#6 M 65 ND RAI IV Mutated Neg Neg
#7 M 66 17p- RAI II Mutated Pos Pos
#8& M 58 Nor RAI II Mutated Neg Neg
#9& M 79 13q-,17p- RAI 0 Unmutated Pos Pos
#10 M 72 Nor RAI IV Unmutated Pos Pos
#11& F 67 ND RAI 0 Mutated Neg Neg
#12 M 56 17p- RAI 0 Mutated Pos Pos
#13 M 77 12 þ RAI II Mutated Neg Neg
#14 M 75 ND RAI III Unmutated Pos Neg
#15& M 73 13q-,11q- RAI IV Unmutated Neg Pos
#16 M 67 Nor RAI 0 Mutated Neg Neg
#17 M 65 ND RAI II Mutated Pos Pos
#18 M 77 12þ RAI IV Mutated Pos Neg
#19& F 75 ND RAI II ND ND ND
Abbreviations: ND, not determined; Nor, normal; þ, trisomy; & , chemonaive patient.
Table 2. Clinical and laboratory features of AML patients
Patient nr. Sex Age Sample source FAB Stage % Blasts
#20 M 53 PB M4 95
#21 F 50 PB M1 78
#22 M 80 BM M0/M1 90
#23 M 78 PB Secondary 80
#24 M 79 PB Secondary 70
#25 F 79 PB M4 80
Abbreviations: BM, bone marrow; PB, peripheral blood.
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retrieval, sections were incubated with primary antibodies at a
dilution of 1:200 and3,30-diaminobenzidine (DAB)was used as a
chromogen. Sections were counterstained with May-Gr€unwald-
Giemsa.
RNA interference
RNAi was performed with an ON-TARGET PLUS SMART pool
targeting ABCB1 (GE Dharmacon). A nontargeting scrambled
negative control siRNA was used as negative control (GE Dhar-
macon). Brieﬂy, OCI/AML3 and MEC-1 cells were transiently
transfected with MDR-1 siRNA with the Amaxa technology
(V-solution with X-001 or U-013 program, respectively).
Statistical analyses
Each experiment was repeated at least three times. Statistical
analyses were performed with GraphPad Prism software 6 using
one-way ANOVA for multiple group comparison or the
unpaired t test for two-group comparison. P values below
0.05 were considered signiﬁcant. Expression levels of NAMPT
in human cancer cell lines were obtained from datasets
collected in Oncomine portals at http://www.oncomine.org
(Barretina Cell Line dataset). Copy-number data for the human
7q22.3 locus (where NAMPT maps) in tumor cell lines was
downloaded from the publicly available database (http://www.
broadinstitute.org/ccle). Next, data were analyzed using the
Integrative Genomics Viewer (IGV) analysis software. Expres-
sion levels of NAMPT in different hematologic tumors, were
obtained from publicly available Gene Expression Omnibus
(GEO) datasets (accession numbers GSE12417 for AML;
GSE4475 for DLBCL and GSE22762 for CLL). Differences in
median-centered transcript levels between different groups of
samples were evaluated by the unpaired Student t test. Drug
synergism was analyzed by isobologram analysis using the Calcu-
Syn Version 2.0 software program (Biosoft). A combination index
(CI) less than 1.0 indicates synergism; CI ¼ 1, additive effect; and
CI > 1, no signiﬁcant combination effect (32).
Results
NAMPT is overexpressed and has adverse prognostic relevance
in hematologic malignancies
We ﬁrst investigated the relevance of NAMPT in hematologic
malignancies by characterizing its expression in a wide range of
cell lines and patient samples. In line with previously published
data (4, 7, 12, 17, 33), an analysis of the Cancer Cell Line
Encyclopedia database (34) revealed higher NAMPT expression
levels in hematologic malignancies (including lymphomas, leu-
kemias, and multiple myeloma) compared with cancer cell lines
of epithelial origin (Fig. 1A). An array-based comparative geno-
mic hybridization analysis of the same dataset showed focal
ampliﬁcation of the NAMPT locus (mapping on 7q22.3) and
NAMPT transcript levels were found to correlate with the DNA
copy number, particularly in cell lines derived from hematologic
malignancies (Pearson value ¼ 0.391; P¼ 0.002; Supplementary
Fig. S1A and S1B). These ﬁndings, supported by the strong
NAMPT expression in leukemia cell lines (Fig. 1B) and by our
previous study of NAMPT's role in multiple myeloma (4, 17, 35),
prompted us to further investigate the role of this enzyme in
leukemogenesis. Using IHC, we were able to conﬁrm that BM
biopsies from newly diagnosed AML and B-CLL) patients exhibit
signiﬁcantly increasedNAMPT levels than samples obtained from
healthy donors (Fig. 1C). We also retrospectively analyzed the
prognostic relevance of baseline NAMPT expression by interro-
gating microarray datasets of AML, DLBCL, and B-CLL patients.
As shown in Fig. 1D, high NAMPT expression in hematologic
malignancies was signiﬁcantly associated with poor overall sur-
vival (OS). Thus, altogether, these data supported the notion
that NAMPT plays an important role in the pathophysiology of
hematologic malignancies and that it represents an attractive
therapeutic target (11, 16, 34, 36).
Pgp inhibitors synergistically cooperate with APO866 to the
killing of human leukemia cells
The variability of APO866 antitumor effects prompted us to
search for drugs that, when combined with this NAMPT inhibitor
would enhance its efﬁcacy (12, 14, 16, 17, 37). To this end, we
screened several agents that are widely used in hematology,
monitoring their effects on viability of primary leukemia cells
(either as single agents or in combination with APO866). As
shown in Fig. 2A, CsA was readily identiﬁed as one of the best
sensitizers of primary B-CLL cells to the activity of APO866. CsA is
an immunosuppressant whose mechanism of action entails the
obstruction of calcineurin and, thereby, inhibition of NF-AT
(nuclear factor of activated T cells) (38–40). However, when
treating primary B-CLL cells with FK506 (tacrolimus), an unre-
lated calcineurin inhibitor, we found that this agent failed to
enhance APO866 activity (Supplementary Fig. S2), suggesting
that the potentiation effect observed with CsA may reﬂect an
alternative mode of action of the latter. In addition to inhibiting
calcineurin, CsA is also a well-known Pgp inhibitor (41–43).
Thus, we reasoned that Pgp inhibition may be the mechanism
underlying CsA-mediated enhancement of APO866 antileukemic
activity and tested other, unrelated Pgp inhibitors in combination
with APO866 to see whether they would recreate the effects of
CsA. Indeed, both verapamil and PGP-4008 strongly enhanced
APO866 activity in two leukemia cell lines (OCI/AML3—AML
andMEC.1—B-CLL; Fig. 2B and C) and in primary leukemia cells
from a cohort of patient that included cases of AML (n¼ 6) and B-
CLL (n ¼ 19; Fig. 2C and Tables 1–3).
Consistent with the hypothesis that APO866 may be a Pgp
substrate, using HPLC/MS, we were able to show that both CsA
and PGP-4008 increase APO866 intracellular levels in primary
B-CLL cells (Fig. 2D and Supplementary Fig. S3). Finally, addi-
tional evidence in support of the notion that APO866 anti-
leukemic activity is regulated by Pgp activity was obtained in
RNAi experiments and in studies with Pgp-overexpressing cell
lines. In a ﬁrst set of experiments, the leukemia cell lines OCI-
AML3 and MEC1 were transfected with Pgp siRNA and Pgp
silencing was veriﬁed by WB 2 days after transfection (Fig. 3A,
upper insets). As shown in Fig. 3A (lower insets), PgP depletion
signiﬁcantly enhanced leukemia cell death upon APO866
treatment vs. control (non-targeting siRNA). Notably, the addi-
tion of CsA in leukemia cells in which Pgp was previously
silenced further enhanced APO866 activity, suggesting that
reducing Pgp protein levels by RNAi may be used to further
increase the efﬁcacy of pharmacologic Pgp inhibitors. Subse-
quently, Doxo40 (44) and LAMA84-r (45), two well-charac-
terized Pgp-overexpressing cell lines, were compared with their
parental cell lines (RPMI8226 and LAMA84, respectively) in
terms of susceptibility to APO866, CsA, and their combination.
As predicted, cells overexpressing PgP were found to be more
resistant to APO866 than the non–Pgp-overexpressing cells
Mechanism of Synergy between APO866 and Cyclosporin-A
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(Fig. 3B). Therefore, collectively, these ﬁndings are consistent
with the hypothesis that APO866 is a substrate of Pgp and that
APO866 activity can be with Pgp inhibitors, including CsA.
Finally, we assessed whether combining APO866 with Pgp
inhibitors would result in an increased cytotoxicity in healthy
PBMC and PBPC, too. However, neither APO866 nor Pgp inhi-
bitors or their combination induced cell death in these cells,
suggesting that these treatments could have a favorable therapeu-
tic index in vivo, too (Supplementary Fig. S5A and S5B).
CsA enhances NADþ shortage, Dcm loss and apoptosis
triggered by APO866
It is well established that APO866-mediated cytotoxicity
largely relies on the depletion of intracellular NADþ stores,
which, in turn, ultimately leads to ATP shortage (2, 36, 46).
Using a cycling enzymatic assay, we monitored the metabolic
changes occurring in primary leukemia cells (AML and B-CLL),
as well as in leukemia cell lines, following their exposure
to APO866, Pgp inhibitors, and their combinations. In line
with our previous studies, APO866 treatment alone consistent-
ly reduced intracellular NADþ content, as well as ATP, in cell
lines and in primary leukemia cells (Fig. 4A and B and Sup-
plementary Fig. S6). Interestingly, Pgp inhibitors alone were
found to also slightly reduce both NADþ and ATP. However, in
response to a treatment with combined APO866 and Pgp
inhibitors, both NADþ and ATP depletion were exacerbated.
To gain further insight into the mechanism of cell death
occurring in response to combined APO866 and Pgp inhibitors,
we monitored Dcm and the occurrence of apoptosis (by
PI/Annexin-V staining), as well as of hypodiploid cell nuclei,
in leukemia cells over time. With this combined approach, we
were able to show that APO866 causes Dcm dissipation, an
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Figure 1.
NAMPT expression and its prognostic relevance in hematologic malignancies. A, NAMPT mRNA expression in solid tumors and hematologic cancers across
lines included in the Cancer Cell Line Encyclopedia (Oncomine at http://www.oncomine.org: Barretina Cell Line dataset). In the box plots, the middle
bars represent the median value, the boxes encompass the values from the lower to the upper quartile (25th–75th percentile), and the whiskers
encompass the 25th percentile minus 1.5 times the interquartile range and the 75th percentile plus 1.5 times the interquartile range. B, whole-cell lysates
from AML (OCI-AML3, OCI-AML2, HEL, KG1a, MV4-11, SET1, and HL60), B-CLL (Mec.1 and Mec.2), and lymphoma (DAUDI, U937, SU-DHL1 and Raji) cell
lines were analyzed for NAMPT expression. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as loading control. C, IHC analysis on three
representative BM specimens derived from healthy donors (HD), AML, and B-CLL affected patients, show NAMPT expression (positive cells are brown)
and hematoxylin and eosin (H&E); magniﬁcation, %60. D, Kaplan–Meier plots showing prognostic relevance of NAMPT expression on OS of AML (n ¼ 79;
GSE12417; ref. 56), chronic lymphocytic leukemia (n ¼ 148; GSE22762; ref. 57), and diffuse large B-cell lymphoma (n ¼ 396; GSE4475; ref. 58) patients.
Medians ' SD are presented. The group of patients with higher SIRT6 expression (red line) had shorter OS than patients with lower SIRT6 expression
(blue line; log-rank test).
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apoptotic cell phenotype (AnnexinVþ/PI# or AnnexinVþ/PIþ),
as well as a strong increase in hypodyploid (apoptotic) cell
nuclei in primary B-CLL cells (Fig. 5A–C). Taken as single
agents, Pgp inhibitors (CsA, PGP-4008 and nilotinib) were
much less effective than APO866. However, adding a Pgp
inhibitor to APO866 consistently led to a much more pro-
nounced Dcm loss and apoptotic phenotype. Because previous
studies showed autophagy to be frequently associated with
APO866-induced leukemia cell death (4, 11, 16, 17), we also
investigated whether an aberrant activation of the autophagic
machinery would also be involved in the cooperation between
APO866 and Pgp inhibitors. However, addition of a Pgp inhib-
itor failed to increase the expression of LC3B-II (a marker of
autophagy activation) above the levels detected with APO866
alone (data no shown). In addition, autophagy inhibition with
3-methyl adenine (3-MA) failed to protect leukemia cells
from APO866 in combination with Pgp inhibitors (data not
shown). Therefore, these data essentially rule out a major role
of autophagy in the observed synergistic effects between
APO866 and Pgp inhibitors.
Evidence for an involvement of ER stress and UPR in leukemia
cells sensitization to APO866 by Pgp inhibitors
Previous studies by our groups showed that APO866 nega-
tively affect endoplasmic reticulum (ER) physiology in suscep-
tible cells. In addition, recent studies have also linked the
anticancer activity of Pgp inhibitors (including CsA and verap-
amil) to the induction of ER stress and of a terminal unfolded
protein response. Thus, because ER stress is a main trigger for
apoptotic responses, we assessed its potential relevance in
the antileukemic effects of APO866, Pgp inhibitors and their
combination (13, 47–51). ER stress inhibition with the chem-
ical chaperone 4-phenyl butyric acid (4-BPA; ref. 52) signiﬁ-
cantly reduced the cytotoxic effects of APO866, CsA, and of
the two combined agents in OCI/AML3 andMEC.1 cells, as well
as in primary B-CLL cells (Fig. 6A). An analysis of ER stress-
related markers was also performed. As predicted, in cells that
were cotreated with APO866 and CsA a stronger increase in
IRE1a, C/EBP-homologous protein (CHOP) and BIP levels
as compared with the single-agent treatments was observed
(Fig. 6B and Supplementary Fig. S7). A marked increase in the
Figure 2.
NAMPT inhibition triggers synergistic antileukemia effect with CsA. A, 2.5 % 104 primary B-CLL cells were incubated in 96-well plates in the presence
or absence of 3 nmol/L APO866 and different antileukemia drugs (0.5 mmol/L melphalan, 0.3 mmol/L doxorubicin, 5 mmol/L ﬂudarabine, 0.01 mmol/L
velcade, and 1 mmol/L CsA) or their combination. Cell death was assessed 96 hours later by PI staining and ﬂow cytometry. Results are means of
triplicates ' SD; ns, not signiﬁcant; && , P ¼ 0.01; &&& , P ¼ 0.002; &&&& , P < 0.0001. B, 2.5 % 104 OCI/AML3 (left) or Mec.1 (right) cells were plated in 96-well
plates and treated with or without increasing doses of APO866 (3 nmol/L) for 48 hours, and then vehicle or Pgp modulators (10 mmol/L verapamil,
1 mmol/L CsA, and 10 mmol/L PGP-4008) were added for further 48 hours. Viability was assessed using PI staining and FACS analysis. Data, means of
triplicate ' SD (n ¼ 3; && , P ¼ 0.02, &&& , 0.001 < P < 0.003, &&&& , P < 0.0001). C, primary leukemic cells from 25 patients (19 B-CLL and 6 AML) were
pleated in 96-well plates and incubated with 3 nmol/L APO866 and various Pgp modulators (verapamil, Nilotinib, or PGP-4008). Cell death was assessed
96 hours later by PI staining and ﬂow cytometry. Results are means of triplicates ' SD. CI values < 1, ¼ 1 and > 1 mean indicate synergistic, additive or infra-
additive effect, respectively. D, 2% 107 primary B-CLL cells per well were plated in 6-well plates and treated for 24 hours with 3 nmol/L APO866 in presence or
absence of CsA 1 mmol/L. Thereafter, cells were harvested and lysed in water. The extracted material was then analyzed by mass spectrometry. APO866
concentration in each extract was normalized to protein concentration.
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molecular chaperone BIP was also detected in primary B-CLL
cells treated with APO866 and CsA (Fig. 6C). Finally, a con-
siderable accumulation of misfolded proteins, detected as a
smear of high-molecular weight adducts (Fig. 6B) in response
to combined CsA and APO866 was also documented, whereas a
weaker smear, previously identiﬁed as made of polyubiquiti-
nated proteins (53), was observed in response to APO866
alone. Thus, overall, these ﬁndings indicate a novel role for
ER stress and unfolded protein accumulation in the antileuke-
mic activity of APO866 and of its combination with Pgp
inhibitors.
Nicotinamide and nicotinic acid completely abolish activity
of cotreatment in leukemia cells
The Preiss Handler pathway (2, 8) for NADþ biosynthesis
sees the conversion of nicotinic acid to nicotinic acid mononu-
cleotide (NaMN) by the enzyme Nicotinic Acid Phosphoribosyl
Transferase (NAPRT1). NaMN is subsequently converted to
NADþby an additional enzymatic reaction. InNAPRT1-proﬁcient
cells, NA addition is typically sufﬁcient to rescue the cytotoxic
activity of APO866, allowing to verify that APO866-induced
cell death is indeed mediated by reduced NADþ availability
(54, 55). On the basis of these premises, we ﬁrst determined
NAPRT1 expression in primary leukemia cells by Q-PCR and
essentially found that NAPRT1 was ubiquitously expressed.
Thereafter, we investigated the speciﬁc role of NADþ depletion
in the observed synergism (between APO866 and Pgp inhibitors)
by rescuing NADþ biosynthesis with NA supplementation. Con-
sistent with our previous ﬁndings (37), NA supplementation
completely abrogated the antileukemic activity of APO866, both
as a single agent and in combination with CsA (Supplementary
Fig. S8A and S8B), conﬁrming the role of NADþ depletion in the
activity of these antileukemic treatments. Interestingly, no pro-
tection fromAPO866, CsA, or their combinationwas conferred to
leukemia cells by tryptophan supplementation, essentially ruling
out a major role for the de novo NADþ biosynthetic pathway in
this type of cancer (data not shown).
Discussion
Here, we show that the antileukemic activity of the
NADþ-lowering agent APO866 is strongly enhanced by
Figure 3.
Modulation of P-glycoprotein (Pgp) activity affects APO866 sensitivity in leukemia cells. A, OCI-AML3 (left) and MEC.1 (right) were transfected using
different concentrations of ON-TARGET PLUS SMART pool targeting MDR-1 or nontargeting negative control siRNA (nt siRNA). Twenty-four hours after
transfection, leukemia cells were treated with 3 nmol/L APO866 in the presence or absence of 1 mmol/L CsA. Cell lysates were obtained 48 hours
after transfection and subjected to Western blot analysis to conﬁrm decrease in MDR1 protein expression. GAPDH was used as loading control. Cell
death was assessed 72 hours later by PI staining and ﬂow cytometry. B, 2.5 % 104 LAMA-84r (left) or Doxo40 (right) cells, in parallel with their parental
cell lines (LAMA84 and RPMI8226, respectively), were plated in 96-well plates and treated with or without increasing doses of APO866 (3 nmol/L) for
48 hours. Then, vehicle or CsA (1 mmol/L) were added for further 48 hours. Viability was assessed using PI staining and FACS analysis. A and B, data, means
of triplicate ' SD (n ¼ 3; &, P ¼ 0.05; && , 0.003 < P < 0.002; &&& , 0.001 < P < 0.0003; &&&& , P < 0.0001).
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combining it with Pgp inhibitors. The latter are shown to increase
APO866 intracellular concentration, exacerbating APO866's
effects on cellular energetics. In addition, a key role for ER stress
in the anticancer activity of APO866 and of its combination with
Pgp inhibitors is demonstrated for the ﬁrst time.
We ﬁrst documented that high levels of NAMPT are express-
ed in several types of hematologic malignancies and demon-
strated the prognostic relevance of this protein. Next, in the
attempt to identify agents that, when combined with APO866,
would enhance its antileukemic activity, we discovered CsA as
Figure 4.
Pgp modulators treatment
combined with APO866 enhances
NADþ and ATP depletion produced
by APO866. A, 2 % 106 primary
leukemic (AML and B-CLL) cells per
well were plated in 6-well plates and
incubated with 3 nmol/L APO866,
1 mmol/L CsA, and 6 mmol/L
Verapamil alone or in combination.
After 24 hours (left) or 48 hours
(right) later, cells were harvested
and NADþ or ATP levels were
determined in cell extracts. B, 1 % 105
Mec.1 cells per well were plated in
6-well plates and incubated with or
without 3 nmol/L APO866 and Pgp
modulators (10 mmol/L Verapamil,
1 mmol/L CsA). After 24 hours (left)
or 48 hours (right) later, cells were
harvested and intracellular NAD
(H)þ and ATP levels were evaluated
and compared with those in control
cells. A and B, means' SD of at least
three independent experiments
are shown; & , 0.05 < P < 0.03;
&& , 0.004 < P < 0.002; &&& , 0.001 < P
< 0.0009; &&&& , P <0.0001.
Table 3. Synergistic interactions between APO866 and efﬂux pump inhibitors in primary leukemia cell
Patient nr. CsA (1 mmol/L) Verapamil (6 mmol/L) APO866 (10 nmol/L) CsAþAPO866 VerapamilþAPO866
#1 2.7 ND 5 67.56 (0.1) ND
#2 1.8 ND 43.5 94.24 (0.4) ND
#3 5.58 ND 1.13 51.33 (0.1) ND
#4 3.42 ND 1.41 44.44 (0.1) ND
#5 6.13 8.8 46.43 75.51 (0.7) 67.35 (0.8)
#6 17.55 2.19 43.11 86.77 (0.7) 73.73 (0.6)
#7 0.9 26 24 84 (0.3) 84 (0.6)
#8 9 ND 5.6 35.7 (0.4) ND
#9 21.1 ND 4.7 89.8 (0.3) ND
#10 14. 6 ND 35.3 99.35 (0.5) ND
#11 35.8 9.5 27.72 83.78 (0.7) 76.5 (0.5)
#12 35.7 ND 0.25 73.3 (0.5) ND
#13 27.6 32.7 24.7 63.2 (0.8) 59.2 (0.9)
#14 41 10.9 30.3 80 (0.8) 55.6 (0.7)
#15 27.6 32.74 24.7 73.9 (0.7) 69.23 (0.8)
#16 5.6 6 46.9 95.4(0.5) 95.1 (0.5)
#17 20.4 13.9 54.9 84.8 (0.8) 85.05 (0.8)
#18 6.6 ND 3.8 42.44 (0.2) ND
#19 21.25 13.9 54 84.81 (0.8) 85.05 (0.79)
#20 56.7 ND 37.6 95.1 (0.9) ND
#21 40.5 ND 24.7 73.5 (0.8) ND
#22 15 ND 7.46 30.31 (0.8) ND
#23 23.4 27.6 37.8 68.63 (0.8) 66.45 (0.9)
#24 21 ND 34 87.5 (0.6) ND
#25 43.4 7.6 37.8 84.5 (0.9) 81.9 (0.5)
NOTE: Primary B-CLL (#1–17) or AML (#18–25) cells were plated in 96-well plates and stimulated with 1 mmol/L CsA, 6 mmol/L verapamil, and 3 nmol/L APO866
alone or their combinations. Speciﬁc cell death was detected four days later by PI staining and ﬂow cytometry. CIs are indicated in parentheses.
Abbreviation: ND, not determined.
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a highly effective potentiator. Notably, the combination of CsA
with APO866, whereas highly active in different types of
leukemias, was found to spare healthy PBMCs and PBPC,
suggesting that this novel regimen should have a favorable
therapeutic index in patients, too.
At the molecular level, the ability of CsA to boost APO866
activity is shown to reﬂect its function as a Pgp inhibitor,
instead of as a calcineurin inhibitor. Consistent with this
notion, CsA and other Pgp inhibitors increase intracellular
APO866 levels, thereby enhancing APO866-induced NADþ
depletion, Dcm loss, and ATP shortage (Supplementary Fig.
S8C). Activation of the apoptosis machinery is one of the
downstream events leading to leukemia cell death in response
to combined APO866 and Pgp inhibitors, as detected by
Annexin-V/PI staining and by the occurrence of hypodyplid
cell nuclei. In addition, we show here for the ﬁrst time that
APO866 and, to a higher extent, its combination with Pgp
inhibitors induce ER stress and that this type of response plays
a role in the anticancer activity of these agents. Notably, this
type of cell death appears to be distinct from the autophagic
cell death that was previously observed with single-agent
APO866 treatment (11, 16). The lack of effect of auto-
phagy inhibition on the cell demise that occurs in response
to APO866 plus CsA could reﬂect the fact that, by strongly
increasing the intracellular levels of APO866 and, consequent-
ly, its metabolic effects (i.e., NADþ and ATP shortage), CsA
leads to a shift in the cell death programs activated by the
NAMPT inhibitor, preferentially activating apoptosis and ER
stress (51).
In conclusion, our data indicate that APO866 is a bona ﬁde Pgp
substrate and that combining this agent with Pgp inhibitors
(including CsA) strongly potentiates its cytotoxic activity on
leukemia, but not on healthy cells. We demonstrate a key role
for ER stress in the observed synergistic interaction between
APO866 and Pgp inhibitors. Our data provide the biologic
rationale for combining Pgp inhibitors with APO866 in leukemia
patients.
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